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I investigated two aspects of in vivo splicing that are poorly understood: 
spliceosome disassembly and recycling, and proofreading. To this end, I used 
the auxin-inducible degron (AID) to individually deplete several splicing 
factors in budding yeast and then I measured the effect on co-transcriptional 
spliceosome assembly through chromatin immunoprecipitation. In addition, 
using RNA next-generation sequencing, I measured the frequency of splicing 
errors following depletion or mutation of the fidelity factor, Prp22. I show that 
formation of the pre-spliceosome (the first stage of spliceosome assembly) is 
rapidly inhibited by global defects in late stages of spliceosome assembly. I 
demonstrate that this is due to the accumulation of arrested spliceosomes that 
sequester the splicing machinery and, as a result, causes a recycling defect. 
This suggests that spliceosomes that lack essential splicing factors are not 
always properly disassembled and recycled in vivo, and warns about potential 
systematic secondary effects when perturbing single components of the 
spliceosome. Secondly, I describe the development of a new version of the AID 
system for budding yeast, called the B-estradiol AID. To the best of my 
knowledge, an AID system for budding yeast that is fast-acting, tightly-
controlled and gratuitous, was lacking until now. Lastly, I show that absence 
of Prp22 protein, which was previously proposed to play a role in splicing 
fidelity, correlates with more mistakes in 3’ss selection of many endogenous 
intron-containing transcripts in vivo. This provides indirect evidence to 
suggest that Prp22-dependent splicing proofreading is physiologically 
important. The data from this analysis will be useful in ongoing studies to try 
to identify common features that could improve our understanding of the 







Every living organism is made up of one or multiple cells, and every cell stores 
within its DNA instructions on how to survive and reproduce. DNA is a very 
long molecule that contains information that resembles the “letters” and 
“words” of language. For these molecular “words” to be read and interpreted 
by the cell, a copy of them is made in the form of RNA. There are many types 
of RNAs. One very special type of RNA is called messenger RNA (mRNA), 
which contains specific information (“words”) on how to build a protein. 
Proteins are essential for cells and there are thousands of different proteins. 
Every single protein is built by reading and translating the information 
contained in mRNAs. However, before an mRNA can be read, there are bits 
of it that should be removed. If these bits are not removed, the message 
contained in the RNA does not make sense to the cell. This process is called 
splicing.  
 
Splicing is essential for complex organisms, such as ourselves or yeast, and 
errors in this process can cause diseases, such as spinal muscular atrophy or 
retinitis pigmentosa – which leads to blindness. This is why it is important to 
understand the details of how splicing works, so we can find good ways of 
treating splicing-related diseases. Splicing is carried out by the spliceosome. 
The spliceosome is a very large molecular complex composed of more than 
150 different parts. One special aspect of the spliceosome is that for every 
splicing event, it is assembled and then disassembled, through a very 
complicated cycle. Just think of it as “cutting and pasting” machine that for 
every single editing event, it is assembled from all its individual pieces in a 
step-wise fashion and, after the process is complete, it falls apart again, so its 
pieces can be recycling into more rounds of “cutting and pasting”, through a 
cycle that goes on and on.  
 
 
One common strategy that researchers use to study the function of cell 
components (for example, RNAs or proteins), is to artificially deplete an 
individual component and then observe what happens to the cells. As part of 
the experimental research I did during my PhD, my first objective was to use 
this depletion strategy to study the function of several protein components of 
the spliceosome. Unexpectedly, I observed that this depletion strategy is not 
always capable of answering the research question that was originally asked. 
My data suggests that this is because depletion of spliceosome components, 
can inhibit the recycling process and cause unwanted secondary effects. This 
discovery is important because it has implications in the way we study the 
function of cell components that are part of large complexes, such as the 
spliceosome. The message is that one has to be careful on how the data is 
interpreted when following a depletion strategy (or other similar ones), which 
suggests that, in some cases, additional controls must be implemented to reach 
an accurate conclusion. Another contribution I made was to generate new 
molecular tools for depleting protein targets in yeast. Compared to previous 
versions, these tools allow very efficient depletion, while minimizing 
unwanted secondary effects. I constructed these tools as an extension of a 
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pre-mRNA splicing is the process of removing the "intragenic region" (intron) 
and ligating the "expressed regions" (exons) of the precursor messenger RNA 
(pre-mRNA). Together with capping and polyadenylation, it is one of the 
main post-transcriptional modifications required for stable expression and 
translation of mRNA. Pre-mRNA splicing is carried out in the nucleus by the 
spliceosome. There are other types of splicing that occur by different 
mechanisms, such as self-splicing introns and tRNA splicing, and are not 
described here. This thesis is exclusively focused on spliceosomal splicing.  
 
What is the function of introns? 
 
The most widespread role of introns is to expand protein diversity, by 
allowing a single gene to encode for a range of protein isoforms, through a 
process called alternative splicing. This generally happens when an exon is 
skipped or an intron is included from the final spliced mRNA product, or from 
the use of alternative splice sites. Alternative splicing occurs widely in 
eukaryotes, especially in higher eukaryotes and is highly regulated. It is 
estimated that in humans about 95% of transcripts from multi-intron genes are 
alternatively spliced (Pan et al., 2008), and it has been predicted that more than 
half of alternative splicing events are differentially regulated between tissues 
(Wang et al., 2008). Alternative splicing is mediated by RNA-binding proteins 
that can enhance (e.g. SR proteins) or silence (e.g. hnRNP) splicing events. 
 
Some introns may have functions unrelated to alternative splicing. For 
example, they have been associated with enhanced expression, 3' end 




localization [reviewed by (Chorev and Carmel, 2012)]. In addition, many 
introns encode non-coding RNAs, such as snoRNAs and miRNAs. One model 
that aims to explain the origin of introns suggests that they appeared early in 
the evolutionary history of eukaryotes, initially as functionless selfish 
elements (Koonin, 2006). According to this hypothesis, it was only later that 
they acquired a diverse range of functions, both on the DNA and RNA level. 
Their tremendous evolutionary success as regulatory elements, is owed in 
great part to their freedom to evolve independently of the coding sequence of 
the gene they inhabit. 
 
Splice sites and the chemistry of splicing 
 
Introns are defined by three short consensus sequences called splice sites. 
These splice sites are located at the start (5' splice site; 5’ss), at the end (3' splice 
site;3’ss) and near the 3' end (branchsite;BS) of the intron. The consensus 
sequences of the splice sites vary between organisms. For example, in humans 
only the -GT (5'ss) and AG- (3'ss) motifs are fully conserved, with only a 
weakly conserved consensus sequence for the branchsite, but contain a 
polypyrimidine tract immediately upstream of the 3'ss. In contrast, budding 
yeast have a strong consensus 5'ss (-GTATGT) and branchsite (ACTAAC), a 
poor consensus 3'ss (T/CAG-), with polypyrimidine tract sequences being 
absent in many budding yeast introns. Due to the well conserved mechanisms 
of splicing catalysis, almost all eukaryotic intron-containing genes contain a -
GT, A and AG- at the 5'ss, branchsite and 3'ss, respectively. One exception to 
this are the -AT/AC- introns that are common in introns spliced by a subtype 
of spliceosome called the U12-dependent spliceosome.  
 
Splicing happens by two consecutive transesterification reactions. In the first, 




phosphate group of the first nucleotide of the intron, which is the conserved -
G of the 5'ss. This forms the lariat intron-exon intermediate. Then, the 3'OH 
end of the first exon attacks the phosphate group of the first nucleotide of the 
second exon, which results in ligation of the two exons and separation of the 
lariat intron. Although these chemical reactions are primarily catalysed by 
RNA, splicing of pre-mRNA requires the help of spliceosomal proteins.  
 
Splicing in budding yeast 
 
Splicing in budding yeast is unusual in several respects. Firstly, only about 5% 
of its protein coding genes contain an intron. However, this does not mean 
that splicing is rare in this organism, as most of its ribosomal protein (RP) 
transcripts are spliced (71%) and, because RPs are very abundant, these 
transcripts represent 24% of the mRNA mass within the cell (Ares et al., 1999). 
So, highly expressed genes of budding yeast tend to have introns.  
 
Secondly, the vast majority of its intron-containing genes only contain a single 
intron, and there are only a couple of cases described of functional alternative 
splicing (Hossain et al., 2016; Juneau et al., 2009). So, virtually all intron-
containing transcripts of this organism are constitutively spliced. 
Nevertheless, the yeast spliceosome is remarkably similar to those of higher 
eukaryotes (Fabrizio et al., 2009; Will and Lührmann); in terms of protein and 
U snRNA composition, the assembly pathway, and the mechanisms of 
splicing catalysis. Probably most differences in protein composition between 
the budding yeast and human spliceosomes, are due to the lack of proteins 
that regulate alternative splicing in the former. For this reason, budding yeast 
is a good model organism to study the mechanisms of splicing.  
Thirdly, budding yeast introns are not essential when cells are grown under 




deleted, revealed that any intron can be deleted without affecting cell fitness. 
However, when cells were exposed to stress, they discovered that 20% of the 
intron deletion strains grew slower than wild-type (Parenteau et al., 2008). 
Furthermore, a similar study associating intron deletion and cell behaviour 
under stress conditions, found that in  40% of the intron deletion strains, 
expression of the intron-deleted gene was reduced (Parenteau et al., 2011). 
Interestingly, they found that about half of the introns of duplicated RP genes 
(from a total of 118 genes = 59 pairs) are required for normal expression level 
of the paralog RP gene. In line with this, evidence suggests that splicing 
regulates the expression of the 13 meiosis-specific intron-containing genes 
(Juneau et al., 2007), probably through an unusual mechanism, in which pre-
mRNA species compete for a limited pool of splicing components (Munding 
et al., 2013). Therefore, although there is still no consensus of the general 
function of introns in budding yeast, it seems that they are important during 
meiosis or when cells are grown under stress conditions, and for RP genes in 
particular.  
 
The spliceosome cycle  
 
The spliceosome is a highly dynamic complex composed of U1, U2, U4, U5 
and U6 uridine-rich small nuclear RNAs (U snRNA) and about 150 proteins 
[reviewed by (Matera and Wang, 2014; Will and Lührmann)]. Each U snRNA 
is bound to seven Sm or Lsm proteins and to several specific proteins. These 
RNA-protein complexes are referred to as U small nuclear ribonuclear protein 
particles (U snRNP).  The spliceosome is assembled from U snRNPs, plus the 
nineteen complex (NTC) and other non-snRNP splicing factors, through a 
process that involves major structural and compositional rearrangements of 




In summary, the classical model of splicing proceeds as follows (Figure 1.1): 
1) the U1 and U2 snRNPs bind the 5’ss and the branchsite (BS), respectively, 
constituting the pre-spliceosome 2) then the tri-snRNP (U4/U6.U5) and the 
NTC join in, and U1 and U4 snRNPs are displaced, forming B activated 
complex, 3) other  rearrangements follow that allow for the two catalytic 
reactions to happen and finally 4) the post-spliceosome is disassembled, 
releasing the spliced mRNA and the spliceosome components that are 
recycled into new rounds of splicing.  
 
In the following sections I will describe the key stages of the spliceosome cycle 
of budding yeast, most of which have been recently modelled by high 
resolution CryoEM (Fica et al., 2017; Galej et al., 2014, 2016; Hang et al., 2015; 
Nguyen et al., 2015, 2016b; Wan et al., 2016a; Yan et al., 2015, 2016). snRNP 











The first step of spliceosome assembly is the binding of U1 snRNP to the pre-
mRNA, through base pairing between the U1 snRNA and the 5'ss. In parallel, 
protein Msl5 (Branchpoint Binding protein; Bbp1) and the non-essential 
protein Mud2 bind the BS and interact with U1 snRNP protein Prp40 (Abovich 
and Rosbash, 1997). It is believed that this interaction forms a bridge that puts 
in close proximity the ends of the intron. This stage was given the name 
commitment complex, as it was suggested that at this point the intron has been 
selected and committed for splicing. 
 
Then, the U2 snRNP binds the intron through base pairing of the U2 snRNA 
with the BS which requires 1) RNA helicase Sub2 to displace the Msl5/Mud2 







































structural conformation through the ATPase activity of RNA helicase Prp5. 
This stage is called the pre-spliceosome. In the canonical model of spliceosome 
assembly, U2 is recruited after U1 snRNP, which has been confirmed in vivo 
(Tardiff and Rosbash, 2006). However, by single-molecule spectroscopy, it 
was observed U2 recruited before U1 in about a third of the productive 
assembly events, suggesting that there may be alternative assembly pathways 
of the spliceosome (Shcherbakova et al., 2013).  
 
B and Bact complexes 
 
The next stage of assembly starts with the incorporation of the tri-snRNP to 
the pre-spliceosome or A complex. The tri-snRNP (Nguyen et al., 2015) is the 
name given to the pre-assembled particle formed by U4, U5 and U6 snRNP, 
where U4 and U6 snRNAs are extensively base paired. This particle contains 
more that 30 proteins, including Prp8, which is a very large (280 kDa) and well 
conserved splicing factor that plays a central role in the spliceosome (Grainger 
and Beggs, 2005). This intermediate complex of the spliceosome that contains 
all five snRNPs is called B complex.  
 
Soon afterwards, the U4/U6 duplex is unwounded by RNA helicase Brr2 
(Laggerbauer et al., 1998; Raghunathan and Guthrie, 1998a), and the U1 
snRNA/5'ss duplex is destabilized by RNA helicase Prp28 (Chen et al., 2001; 
Staley and Guthrie, 1999), in an ATP dependent manner. These 
rearrangements allow U6 snRNA to base-pair with the 5'ss and with U2 
snRNA, and leads to the dissociation of U1 and U4 snRNPs from the 









The NTC is composed of up to 16 proteins (Ohi et al., 2002). 8 of these are 
referred to as NTC core components, including Prp19 and 7 other proteins that 
were found to be tightly associated with it (Tarn et al., 1994), including Prp46, 
Cef1 and Syf1. The other 8 NTC components were identified later (Ohi et al., 
2002), and are now referred to as NTC-associated or NTC-related, which 
includes Prp45.  
 
The NTC is recruited to the B complex during or immediately after 
dissociation of U4 snRNPs, (Tarn et al., 1993) and was shown to be required 
for stable binding of U5 and U6 snRNPs to the spliceosome and the 5'ss (Chan 
and Cheng, 2005; Chan et al., 2003). One can now observe in the high 
resolution Cryo-EM models, that the NTC adopts an extended and 
interconnected architecture within the spliceosome, and occupies much of the 
periphery and part of the catalytic core (Yan et al., 2015). Thus, it seems that 
most of the NTC components work as scaffolds that provide structure and 
flexibility to the spliceosome.    
 
Interestingly, it could be that some NTC components are recruited to the 
spliceosome even before U2 snRNP recruitment. This is mainly based on 
evidence that in mammals the NTC interacts with U2AF65, homologue of 
Mud2 (David et al., 2011) that is displaced during the commitment complex 
to pre-spliceosome transition. In addition, in budding yeast the NTC 
component Syf3 directly interacts with Mud2 and Prp40 (U1) (Chung et al., 
1999). However, as NTC components have not been generally found 
associated to the commitment complex or the pre-spliceosome, it could be that 





B* and the first catalytic step of splicing 
 
The final step before catalysis is the Prp2-mediated (RNA helicase) release of 
the SF3a/b U2 snRNP proteins and RES complex (Lardelli et al., 2010; 
Warkocki et al., 2009). Most of these proteins surround the U2/BS duplex 
(Schneider et al., 2015; Yan et al., 2016), and in their absence, Cwc25 and Yju2 
bind that BS and position it at the 5'ss for splicing catalysis (Chiang and Cheng, 
2013; Galej et al., 2016; Wan et al., 2016a). This stage, where the catalytic centre 
of the spliceosome is ready to splice, is referred to as catalytically activated B 
complex (B* complex).  
 
The key components of the catalytic centre, are loop I of U5 snRNA that holds-
on to the end of the first exon, the U6 snRNA loop bound to the 5'ss, the U2 
snRNA bound to the BS, the intramolecular stem loop (ISL) of U6 snRNA 
carrying two magnesium ions (Mg2+), helix I of the U2/U6 duplex, and the 
cavity of Prp8 that acts as a scaffold for the catalytic centre (Galej et al., 2013), 
stabilizing the catalytic RNA structures. This conformation allows the Mg2+ 
ions in the ISL (Fica et al., 2013; Hang et al., 2015; Yean et al., 2000) to catalyse 
the first step of splicing that produces the lariat intron-exon structure, and is 
observed with astonishingly high detail on the CryoEM models (Galej et al., 
2014, 2016; Wan et al., 2016a; Yan et al., 2015) 
 
C complex and the second catalytic step of splicing 
 
The stage immediately after the first catalytic step of splicing is called C 
complex. Afterwards, the splice sites are repositioned to form catalytically 
active C complex (C* complex). Specifically, Cwc25 and Yju2 are displaced by 
RNA helicase Prp16 through its ATPase activity (Galej et al., 2016; Tseng et al., 
2011), which leads to the repositioning of the BS away from the catalytic core 




rearrangements are promoted by other splicing factors, additional to Prp16, 
that are specifically recruited at this stage; including Prp18 and Slu7 that help 
to position the 3'ss (Fica et al., 2017; Ohrt et al., 2013), which is held by loop 1 
of U5 snRNA (Newman and Norman, 1992; Sontheimer and Steitz, 1993); and 
Prp8 (Teigelkamp et al., 1995). RNA helicase Prp22 acts later for mRNA 
release. Finally, the two exons are joined by an analogous mechanism as the 
first catalytic step of splicing. 
 
Post-spliceosome and disassembly 
 
Then, the spliced mRNA is released from the post-catalytic spliceosome, also 
called the post-spliceosome. After Prp16 has acted and left during the C to C* 
complex transition, RNA helicase Prp22 binds the second exon at a position 
around 17 nt downstream of the exon-exon junction. Then, after exon ligation, 
the 3' to 5 RNA helicase Prp22, disrupts the mRNA/U5 snRNA interactions, 
releasing the spliced mRNA from the post-spliceosome (Aronova et al., 2007; 
Fica et al., 2017; Schwer, 2008; Wagner et al., 1998).  
 
Finally, Prp43, Ntr1 and Ntr2, which form an heterotrimer sometimes referred 
to as NTR, promote disassembly of the post-spliceosome. This heterotrimer is 
recruited to the post-spliceosome after Prp22 has acted and left (James et al., 
2002). The RNA helicase Prp43 then releases the excised lariat from the post-
spliceosome through a reaction that requires NTP (Fourmann et al., 2013; 
Martin et al., 2002; Tsai et al., 2005). This makes the lariat accessible for 
debranching by Dbr1 (Martin et al., 2002) followed by cytoplasmic 5' to 3' 
endonuclease degradation (Hilleren and Parker, 2003). Additional to lariat 
release, the NTR promotes separation of U2, U5, U6, and the nineteen complex 





The NTR does not act alone, as it was demonstrated that it requires U5 snRNP 
proteins Snu114 and Brr2 for disassembly (Small et al., 2006). Although the 
model was later challenged (Fourmann et al., 2013), Small and others 
proposed that Snu114 regulates Brr2 to unwind the U2/U6 duplex after 
splicing catalysis, through a mechanism analogous to U4/U6 unwinding at 
the B complex stage. This model proposed by Small and others, agrees with 
previous observations that the ATPase activity of Brr2 is particularly 
stimulated by U2/U6 snRNA (Xu et al., 1996). Furthermore, it was shown that 
NTR is bound to the U5 snRNP of the post-spliceosome through interaction of 
Ntr2 with Brr2 (Tsai et al., 2007). Thus, a likely scenario is that mRNA release 
allows recruitment of NTR to Brr2-U5 snRNP where it coordinates with 
Snu114-Brr2 to release the excised lariat and separate the remaining 
components. 
 
It was proposed that when spliceosome assembly happens inefficiently or is 
interrupted, for example when the pre-mRNA substrate contains sub-optimal 
splice sites, the aberrant spliceosome is targeted for disassembly by NTR 
through an analogous mechanism as the one described above. This aspect of 




Additional rearrangements are required before the released U snRNPs can be 
recycled. Some but not all aspects of U snRNP recycling have been described. 
Of particular importance is the process of reannealing U6 with U4 snRNA that 
precedes tri-snRNP reassembly. RNA-binding protein Prp24 is essential for 
this process (Ghetti et al., 1995; Raghunathan and Guthrie, 1998b). After post-
spliceosome disassembly, U6 snRNA binds Prp24. Then, its internal stem loop 




with U4 snRNA, giving rise to U4/U6 snRNP. In addition, U4/U6 snRNP 
formation requires the association of U6 snRNA with its Lsm proteins that 
were released during the B to Bact transition (Achsel et al., 1999; Mayes et al., 
1999; Ryan et al., 2002; Verdone et al., 2004).  Based on the crystal structure of 
U6 snRNA-Prp24 (Montemayor et al., 2014) together with data of previous 
reports (Bae et al., 2007; Didychuk et al., 2016; Martin-tumasz et al., 2011), it 
was proposed that Prp24 acts like a chaperone that stabilizes the transitional 
conformation of U6 between its catalytic conformation and that of di-snRNP.  
 
Afterwards, U5 binds U4/U6 snRNPs to form the tri-snRNP, through a 
mechanism elucidated for human cells but that could also exist in yeast (Song 
et al., 2010). Firstly, Prp19 binds to U4/U6 snRNPs and then ubiquitinates 
Prp3 (U4). This increases affinity of Prp3 for Prp8 (U5) resulting in U5 
association with U4/U6 snRNPs to form the tri-snRNP. In addition, it was 
proposed that release of U4 during the B to Bact transition of the spliceosome 
is aided by Prp3 deubiquitination.  
 
Post-catalytic U2 snRNP also undergoes structural and compositional 
rearrangements before it is re-used (Behrens et al., 1993; Brosi et al., 1993; van 
Roon et al., 2017). U2 snRNP is released from the post-spliceosome as a particle 
that contains Sm proteins and U2-specific factors Msl1 and Lea1, and is 
analogous to the 12S U2 particle of human cells. Next, this particle binds three 
SF3a and six SF3b proteins displaced during the Bact to B* transition, forming 
the active U2 snRNP that is analogous to the 17S U2 of human cells. At this 









The idea that splicing can occur co-transcriptionally was first proposed based 
on the observation that spliceosomes are bound to splicing junctions of 
nascent RNA (Osheim et al., 1985). But it wasn’t until two decades later that a 
series of snRNPs ChIP analyses demonstrated that step-wise spliceosome 
assembly occurs co-transcriptionally, in agreement with the classical model of 
splicing (Görnemann et al., 2005; Kotovic et al., 2003; Lacadie and Rosbash, 
2005; Listerman et al., 2006). These data show co-transcriptional recruitment 
of U1 snRNP followed by U2 snRNP and, finally, U5 snRNP together with the 
NTC. The rationale behind these assays is that if splicing occurs co-
transcriptionally, splicing factors can be cross-linked to DNA, as nascent pre-
mRNA lies adjacent to the DNA (Wetterberg et al., 2001). 
 
It was later demonstrated, by high density tiling microarray analysis of 
nascent RNA, that most introns are co-transcriptionally spliced (Carrillo 
Oesterreich et al., 2010). The authors observed that >80% of pre-mRNA is 
spliced before transcription termination, in close to half of the intron-
containing genes analysed. Surprisingly, they showed that even genes with 
short second exons splice co-transcriptionally, and argued that this is due to 
Pol II pausing on terminal exons. In agreement, a parallel study demonstrated 
the existence of splicing-dependent Pol II pausing near the 3’ splice site 
(Alexander et al., 2010a). Although it is possible that Pol II pausing observed 
by Oesterreich and others (2010) and Alexander and others (2010) are of a 
different nature. Recently, it was shown by nascent RNA sequencing, that 
splicing can happen incredibly close to the exit channel of Pol II (Carrillo 
Oesterreich et al., 2016). Overall, the data support the idea that splicing is 
tightly coupled to transcription. Most of the first analyses of co-transcriptional 




other reports confirming that most splicing in higher eukaryotes also happens 
co-transcriptionally (Brugiolo et al., 2013).  
 
Mechanisms of co-transcriptional splicing 
 
Two non-mutually exclusive models have been proposed to explain co-
transcriptional splicing. In the “recruitment model”, co-transcriptional 
splicing is facilitated by direct recruitment of splicing factors to the 
transcription machinery. The first evidence in support for this was the 
demonstration that the absence of the carboxy-terminal domain (CTD) of the 
RNA Polymerase II (Pol II) can reduce splicing efficiency in mammalian cells 
(McCracken et al., 1997), suggesting that the CTD acts as a platform that 
recruits and directs RNA-processing machines. Since then, some physical 
links have been found between Poll II and splicing factors, including human 
orthologues of Mud2 and Prp19, and yeast Prp40 (U1) and Syf1 (NTC) 
(Chanarat et al., 2011; David et al., 2011; Morris and Greenleaf, 2000).  
The kinetic model states that transcription elongation rate is modulated to 
allow time for splicing to occur before transcription termination, offering a 
“window of opportunity” for splicing factor recruitment. In this scenario, the 
rate of splicing competes with transcription elongation rate, and possibly also 
with 3’ end formation. In support for this model, it was shown that splicing is 
altered in response to changes of Pol II elongation rate. Of particular 
importance, experiments with budding yeast and mammalian cells show that 
a slow Pol II can favour use of upstream weak splice sites (Howe et al., 2003; 
Mata et al., 2003). In addition, it was observed that Pol II mutants of slow and 
fast transcription elongation rates affect splicing efficiency (Braberg et al., 





As an extension of the kinetic model, a splicing dependent transcriptional 
checkpoint was proposed. This checkpoint model is based on evidence that a 
transcriptional elongation defect takes place, when stable binding of U2 
snRNA with the BS is compromised, and that this transcription defect is 
mediated by transcriptional elongation factor Cus2. This suggests that there is 
a checkpoint that triggers Pol II pausing when pre-spliceosome formation is 
less efficient, as if transcription is "waiting" for splicing (Chathoth et al., 2014). 
So, Pol II pausing could be a mechanism by which the kinetics transcription is 




Accurate splicing is accomplished not only by selecting the appropriate splice 
sites, but also by suppressing suboptimal ones – a concept known as splicing 
fidelity. The kinetic model of splicing fidelity proposes that proofreading 
mechanisms reject suboptimal substrates due to their slow kinetic rates of 
catalysis  [reviewed by (Semlow and Staley, 2012)]. Spliceosomal RNA 
helicases are central to this model.  
 
Spliceosomal RNA helicases as fidelity factors 
 
Most spliceosomal RNA helicases interact transiently with the spliceosome 
and are special in that, through their ATPase activity, they trigger the 
structural rearrangements that define the various phases of the spliceosome 
cycle (as described in the previous sections). In addition to their main role in 
splicing, there is evidence to suggest that these proteins proofread the first and 
the second step of splicing, by rejecting sub-optimal splice sites through their 





Prp16 and the kinetic model of splicing fidelity 
 
Prp16 was the first RNA helicase to be described as a splicing fidelity factor. 
An early report identified a prp16 mutation that  suppresses a splicing defect 
caused by a branch site mutation from TACTAAC to TACTACC within a 
reporter gene (Couto et al., 1987). This work was soon followed by further 
characterizations of the mechanism of Prp16's activity (Burgess and Guthrie, 
1993; Burgess et al., 1990). Altogether, these studies lead to the proposal of a 
molecular framework of splicing fidelity by the Guthrie lab. This model, 
which is referred to as the kinetic proofreading model, or the timer model, 
proposes that the action of RNA helicases can antagonize splicing catalysis, 
and that the rate of ATP hydrolysis by RNA helicases competes with the rate 
of splicing catalysis. In other words, sub-optimal substrates are rejected 
because they are not spliced quickly enough. For instance, if a spliceosome is 
assembled on a pre-mRNA containing a non-consensus branchsite sequence 
that does not properly base-pair with U2 snRNA, Prp16 may release Cwc25 
and Yju2 before the intron is branched. 
 
More recent studies have confirmed and extended the splicing fidelity model 
that was first proposed. Of particular importance, is evidence produced by the 
Staley lab, which showed that the Prp16-dependent discard of a pre-mRNA 
with mutated branchsite requires spliceosome disassembly factor Prp43 
(Koodathingal et al., 2010; Mayas et al., 2010). This suggests that proofreading 
happens by two consecutive steps. In the first, the non-consensus splice site is 
rejected by an RNA helicase (e.g. Prp16) that would shift the structure of the 
catalytic centre into an unproductive state. This conformation would then 
trigger RNA helicase Prp43 to discard the sub-optimal substrate and 






Figure 1.2. (Semlow and Staley, 2012) “Functions of known proofreading 
DExD/H-box ATPases in the splicing pathway”.  
 
 
In another report by the same lab, an in vitro assay was developed where the 
rate of splicing was reduced by introducing a mutation in the ISL of U6 snRNA 
that disrupts the catalytic centre. Interestingly, they observed a correlation 
between a reduced rate of splicing and an increased rejection of defective 
spliceosomes (Koodathingal et al., 2010), which required ATPase activity of 
Prp16 – arguably the best mechanistic evidence so far in support of the kinetic 




Prp22's role in proofreading the 3'ss    
 
Prp22 was the second RNA helicase to be described as a splicing fidelity factor. 
Although this role of Prp22 has not been as well characterized as that of Prp16, 
there is good evidence to support it. Of special importance is in vitro work 
from the Staley lab (Mayas et al., 2006). In wild-type conditions, a pre-mRNA 
containing a UAG to UAC mutation in its 3'ss undergoes the first but not the 
second step of splicing. However, when recombinant mutant Prp22 proteins, 
with impaired ATPase and/or RNA unwinding activity, were added to 
affinity purified spliceosomes, the UAC pre-mRNA could now undergo the 
second step of splicing to some extent. This suggests that the ATPase activity 
of Prp22 suppresses sub-optimal 3'ss, and that splicing proofreading is a 
general function of spliceosomal RNA helicases.   
 
Furthermore, the authors observed that the transcript of a ACT1-CUP1 
reporter, containing a UAG to GAG mutation at its 3'ss, was spliced in vivo by 
a cold-sensitive (ATPase deficient) prp22 strain but not by wild-type strain. 
Although the reporter they used is an artificial gene, this confirms that the 
ATPase activity of Prp22 has an effect on 3'ss selection in vivo. Another 
intriguing observation is that the prp22 mutants also affected the second step 
of splicing of a substrate containing non-consensus 5'ss or branchsite 
sequences. This was observed by purifying arrested spliceosomes containing 
branched intermediates with a GUAUGU to AUAUGU mutation at the 5'ss, 
or a UACUAAC to UACUAGC mutation at the branchsite. Then, addition of 
recombinant mutant Prp22 protein, but not wild-type Prp22 protein, allowed 
exon ligation of some proportion of the branched substrates. This suggests that 
Prp22 may also assist in the proofreading of 5'ss and branchsite, although it 





Consistent with its 3'ss proofreading role, previous evidence showed that 
Prp22 crosslinks around 17 nt downstream of the exon-exon junction (Schwer, 
2008) and, in addition, recent Cryo-EM models have located Prp22 in the yeast 
(Fica et al., 2017) and human (Bertram et al., 2017) C* complex of the 
spliceosome (Figure 1.3). Although Prp22 was observed to interact with Prp8 
away from the catalytic centre, this distance can accommodate 15-16 nt and 
therefore allow for a potential interaction between Prp22 and the first 15 nt of 
the second exon. Taken together, the data indicate Prp22 is timely and 
spatially positioned to translocate along the pre-mRNA in a 3' to 5' direction 
and, therefore, may potentially disrupt interactions that stabilize the 3'ss at the 
catalytic centre just before exon ligation. This is also consistent with evidence 
indicating Prp22 discards suboptimal substrates before but not after exon 
ligation (Mayas et al., 2006), and that Prp22-mediated rejection correlates with 






Figure 1.3. (Fica et al, 2017) “Prp22 and ATP-mediated transitions at the 
catalytic stage of splicing”. Figures a and b are representations of the structures 
resolved by the authors through CryoEM, focusing on the position of Prp22 within the the C* 
complex. Figure c is a schematic of the model of the Prp16-mediated remodeling.   
 
 
Prp16 and Prp22 may act by pulling the RNA at a distance 
 
It was recently proposed, also by the Staley lab, that Prp16 and Prp22 influence 
splicing fidelity at a distance from the splice sites (Semlow et al., 2016). 
Evidence for this is based on in vitro splicing extracts with artificial pre-mRNA 
substrates containing 1) a chemically modified branchsite that is inefficiently 
branched or 2) two 3'ss separated by 3 nt, both with UAG consensus sequence. 
The first and the second type of substrates were used to study the role of Prp16 
and Prp22, respectively. Using this assay, they first showed that the ATPase 
activity of these proteins is required for selection of alternative splice sites. For 
instance, either of the tandem 3'ss were spliced in wild-type splicing extracts, 
but when an ATPase-deficient mutant Prp22 protein was added to the extract, 
only the distal 3'ss was used.  
 
Next, they truncated the substrates at different positions downstream of the 
branchsite or 3'ss splice site. With this they confirmed that a 3' tail after the 
splice sites is required for the function of Prp16 and Prp22, as previously 
suggested. Alternatively, by introducing DNA substitutions into the RNA 
substrate, they blocked the ability of the RNA helicases to translocate along 
the substrate beyond specific positions. Unexpectedly, they observed that the 
DNA substitutions closest to the splice sites did not inhibit the function of 
Prp16 or Prp22, suggesting that these proteins do not translocate through the 
splice sites, as was previously proposed based on crosslinking data 
(McPheeters and Muhlenkamp, 2003; Schwer, 2008). Overall, their data 




but possibly also for alternative splicing, as they allow flexibility of splice site 
selection, and 2) that these proteins act by pulling the RNA substrate at a 
distance, possibly to allow the catalytic centre to sample several potential 
splice sites. The latter is in agreement with the recent Cryo-EM models of the 
spliceosome (see above subsection). 
 
Prp5's role in proofreading the branchsite sequence 
 
RNA helicase Prp5 has also been associated with splicing fidelity (Xu and 
Query, 2007). Several prp5 mutants were identified that, compared to wild-
type PRP5, increase the in vivo splicing efficiency of a pre-mRNA containing 
single nucleotide substitutions at one of two positions (underlined) of the 
branchsite sequence TACTAAC, which are otherwise poorly spliced with 
wild-type PRP5. They also showed that prp5 mutants increase, although only 
slightly, the splicing efficiency in the presence of a mutation in the U2 snRNA 
that disrupts its base-pairing with the wild-type branchsite. Overall, the data 
suggest that Prp5 proofreads branchsite selection. However, the mechanism 
for this may be different to that of Prp16- or Prp22-mediated splicing 
proofreading, as Prp5 appears to proofread branchsite recognition by 
stabilizing U2 snRNA base pairing with the branchsite, instead of actively 
rejecting sub-optimal splice sites as is proposed for Prp16 and Prp22.  
 
Non RNA-helicases associated with splicing fidelity 
 
Splicing requires the correct assembly, structure and timely coordination of 
more than 150 protein and RNA components. For this reason, it is expected 
that many of these components contribute, directly or indirectly, to the 
selection of proper splice sites. For example, it has been observed that isy1∆ or 
cwc21∆, or mutations in Prp8, Slu7, U2, U5, U6 snRNAs affect the accuracy of 




Gautam et al., 2015; Lesser and Guthrie, 1993; Newman and Norman, 1992; 
Umen and Guthrie, 1996; Villa and Guthrie, 2005). However, my focus is not 
splice site selection per se, but rather the proposed model of splicing fidelity 
where RNA helicases reject sub-optimal splice sites. Although the process of 
selecting the optimal splice site and the process of rejecting sub-optimal splice 
sites are interdependent, they are two different aspects of splicing. While the 
first represents the correct functioning of the machine, the second represents 
quality control.  
 
Tools to control gene expression in budding yeast 
 
To study the in vivo function of an essential gene, it is very common to start by 
conditionally blocking its expression or activity, followed by phenotype 
analysis. Ideally, the conditional expression system should be fast and specific, 
to avoid secondary and off-target effects. The traditional conditional systems 
for budding yeast are temperature-sensitive mutants and metabolic regulation 
(e.g. GAL and MET promoters). These tools have been extremely useful in 
functional studies. However, they have several inconveniencies, including the 
secondary effects associated with temperature or media changes. Alternative 
tools were developed more recently, including artificial on/off promoters, 
anchor-away, riboswitches and degrons. In the following sections I will 




Temperature sensitive (ts) strains typically contain a mutation in a single 
essential gene, which renders them able to grow at the permissive, but not 
restrictive temperature. Most mutant strains are generated by incubating the 
cells with a mutagen (e.g. EMS), followed by strain selection based on 




permissive temperature can range between 24-30 °C, and the restrictive 
temperature is around 16°C, for cold-sensitive mutants (cs), or 30-37 °C for 
heat-sensitive mutants (hs). It is believed that the heat-sensitivity is due to a 
structural instability of the mutant protein, and the cold-sensitivity to an 
inability to destabilize RNA:protein or RNA:RNA interactions (e.g. cs RNA 
helicases). Thus, by shifting the temperature of a ts culture one can almost 
instantaneously inactivate the function of protein of interest.  
 
Temperature-sensitive mutants are the "workhorse" of yeast genetics. They are 
especially useful for screening libraries of ts strains against a reporter system. 
For example, a good proportion of splicing factors were identified by isolating 
strains from a ts library for their inability to splice. Also, mutants can be 
crossed with other mutants or with deletion strains, to identify suppressors or 
synthetic lethal strains that would allow one to infer functional interactions 
between proteins or RNA components. This can be done following a low-
throughput or high-throughput approach. Over the past three-four decades, a 
combination of powerful yeast genetics and biochemical studies, allowed 
researchers to understand in great detail most of the assembly pathway of the 
spliceosome and the mechanisms of splicing catalysis. 
 
Despite the extreme usefulness of ts mutants, they are far from ideal when it 
comes to individually studying the functions of genes. The main reason for 
this is that temperature shifts stress the cells, affecting splicing efficiency and 
other cellular processes (Bergkessel et al., 2011). Therefore, the specific effect 
of the mutation on splicing may be obscured by non-specific effects. In 
addition, many ts strains are sick even at the permissive temperature, which 
further decreases the contrast between the permissive and restrictive 







Two types of promoters are used as molecular tools, constitutive promoters, 
such as PADH1, PTEF1 and PPGK1; and conditional promoters (CP). CPs allow 
control of timing and level of expression of the gene of interest (GOI). Most of 
these can be used to either repress or induce transcription. CP are commonly 
used as research tools to study gene function, and also for over-expression of 
heterologous proteins for industrial biotechnology.  
 
One benefit of using a CP to inhibit expression, over other knockdown 
techniques, is that the sequence of the GOI need not be altered. However, by 
swapping the native promoter of the GOI for a CP means that, prior to 
repression, the expression levels of the GOI are different from wild-type. The 
second inconvenience is that the speed of repression is limited by the turnover 
rate of both the mRNA and the protein product of the GOI. That is why, it is 
not unusual having to wait 12-24 hours (e.g. after galactose to glucose shift) 
before complete protein depletion is observed. On the other hand, maximum 
protein levels are typically reached within 0.5-2 hours after inducing 
expression through CP. 
 
The large variety of conditional promoters (CP) can be categorized based on 
the type of molecule that controls their transcription. There are natural 
occurring promoters that respond to cell metabolites or metals (e.g. galactose 
or Cu2+), and there are modified promoters that respond to non-metabolizable 
drugs (e.g. tetracycline or B-estradiol). Each CP has a combination of 
characteristics that influence its overall usefulness, including but not limited 
to: 1.- expression level 2.- leakiness 3.- dynamic range 4.- tunability 5.- 
innocuousness and 6.- specificity.  Although obviously not all work equally 





Native conditional promoters 
 
GAL1, GAL5, GAL7 and GAL10 genes encode enzymes required to catabolize 
galactose. The expression of these, as well as many other metabolic-pathway 
genes, is highly regulated to manage cell resources based on the availability 
of nutrients. As high priority is given to glucose over other carbon and energy 
sources, GAL genes are highly expressed in the presence of galactose but 
strongly repressed by glucose. A glucose to galactose shift in the culture 
medium can result in a 1000-fold increase in transcription of galactose-
controlled genes (Weinhandl et al., 2014). For these reasons, galactose-induced 
promoters (e.g. PGAL1 and PGAL10) are one of the most commonly used CPs.  
 
Key regulators of GAL promoters are transactivator Gal4 and its repressor 
Gal80. Gal4 activates GAL promoters by binding to their upstream activation 
sites (UAS) as a homodimer. Expression of Gal4 is repressed by glucose; and 
in absence of galactose, Gal80 forms a heterodimer with Gal4, thereby 
inhibiting its activity. The main disadvantage of the GAL expression system 
is that changing the nutritional contents of the medium can drastically affect 
global gene expression. For instance, it was observed that when cultures 
grown on galactose were subjected to pulses of glucose, the expression of 
about 25% of genes was changed at least 2-fold (Ronen and Botstein, 2006).  
 
Other commonly used CPs are copper-induced and methionine-repressed 
promoters. When intracellular Cu2+ ions reach high levels, the expression of 
Cu2+ responsive genes is upregulated to reduce the excess Cu2+ and prevent 
intoxication. One of these genes is CUP1, which encodes a metallothionein 
protein that binds and sequesters Cu2+. Expression of CUP1 is activated when 
transcription factor Ace1 binds metal regulatory elements within PCUP1, in the 
presence of Cu2+. Thus, by situating PCUP1 directly upstream of the GOI, one 




medium, in a reversible manner. One benefit of using  PCUP1 is that its 
induction does not require a media change, addition of CuSO4 does not 
perturb the cells as much as carbon source shifts, and high expression levels 
have been observed (Da Silva and Srikrishnan, 2012). However, it has been 
reported to be leaky without addition of its inducer, and its dynamic range is 
usually low (10-25 fold) (Maya et al., 2008). 
 
MET3 and MET25 encode two enzymes required for methionine biosynthesis 
and metabolism. PMET3 or PMET25 have been used to conditionally repress 
expression of GOI (Mao et al., 2002). These promoters are characterized by a 
weak expression in the absence of Met, probably 10-fold less compared to a 
GAL promoter on gal+/glu- medium, and by a good repression by addition 
of Met ( > 0.1 mM Met) to the medium, about 10-fold less expression than in 
Met-. Therefore, compared to GAL promoters, MET promoters can be used 
when wanting to avoid overexpressing the GOI (aiming at close to wild-type 
levels) in Met-, while avoiding the drastic nutritional changes in the growth 




Several promoters have been engineered to respond to drugs. There are 
significant benefits to this. Firstly, the drugs used for this purpose are non-
metabolizable, so adding small amounts of them to the culture medium can 
have a strong and lasting effect on GOI expression. Secondly, these drugs do 
not normally interfere with cell metabolism so secondary effects are minimal. 







Tet On/Off expression system 
 
The Tet-On/Off expression system was first developed for mammalian cells 
(Gossen and Bujard, 1992) and adapted to yeast (Garí et al., 1997) shortly 
afterwards, and has worked efficiently in both of these organisms. The DNA 
element of the system is composed of 2 or 7 copies of the bacterial tetracycline-
resistance operator (tetO) fused to a minimal CMV or CYC1 promoter, which 
together form the tetracycline-responsive promoter Ptet. The original protein 
element of the system is the bacterial tetracycline repressor (tetR). In the 
presence of tetracycline, tetR represses Ptet by binding to its tetO element. In 
the yeast Tet-Off, tetR is fused to transcriptional repressors Ssn6 or Tur1. The 
Tet-On version was created by fusing tetR to the activation domain of virion 
protein 16 (VP16) of herpes simplex virus. This fusion protein is called 
tetracycline-controlled transactivator (tTA) and, in the presence of 
tetracycline, it activates Ptet when bound to its tetO element.  
 
Later, a mutated tetR was created that behaves in the opposite way to the wild-
type version, as it only binds to tetO in the absence of tetracycline. These 
mutants (tetR' and tTA') were then used in combination with tetR and tTA, to 
create the dual Tet-On/Off system with improved expression control. For 
example, in the dual Tet-ON, when tetracycline is added to the cells, the tetR' 
is released from the Ptet and tTA' binds in its place. So, the coordinated action 
of repressor and activator ensures both tight-control and strong expression. 
For instance, in the dual Tet-On/Off of yeast, the reporter protein can reach 
maximum levels comparable to that of the GAL system, with an impressive 
dynamic range of more than 1,000-fold (Bellí et al., 1998).  
 
The general experience of the Beggs lab (personal communication from 
several lab members), is that the Tet-On/Off system can work well, but 




is based on the speculation that activator and repressor should be expressed 
to optimal levels for the system to work efficiently. If true, one should test a 
combination of constructs to find one that works well.  For instance, the lab 
was able to generate a Tet-On strain only after several rounds of trial and error 
(Alexander et al., 2010b). An additional complication is that several rounds of 
transformation are required, as the system is composed of at least three 
separately encoded elements: promoter, activator, and repressor. This can be 
solved by putting all elements into a single centromeric plasmid; however, a 
recent attempt to accomplish this was not entirely successful.  
 
The B-estradiol expression system 
 
Relatively recently, a B-estradiol-inducible expression system was developed, 
in which an artificial transcription factor (ATF) activates an artificial promoter, 
only in presence of B-estradiol human hormone. Although this system is easy 
to use, highly efficient and very specific, at the moment it has only been tested 
for budding yeast.  
The ATF of this system is a fusion of a DNA-binding domain, the human 
estrogen receptor and the VP16 transactivator. In the latest version (McIsaac 
et al., 2013), the DNA-binding domain is a truncated Gal4 than contains, 
instead of its own DNA-binding motif, a triple zinc-finger array from mouse 
(Z3) or a rationally designed quadruple zinc-finger array (Z4). The ATFs 
containing these elements are referred to as Z3EV and Z4EV. The artificial 
promoter is a modified PGAL1, where the Gal4-binding sequence was 
exchanged for the corresponding zinc-finger-binding sequence; these 
promoters are referred to as Z3EVpr and Z4EVpr (in accordance with yeast 





The B-estradiol expression system works in the following way. In the absence 
of B-estradiol, chaperone Hsp90 binds to the human estrogen receptor of the 
ZnEV and stops this protein from translocating from cytoplasm to the nucleus. 
Conversely, in the presence of B-estradiol, ZnEV translocates to the nucleus 
where it binds to the zinc-finger-binding sequence within ZnEVpr, which 
results in transcriptional activation of this promoter (Figure 1.4). Using GFP 
as a reporter gene controlled by the Z4EV, the authors observed about a 50-
fold and 150-fold increase in GFP transcript abundance 15 and 60 minutes, 
respectively, after B-estradiol addition (1 uM) to the medium. Similar, but 
slightly lower induction levels were observed using the Z3EV version.   
 
 







Furthermore, they showed that incubating cells with B-estradiol 1) does not 
reduce growth rate and 2) does not affect the global transcription profile of the 
cells. Evidence for this is based on a microarray analysis showing that only 
two transcripts, from non-essential genes RPS8A and YDR133C, are 2-fold 
more abundant compared to the control. In contrast, a similar analysis of a 
previous version of the B-estradiol system, which is constituted by an ATF 
with full-length Gal4 and no zinc-fingers, showed that the abundance of about 
400 gene transcripts is either reduced or increased by > 2-fold following B-
estradiol incubation. Overall, their data indicates that induced-expression 




Riboswitches are RNA-based devices that can be used to control gene 
expression. Typically, these RNA molecules reside within a non-coding region 
of an mRNA, and are composed of one or more aptamers that changes 
structure when bound to a small-molecule ligand. This change in structure can 
then regulate expression of its host mRNA through a variety of mechanisms, 
including modulation of transcription termination, translation inhibition, 
modulation of mRNA stability and alternative pre-mRNA splicing. The 
ligands of riboswitches can be cell metabolites (e.g. vitamins), ions or metals, 
or even antibiotics.  
 
All known natural-occuring riboswitches exist within prokaryotes, with the 
one exception of the Thiamine riboswitch that regulates alternative splicing in 
several eukaryotic organisms (Nguyen et al., 2016a). Their function is to sense 
the intracellular levels of small molecules. One example, there is a riboswitch 
that binds to Mg2+ and resides within the 5' UTR of mgtA transcripts of 




promotes Rho-dependent transcriptional termination of mgtA, and therefore 
prevents transcription of the coding region of this gene, which encodes a 
transporter of Mg2+ (Hollands et al., 2012).  
 
Since riboswitches were discovered, many of them have been engineered as 
tools to control trans-gene expression. Perhaps the most important advantages 
of riboswitches, are that they are easy to use, as they are constituted by a single 
element; and that they can be modified, for example to switch the specificity 
of the aptamer so that it binds to a different molecule. There are not many 
examples of engineered riboswitches for control of gene expression in yeast. 
However, there is one worth mentioning that worked with high efficiency. 
This riboswitch was generated by inserting an array of three aptamers before 
the start codon of the gene. When bound to their ligand tetracycline, the 
aptamers adopt a strong secondary structure, which is believed to prevent 
stable binding of ribosomes to the mRNA. Using this tool, an almost complete 
depletion of the target protein was achieved after 4-6 hours of tetracycline 
addition (Kötter et al., 2009).   
 
Domain to induce degradation 
 
A quick way to conditionally knockdown a gene product, is to directly 
degrade the protein of interest (POI). This is accomplished by fusing the POI 
with a domain that induces degradation, known as a degron [reviewed by 
(Kanemaki, 2013)]. Generally, the advantages of degrons are 1) fast depletion, 
2) most genes can be targeted, 3) not necessarily species-specific and 4) 
reversibility. Typically, depletion of the target is achieved within 0.5-2 hours 
after induction. One disadvantage is that the fused degron by itself, without 
induction, may disrupt the POI by altering its structure or directly interfering 




types of degrons, including the temperature-sensitive (ts) degron and the 
auxin-inducible degron. In addition, there is a different class of degrons 
developed for mammalian cells, which rely on conditionally exposed 
hydrophobic domains that are also targeted for degradation by the 
proteasome. However, these degrons either do not work on yeast, or have not 




The ts degron is comprised of a ubiquitin moiety followed by ts protein Dhfr, 
and is fused to the N-terminal of the POI. When this fusion protein is 
expressed, the ubuiquitin moiety is cleaved by a deubiquitinating enzyme, 
releasing the N-terminal Met. Then, by shifting the temperature to 37°C, the 
Dhfr unfolds exposing its N-terminal Arg and therefore, as this amino acid 
residue is not a Met (the N-end rule), the fusion protein is rapidly 
polyubiquitinated and degraded by the proteasome (Dohmen and 
Varshavsky, 2005). The ts degron worked well on yeast. However, because 
temperature shifts cause unwanted secondary effects and because the ts 
degron could not be implemented in mammals, this system is not widely used. 
Similar to the ts degron, the protease-induced protein inactivation (TIPI) 
degron works by exposing an N-terminal non-Met amino acid, caused by 
specific cleavage of the N-terminal end of the target protein by the induced-
expression TEV protease (Taxis and Knop, 2012).  
 
The auxin-inducible degron 
 
The auxin-inducible degron (AID) was developed by transplanting the plant 
auxin/Tir1 pathway into other eukaryotes  (Nishimura et al., 2009). The main 
benefits of this system are 1) the inducer does not perturb the cells and 2) it 




fission yeast, human cells, chicken cells and roundworm. For these reasons, 
the AID has quickly become a popular tool to study gene function in non-plant 
eukaryotes. 
 
The physiological role of the plant hormone auxin, indole-3-acetic acid (IAA), 
is to mediate growth and development in plants. The process starts with 
binding of auxin to its receptor, a substrate specific F-box protein called Tir1, 
which is part of the plant E3 ubiquitin ligase SCF complex. Then, Auxin/Tir1 
binds to its target, an IAA transcriptional repressor and, as a result, IAA is 
poly-ubiquitinated by the SCF complex and then degraded by the proteasome.   
 
The AID system exploits the fact that Tir1 is specific to plants; and that the SCF 
complex and the ubiquitin proteasome pathway are evolutionarily conserved. 
Therefore, this protein depletion system can be readily transplanted to non-
plant organisms. This requires heterologous expression of Tir1 and C-terminal 
tagging the gene of interest with the degron (e.g. IAA17 or any of its 
derivatives). Then, to promote depletion of the POI, auxin is added to the 
culture medium (Figure 1.5). Using this system almost complete depletion of 






Figure 1.5. Schematic representation of the auxin-inducible system –   slight 
modification of (Kanemaki, 2013). The protein of interest (POI) fused to the AID tag 
(IAA17) is targeted for degradation in the presence of the auxin plant hormone. 
 
There are several variants of the elements that constitute the AID system. 
When the yeast AID system was created, Nishimura and others (2009) initially 
used the Arabidopsis thaliana Tir1 protein, but then switched to Oryza sativa 
(rice) Tir1 (OsTir1), as they observed that the latter allowed higher depletion 
efficiency at higher temperatures (e.g. 30°C). OsTir1 is now the popular choice. 
Also, initially the expression of Tir1 was driven by a GAL promoter. Other 
Tir1-expressing constructs became available shortly after, for example the 
ones where Tir1 is constitutively expressed by the ADH1 promoter.  
 
The first AID tag used was the full length Iaa17 protein (25 kDa), as it is a 
natural target of the auxin/Tir1 pathway. As smaller tags are preferable to 
larger tags, the Kanemaki lab and others (Morawska and Ulrich, 2013) 
independently generated various truncations of Iaa17 and found one that 
works as well as the full version. These truncations were called miniAID (7.2 




auxin that can also be used with the AID. Both IAA and NAA appear to work 
with similar efficiency, although Nishimura and others (2009) reported that 
there are some targets that are depleted more efficiently with one type of auxin 




The anchor-away technique (Haruki et al., 2008) was developed at about the 
same time as the AID and is also a popular choice for depleting proteins of 
interest in budding yeast. The strategy of this technique is to conditionally 
translocate a nuclear protein to the cytoplasm. The elements of the anchor-
away are the human FKBP12 protein (the anchor protein) and its binding 
partner: the FKBP12-rapamycin-binding (FRB) domain of the human mTOR 
protein. The anchor-away strain was generated by fusing FKBP12 to the 
ribosomal protein Rpl13A, and the FRB to the protein of interest (POI).  
 
Addition of rapamycin to the culture, allows association between Rpl13A-
FKBP12, POI-FRB and rapamycin. This then leads to the sequestering of POI-
FRB to the cytoplasm as it is carried away by newly assembled ribosome 
particles, as they are being translocated from the nucleus to the cytoplasm. In 
addition, the authors mutated TOR1 (tor1-1), to avoid rapamycin toxicity, and 
deleted FPR1 that is the homolog of human of FKBP12, to avoid binding 
competition between Fpr1 and FRB for rapamycin and FKBP12.  
 
The main benefits of the anchor-away technique are its fast depletion and its 
high specificity. Using this system, the authors observed good depletion of all 
the 43 proteins they tested, within 15 minutes of rapamycin addition. Thanks 
to the modifications they did to the anchor-away strain, rapamycin does not 




control strain incubated with rapamycin, on the spotting assay. When using 
this technique, depletion efficiency is examined by changes in growth rate and 
changes in cellular localization observed by fluorescent microscopy 
(facilitated by the use of a FRB-GFP tag).  
 
The aims of this study 
 
In the past years, many novel tools to control gene expression have been 
created. One of those is the auxin-inducible system. This system offers several 
advantages over previous methods (e.g. ts mutants and GAL promoters), 
including high specificity and speed of depletion. My preliminary objective 
was to use the AID system to study several interesting splicing factors 
including Prp45 and its interaction partners Prp46 and Prp22.  
 
However, I observed that the targeted depletion of these proteins causes 
unexpected secondary effects on early stages of spliceosome assembly. The 
hypothesis to explain this was that these secondary effects were not caused by 
the AID system by itself but were caused by the accumulation of stuck 
spliceosomes that were preventing the recycling of splicing components – a 
phenomenon that has not been well described in vivo. During the first part of 
my PhD, my objective was to test this hypothesis. 
 
After more than a year of using the AID system, the lab and I observed that 
AID strains expressing different levels of Tir1 have different depletion 
efficiencies. The hypothesis was that an optimal expression level of the Tir1 is 
critical for the efficient depletion of the target protein. My second objective 
was to test this hypothesis while creating a new version of the AID system for 
yeast with a more efficient depletion, by allowing a better control of the level 




During the final stage of my PhD, I used this new version of the AID system 
as a novel way of swapping expression of wild-type Prp22 for mutants of 
Prp22, in combination with a genome wide analysis of splicing. The objective 
of this approach was to study the role of Prp22 in splicing fidelity. Although 
the models that explain splicing fidelity are well supported by in vitro 
evidence, this phenomenon has rarely been studied globally in vivo. Therefore, 
this novel approach offered the opportunity to discover new insights into the 























Chapter 2: Materials and Methods 
 
Sources of reagents 
 
Common chemicals were purchased through Sigma-Aldrich, unless stated 
otherwise. Speciality reagents, commercial kits, or chemicals particularly 
important for the methods described in this thesis, are listed in the tables 
below. % units refer to weight/volume when the chemical was in powder 
form and volume/volume when the chemical was in liquid form. 
 
Table 2.1. Reagents 
Name Company Use Cat. No. 
20 mg/mL glycogen  Roche 4tU labelling 10901393001 
4tU Acros  Organics 4tU labelling 359930010 
Biotin - EZlink HPDP Thermo Scientific 4tU labelling 21341 
magnetic beads - Streptavidin New England Biolabs 4tU labelling S1420S 
RNase inhibitor: Superasin Ambion 4tU, RT and RIP AM2696 
IAA Acros  Organics AID 122160100 
2 mg/mL BSA Sigma-Aldrich Bradford 1076192 
5 x Bradford solution Bio-rad Bradford 5000006  
magnetic beads - Protein A Life Technologies ChIP 10001D 
magnetic beads - Protein G Life Technologies ChIP 10003D 
Phenol/Chloroform(1:1) pH 5.2 Fisher DNA extraction BP17531 
Monarch DNA Gel New England Biolabs gel extraction T1020S 
QIAquick PCR  Qiagen DNA purification 28106 
MinElute PCR Qiagen DNA purification 28006 
Gibson Assembly Master Mix New England Biolabs Gibson Assembly E2611S 
QIAprep Miniprep Qiagen Miniprep 27106 
Zirconia beads 0.5 mm Thistle Scientific multiple 11079105z  
B-estradiol Sigma-Aldrich multiple E8875 
cOmplete proteinase inhibitor Roche multiple 11836145001 
DNA Polymerase - Phusion  New Englang Biolabs PCR M0535L 
dNTP mix 10 mM each Promega PCR and RT U1515 
2x SYBR green III master mix Agilent qPCR 60088251 
Phenol pH 4.3 Sigma-Aldrich RNA extraction P46082 
Phenol/Chloroform (5:1) pH 4.3 Fisher RNA extraction BP17541 
Reverse Transcriptase Roche RT 3531287001 
DNAase I - RQ1 Promega RT M6101 
10 mg/mL fragmented SSDNA Roche transformation 11467140001 
E. coli competents: NEB5-a New England Biolabs transformation C2987H 
NuPAGE minigels Invitrogen Western blot NP0323BOX 
MOPS SDS Running buffer Invitrogen Western blot 1862491 
Odyssey MWM Li-cor Western blot 928-40000 




Table 2.2. Antibodies 
Antigen Clone Organism Company Use Dilution Cat. No. 
FLAG  Rat Agilent WB 1:1000 200474 
Gapdh  Mouse Abcam WB 1:500 Ab9485 
Pgk1  Mouse Abcam WB 1:5000 Ab113687 
HA 12CA5 Mouse Roche WB 1:500 11583816001 
Myc 9E10 Mouse Millipore WB 1:500 05-419 
V5  Mouse Invitrogen WB 1:2500 MA5-15253 
V5  Rabbit Abcam WB 1:2500 Ab15828 
Rat IgG  Goat Li-cor WB 1:5000 925-32219 
Mouse IgG  Goat Li-cor WB 1:5000 925-68020 
Mouse IgG  Goat Li-cor WB 1:5000 925-32210 
HA F-7 Mouse Santa Cruz ChIP  sc-7392 X 
Myc 9E10 Mouse Santa Cruz ChIP  sc-40 X 
FLAG M2 Mouse Sigma-Aldrich ChIP  F1804 
 
 
Growth media and buffers 
 
The ingredients for the growth media where purchased from Formedium. 
Growth media was prepared by the local media services in the WCCB using 
standard procedures, and stored at room temperature for up to one month. 
Rich media (YPDA, LB and SOC) were sterilized by autoclave at 121C for 15 
minutes. Minimal media was filtered sterilized through 0.2 uM filter units. 
Solid media contained 2% bacto-agar. Media used are listed in the table below.  
 
Table 2.3. Media and commonly used buffers 
Name Component Concentration 
YPDA 
Yeast extract 1% 
Bacto-peptone 2% 
Glucos 2% 
Adenine Sulfate 0.003% 
YMM 




out mixture according to instructions 
LB 
Bacto-tryptone 1% 
Yeast extract 0.5% 
NaCl 0.5% 











NaCl  140 mM  
KCl  3 mM  
Na2HPO4  8 mM  
H2PO4  1.4 mM  
MgCl2  20 mM  
TAE 
Tris base  2 M  
Acetic acid  5.71% 
EDTA  50 mM  
TE Tris base  2 M  
Acetic acid  5.71% 
TBS Tris-HCl 10 mM 
NaCl  150 mL 
Tris-glycine transfer buffer Tris base  20 mM  
Glycine 150 mM 
 
Table 2.4. Special buffers 
Name Component Volume 
DNA extraction 
Triton-x100 4 mL 
10% SDS 20 mL 
4 M NaCl 5 mL 
1 M Tris pH 8 2 mL 
0.5 M EDTA pH 8 0.4 mL 
ddH20 to 200 mL 
RNA extraction buffer 
3 M NaOAc pH 5.3 3.3 mL 
0.5 M EDTA, pH 8  4 mL 
ddH20  to 200 mL 
4xLaemmli 
1 M Tris, pH 6.8  5 mL 
0.5 M EDTA, pH 8  0.4 
10% SDS  20 mL  
Glycerol  10 mL  
Orange G a pinch 
ddH20  to 50 mL 
4xLaemmli/4MTris buffer 
4xLaemmli  21 mL 
1 M Tris-base  9 mL  
2-mercaptoethanol*  14 uL / 1 mL 
ddH20  to 30 mL 
IPP150 
1 M Tris pH 8 1 mL 
5M NaCl  3 mL 
10% NP-40 1 mL 
1M MgCl2 150 uL 
cOmplete Prot.In. 1 tab/50 mL 
ddH20  to 100 mL 
1M NaPi pH 6.8 
1M NaH2PO4  50 mL 
1M Na2HPO4  50 mL 
ddH20  to 100 mL 
10xNaTMg 1M Tris Cl pH7.0  1 mL 




1M MgCl2 2.5 mL 
ddH2O to 10 mL 
NaSTPMg  
10xNaTMg  5 mL 
1M NaPi pH 6.8 5 mL 
10% SDS 0.5 mL 
ddH2O to 50 mL 
FA1 
HEPES KOH 0.5 M pH 7.5  25 mL 
NaCl 4M  8.75 mL 
EDTA 0.5M pH8  0.5 mL 
TRITON  2.5 mL 
Na deoxycholate 10%  2.5 mL 
cOmplete proteinase inhibitor 1 tab/50 mL 
ddH20 to 250 mL 
FA2 
HEPES KOH 0.5 M pH 7.5  25 mL 
NaCl 4M  31.25 mL 
EDTA 0.5M pH8  0.5 mL 
TRITON  2.5 mL 
Na deoxycholate 10%  2.5 mL 
ddH20 to 250 mL 
FA3 
Tris-HCl pH8 1M  2.5 mL 
LiCl 4M  15.6 mL 
EDTA 0.5M pH8  0.5 mL 
NP-40  1.25 mL 
Na deoxycholate 10%  12.5 mL 
ddH20 to 250 mL 
ChIP elution buffer 
5 ml TRIS-HCl pH 7.5 1M  5 mL 
1.75 ml EDTA 0.5mM  1.75 mL 
SDS 10%  5 mL 
















S-22 (F) tggagatgctgaaagccagtctagg 





S_Lea1_CT (F) CGATGGAGATCATGAATTTGG 








S_YHC1_CT (F) gcaaaccacgatcaaggagt 





S_Prp45_CT (F) TTATGACAACCCACTGTTCGTCC 





S_Prp46_CT (F) GTGAACGGAGTGTTCTTTGTAGCAC 





S-Syf1 (F) ATGCTCCCAACTCGCATACT 
S-Syf1 (R) CACAACCCAAACATCCACAG 
 
Table 2.6. oligonucleotides for RT-qPCR 
Name Sequence 
ACT_B_F AGGGGCTTGAAATTTGGAAAAA  
ACT_L_F AGGGGCTTGAAATTTGGAAAAA  






































U1_ F  TGATTTTTGGGGCCCTTTGTT 
U1_ R  TCTTTTGAAAGGCCCCAGCTC 
U2_F TTATGTCCAACGCGGGATTTG 
U2_R CCGCACTAGCACCCCATACC 
U4_F  TGAGGATTCGTCCGAGATTGTGT 





ECM33_V_F  AGTGCCTCCGCTCTAGCTGgt 
ECM33_V_R  cgagatttgtgaggaaagaggcaaa 
ECM33_3_F  tctaagcagCTAACTCAACTACTTCTATTCCATC 
ECM33_3_R  TTTTGTCCAAATCAGCTTGAGCAGT 
ECM33_m_F  GCCTCCGCTCTAGCTGctaactc 
ECM33_m_R ttgagcagtagcagtggcagaagt 
ECM33_E_F  CTTCTGCCACTGCTACTGCTCAAG 
ECM33_E_R  AGCAGCGGAACCCAAGTCAC 
SCR1-F tctctgtctggtgcggcaag 
SCR1-R tcacgggtcacctttgctga 
Oligonucleotides in bold where added to the reverse mix 
 
Table 2.7. oligonucleotides for ChIP 
Name Sequence 
I ACT1 -71 F TACATCAGCTTTTAGATTTTTCACGCTTACTGCTT 
I ACT1 +34 R GATGGTGCAAGCGCTAGAACATACCAGAAT 
II ACT1 +368 F TGTACTAACATCGATTGCTTCATTCTTTTTGTTGC 
II ACT1 +413 R GACGATAGATGGGAAGACAGCACGAGGA 
III ACT1 +561 F ATCTGGCATCATACCTTCTACAACGA 
III ACT1 +653 R GTTTGATTTAGGGTTCATTGGAGCTT 
IV ACT1 +1119 F TCTGCCGGTATTGACCAAACTACTTA 
IV ACT1 +1210 R CCGGACATAACGATGTTACCGTATAA 
V ACT1 +1595 F ATGTGTTTTGTCTCTCCCTTTTCTACGAAAATTTC 
V ACT1 +1734 R TGATCATATGATACACGGTCCAATGGATAAACAT 
I ECM33 -592_F GCAGTATCATCCTTCACGACCC  
I ECM33 -510_R GCGTCTTTCCCGTTTTTGC  
II ECM33 +9_F CAAGAACGCTTTGACTGCTACTG  
II ECM33 +145 _R GAAGAGGACCACGAATCTACTCG  
III ECM33 +430_F ACTTCTGCCACTGCTACTGCTC  
III ECM33 +562_R AGGAACCATCAATCTCTTGGATAC  
IV ECM33 +1073_F TTGGTCAATCTTTGTCTATCGTCTC  
IV ECM33 +1173_R TGTGTTGTTAGCAATGATGAAACC  
V ECM33 +1531_F TCTAAGAAGTCTAAGGGTGCTGCTC  




I RPS13_Pm_F agtcgtgattgaattaacaatttctttctca 
I RPS13_Pm_R GCACTGTGCATACGACCCATttt 
II RPS13_I_F  gctgggtgattccaatttcttttaca 
II RPS13_I_R  cataaaggcggctagccatcag 
III RPS13_3_F tccaattccactaaatattactttaaacagGGTA 
III RPS13_3_R CTTGAACCAAGCTGGAGCATTTCT 
IV RPS13_Eb_F TTCACAGATTGGCCAGATACTACAGAAC 
IV RPS13_Eb_R TTGACCAAAGCGGAGGCAGT 
V RPS13 +1288_F GGACCGTTCTCAGAAACATTCCA 






To generate plasmids pURA3-AID*-6FLAG (Figure S2.1), pURA3-AID*-9myc 
and pURA3-AID*-6HA, HPH marker in pHyg-AID plasmids was replaced by 
Kluyveromyces lactis URA3 marker from pVAS-osTIR, using AscI and SacI 
restriction sites. This special URA3 marker, called URA3-looper, is flanked by 
a 142 nt repeat sequence from its 5’UTR which allows to pop-out the marker 
by 5-FOA selection. The series of plasmids containing the AID* tag were 
kindly provided by the Ulrich lab (Morawska and Ulrich, 2013) through the 
request of Jane Reid.  
 
The pBest-TIR1-LEU2 centromeric plasmid (Figure 4.6), which contains all 
elements for the controlled expression of OsTIR1, was constructed by Gibson 
Assembly (NEB master mix), following the instructions of the manufacturer. 
Gibson Assembly is a technique that does not require restriction enzyme 
ligation, where up to five PCR products with complementary ends are cloned 
into the desired plasmid in a single reaction. pBest-TIR1-LEU2 was generated 
from the following parts: (1) pRS415 was digested with SpeI/AscI (2) PZ4EV 
from pMN10 (3) OsTIR1-V5-TTEF1 from pVAS-osTIR and (4) PACT1-Z4EV from 
YMN3 genomic DNA. pMN10 was kindly provided by the McIsaac lab 





Plasmids were constructed containing wild-type PRP22 and prp22 mutants, C-
terminally tagged with V5. This was performed by Gibson Assembly using 
the following parts: (1) MscI/SalI digested p360-PRP22 (Figure S2.2) (2) C-
terminal end of PRP22 from p360-PRP22-URA3, p358-T757A-TRP1 or p358-
I764A-TRP1 (2) 3'UTR of PRP22, plus V5 tag as part of a primer, from p360-
PRP22. Then, these plasmids were further modified to substitute the native 
promoter for the Z4EV promoter of the B-estradiol expression system. This 
was performed by Gibson Assembly using the following parts: (1) 
Eco53KI/ClaI digested p360-PRP22-V5 (2) PZ4EV from pMN10 (3) 5' end of 
PRP22 from p360-PRP22-V5. This resulted in plasmids: p360-Z4p-PRP22-V5, 
p360-Z4p-T757A-V5 and p360-Z4p-I764A-V5 (Figure S5.1). Plasmids p360-
PRP22-URA3, p358-T757A-TRP1 and p358-I764A-TRP1 were kindly provided 
by Beate Schwer (Schneider et al., 2004).  
 
The plasmids were cloned on E. coli NEB-5-alpha strains (NEB), and verified 
by sanger sequencing through the DNA Sequencing and Services of 
MRC/PPU of the University of Dundee.  
 
Table 2.8. Plasmids 
Name  Description Source  
pMK200 To integrate PADH1-689-OsTIR1 into 
ura3 locus YGRC Osaka University 
pHyg-AID*-6FLAG To C-terminally tag a gene of interest  Ulrich lab 
pHyg-AID*-9myc To C-terminally tag a gene of interest  Ulrich lab 
pHyg-AID*-6HA To C-terminally tag a gene of interest  Ulrich lab 
pVAS-osTIR1 To integrate PADH1-397-OsTIR1 into 
ura3 locus Vahid Aslanzadeh 
pURA3-AID*-6FLAG URA3-looper version of pHyg-AID*-
6FLAG This study 
pURA3-AID*-9myc URA3-looper version of pHyg-AID*-
9myc This study 
pURA3-AID*-6HA URA3-looper version of pHyg-AID*-6HA This study 
pBest-TIR1-LEU2 For the B-estradiol overexpression of 
OsTir1 (CEN) This study 
pRS425-FUI1-LEU2 For overexpression of yeast uracil 
permease FUI1 (CEN) David Barrass 
p360-PRP22-URA3 For expression of wild-type Prp22 under 





For expression of mutant Prp22 protein 




For expression of mutant Prp22 protein 
I764A under control of its native 
promoter (CEN) 
Beate Schwer 
p360-PRP22-V5 C-terminal V5 tagged version of p360-
PRP22 (CEN) This study 
p360-T757A-V5 C-terminal V5 tagged version of p358-
T757A (CEN) This study 
p360-I764A-V5 C-terminal V5 tagged version of p358-
I764A (CEN) This study 
p360-Z4p-PRP22-V5 For the B-estradiol overexpression of 
wild-type Prp22 (CEN) This study 
p360-Z4p-T757A-V5 For the B-estradiol overexpression of 
mutant Prp22 T757A (CEN) This study 
p360-Z4p-I764A-V5 For the B-estradiol overexpression of 




YGM1 contains the PADH1-689-OsTIR1 cassette and was created by integrating 
a StuI-linearized pMK200 into the ura3-1 locus of W303. YBRT1 strain contains 
the PADH1-396-OsTIR1 cassette and was kindly provided by Barbara Terlow 
(this lab). YZTR41 strain was created by integrating a KanMX-PZ4EV PCR 
amplicon using pMN10 as template, directly upstream of APE2 start site, 
followed by URA3 pop-in/pop-out substitution of APE2 coding region for 
OsTIR1-V5. AID-tagged strains were created by transforming YGM1 or 
YZTR41 with PCR products of the pHyg-AID*- or pURA3-AID*- cassettes, 
respectively. UPF1 gene was deleted on some genes using the URA3-looper 
marker. pMK200 plasmid was created by the Kanemaki lab and obtained 
through the Yeast Genetic Resource Centre, Osaka University. pYMN3 









Table 2.9. Strains 
Name  Genotype Source  
W303 MATα ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 
can1-100   
YGM1 MATα ade2-1 his3-11,15 trp1-1 leu2-3,112 can1-
100 ura3-1::URA3-PADH1-689-OsTIR1 This study 
YBRT MATα ade2-1 ura3-1 trp1-1 leu2-3,112 can1-100 
his3-11,15::PADH1-397-OsTIR1 B. Terlow 
YMN3 MATα ura3∆ leu2∆0::PACT1-Z4EV-NatMX S. 
McIsaac 
YZTR41 MATα ura3∆ leu2∆0::PACT1-Z4EV-NatMX 
ape2::PZ4EV-OsTIR1-V5 This study 
Prp22-AID*(YGM1) 


































Yhc1-AID*(YZTR41) MATα ura3∆ leu2∆0::PACT1-Z4EV-NatMX 
ape2::PZ4EV-OsTIR1-V5 YHC1::YHC1-AID*-6FLAG This study 
Prp22-AID*(YZTR41) 









YZTR41-du MATα ura3∆ leu2∆0::PACT1-Z4EV-NatMX 
ape2::PZ4EV-OsTIR1-V5 upf1∆ This study 
Prp22-AID*(YZTR41)-
du 





MATα ura3∆ leu2∆0::PACT1-Z4EV-NatMX 
ape2::PZ4EV-OsTIR1-V5 PRP22::PRP22-AID*-
6FLAG upf1∆ p360-Z4p-PRP22-V5 
This study 
Prp22-AID*-du-Z57CEN 
MATα ura3∆ leu2∆0::PACT1-Z4EV-NatMX 
ape2::PZ4EV-OsTIR1-V5 PRP22::PRP22-AID*-
6FLAG upf1∆ p360-Z4p-T757A-V5 
This study 
Prp22-AID*-du-Z64CEN 
MATα ura3∆ leu2∆0::PACT1-Z4EV-NatMX 
ape2::PZ4EV-OsTIR1-V5 PRP22::PRP22-AID*-





General manipulation and preservation of yeast cultures 
 
Yeast liquid cultures were grown in flasks at 30C and shaken at 180 rpm. 
Except during transformation, only yeast that contain a plasmid were grown 
on the appropriate selective media, otherwise they were grown on YPDA 
without antibiotics. Log-phase cultures were prepared by diluting an 
overnight culture to OD600 of 0.2, and then allowing it grow for at least two 
doublings. Cells were harvested by centrifugation at 3,000 x g for 2 minutes in 
a swinging-bucket centrifuge, or in a fixed-rotor centrifuge for cultures 
smaller than 2 mL, unless otherwise stated. Isolated colonies of yeast strains 
were kept at 4C in agar plates for up to two weeks. For long-term storage, a 
saturated culture was diluted 1:1 with 50% glycerol and stored at - 80C. All 




Yeast were transformed using the TRAFO LiAc/PEG method (Gietz and 
Schiestl, 2007). To prepare the competent cells, 50 mL of log-phase culture at 
OD600 of 1, was washed twice with 10 mL of ddH2O, and then once with 1 mL 
of 0.1 M LiAc. The pellet was resuspended in 100 uL of 0.1 M LiAc, and placed 
left on ice. An aliquot of 10 mg/mL SSDNA carrier was boiled for 5 minutes 
and placed on ice. The transformation mix was freshly prepared by 
thoroughly mixing 240 uL of PEG 4000 50%, 36 uL of 1 M LiAc, 20 uL of freshly 
boiled SSDNA carrier and 25 uL of transformation DNA (20 ug of purified 
PCR product or 100 ng of plasmid) 
To transform, 40 uL of the competent cells were added to the transformation 
mix, and thoroughly vortexed for approximately 1 minute. The tube was 
incubated at 30C for 30 minutes, and then at 42C for 40 minutes in a water 
bath. The tube was spun at 3,000 x g for 5 seconds, and the supernatant 




PBS, spread on YPDA agar using glass beads and incubated at 30C overnight. 
The next day, the cells were replica plated on selective media and incubated 
for 2-4 days until colonies were visible. Then, to colony purify, single colonies 
were re streaked on selective media. Positive transformants where verified by 
PCR and, in the case of gene tagging, by western blotting.   
 
PCR and agarose gel electrophoresis 
 
End-point PCR was performed using DNA polymerase Phusion HF Hot-Start, 
following the instructions of the manufacturer. To improve PCR efficiency, 
DMSO was routinely added to the PCR mix at a final concentration of 2.5%. 
The thermocycler program used is stated in the table below. PCR products 
were separated on 1.5-2% agarose TAE gels and SYBR safe, and the bands 
visualized under UV light using a Syngene gel doc system.      
 
End-point PCR program 
Step 1: 98°C 00:30 
Step 2: 98°C 00:10 
Step 3: 60°C 00:20 
Step 4: 72°C 1 min/kb 
Step 5: repeat steps 2-4 x 35 




DNA template for PCR was extracted from yeast cells with 
phenol/chloroform. Using a 1 mL micro pipette tip, a patch of cells was taken 
from an agar plate, and resuspended in a microfuge tube containing 300 uL of 
DNA extraction buffer, 300 uL of phenol/chloroform (1:1) pH 5.2, and 300 uL 
of zirconia beads. The tube was shaken for 2 minutes in a Mini-Beadbeater-24 




minutes. 200 uL of the aqueous phase was take and placed in a new tube 
containing 200 uL of isopropanol and 20 uL of NaAc buffer. The contents were 
mixed by inverting the tube three times and then the tube was placed at -80C 
for 5 minutes. Then, tube was spun at maximum speed for 5 minutes and the 
supernatant was carefully discarded by aspiration. The pellet was washed 
once with 70% ethanol and, finally, the pellet was resuspended in 100 uL of 




Growth rate was analysed through a spotting assay or through a growth curve 
analysis. For a growth curve analysis, log phase cultures were re diluted to 
OD600 of 0.1 and then OD600 measurements were taken every following hour 
for up to 6 hours, using 1-mL cuvettes and a standard spectrophotometer. For 
a spotting assay, log phase cultures were diluted to OD600 of 0.3 and then, 
three serial dilutions of 10-fold were made on a flat-bottom 96-well plate, with 
a total volume of 250 uL per well. These serially diluted cultures were then 
spotted on agar plates using a hedgehog. YPDA control plates were included 
at the start and end of the spotting procedure. Plates were incubated at 30C 
for 1-2 days before taking images using a Syngene gel doc system.  
 
Auxin-inducible depletion  
 
 
AID depletion was performed though the following procedure. A 2.5 mL 
solution stocks of 1.5 M IAA was prepared by dissolving 440 mg of IAA into 
2 mL of DMSO, and stored at -20C for up to 2 months. Then, no more than 
one hour before the log phase culture is ready, the IAA stock solution was pre-
diluted 1:500 in 25% ethanol. Finally, to deplete the target, the pre-diluted IAA 




strictly necessary but, by doing this, the IAA is dissolved more efficiently in 




For the B-estradiol system, a stock solution of 10 mM B-estradiol (in ethanol) 
was prepared and stored at -20C for up to 2 months. To induce expression, 
B-estradiol is added to a log phase culture at a final concentration of 1-10 uM. 
Just as with the IAA stock, a pre-dilution of the B-estradiol stock on 25% 






First, total proteins were extracted following the NaOH/TCA precipitation 
method with a few modifications. 5 mL of a log phase culture were taken and 
added to a 15-mL falcon tube containing 5 mL of methanol chilled on dry ice. 
The contents were mixed by inverting the tube twice. Cells were then 
harvested by centrifugation, washed with 1 mL of cold PBS and placed in a 1.5 
mL safelock tube. The pellet was resuspended in 540 mL of 0.2 M NaOH and 
incubated on ice for 10 minutes. 30 uL of 100% TCA was added to the pellet. 
The tube was vortexed briefly and incubated on ice for 5 minutes. The cells 
were spun at 3,000 x g for 30 seconds, the supernatant was eliminated by 
aspiration, and the tube was spun again and aspirated to eliminate the dregs. 
60 uL of 4xLaemmli/4MTris was added to the pellet, and the tube was placed 
on a thermomixer at 1400 rpm and 65C for 5 minutes to resuspend the pellet. 
Then, the samples were boiled for 5 minutes and then spun at maximum speed 
for 5 minutes. The supernatant was placed in a new tube and stored at -20C 






Total proteins were quantified, using the Bradford Bio-rad reagent in 1 mL 
cuvettes, following the instructions of the manufacturer. In order to keep the 
SDS concentration below the threshold of compatibility, the Laemmli protein 
samples were first diluted 1:20 in water, and then 6 uL of this was mixed with 
1 mL of 1 x Bradford solution into a cuvette. A blank solution was prepared 
by diluting  4xLaemmli/4MTris 1:20 in water. The standards were generated 
by mixing 1, 2, 3, 4, 5 and 6 uL of 1 mg/mL of BSA, with 6 uL of blank solution 
and 1 mL of 1 x Bradford solution, into a cuvette.  The contents of the cuvettes 
were mixed with a micropipette and then measured at 595 nM with a 
spectrophotometer. Using the OD readings, a standard curve was generated 
in Excel and the protein concentration was estimated for each sample using 
the standard curve.  
 
SDS-PAGE and electro-transfer 
 
SDS-PAG was performed using the Invitrogen NuPAGE electrophoresis 
system, with mini Bis-Tris gels of 10-15 wells and 4-15% gradient acrylamide. 
Each well was loaded with 10-30 ug of protein extract. 2 uL of Odyssey 
molecular weight marker was added to one well. The proteins were separated 
by running the gel at 120 V until the dye reached the bottom of the gel. Then, 
the gel was taken and assembled into the Mini Trans-Blot Cell (BioRad), 
following the instructions of the manual. Protein was transferred to a low-
fluorescent PVDF membrane (Millipore) using Tris-Glycine transfer buffer, at 









The transferred proteins were immunodetected by fluorescence using the Li-
cor system through the following procedure. The membrane containing the 
transferred proteins was (1) incubated for 30 minutes in 5% skimmed milk PBS 
on gentle shaking (2) incubated for 1 hour with the primary antibody in 5% 
skimmed milk PBS and 0.2% Tween-20 with gentle shaking (3) washed for 10 
minutes with 0.1% Tween-20 PBS three times (4) incubated for 1 hour with the 
secondary antibody in 5% skimmed milk PBS 0.2% Tween-20 and 0.01% SDS 
with gentle shaking and (5) washed for 10 minutes with 0.1% Tween-20 PBS 
three times. Finally, the membrane was scanned in the Li-cor Odyssey scanner 




RNA was extracted from yeast following a modified method of 
phenol/chloroform extraction. First, 5 mL of a log phase culture were added 
to a 15-mL falcon tube containing 5 mL of methanol chilled on dry ice, and 
mixed. Cell pellet was harvested by centrifugation, washed once with 1 mL of 
cold PBS and placed in a 2-mL screw cap tube. 300 uL of zirconia beads, 700 
uL of RNA extraction buffer, and 700 uL of phenol pH 4.3 were added to the 
cell pellet. To lyse the cells, the tube was shaken for 2 minutes at 2,000 rpm in 
a Mini-Beadbeater-24 (BioSpec Products), placed on ice for 2 minutes, and this 
cycle repeated twice. The tube was placed on dry-ice for 5 minutes and then 
spun at maximum speed for 8 minutes. The aqueous phase was taken and put 
into a new tube containing 800 uL of phenol/chloroform (5:1) pH 4.3, 
vigorously vortexed for 30 seconds, and spun for 3 minutes at maximum 
speed. The aqueous phase was taken, put into a new tube containing 700 uL 




maximum speed. To precipitate, the aqueous phase was taken and put into a 
new tube containing 300 uL of 10 M LiCl, mixed by inversion, and placed at -
20C for 2 hours. The pellet was recovered by spinning at maximum speed for 
5 minutes at 4C, and washed by adding 1 mL of 70% ethanol and placing in 
a rotating wheel for 10 minutes. 15 uL of ddH20 were added to the pellet, and 
incubated at 65C for no more than 5 minutes, until the pellet is dissolved. The 
dissolved RNA was analysed by Nanodrop to determine concentration and 




To obtain cDNA, RNA extracted as described above were reverse transcribed 
through the following procedure. RNA concentration was equalized across 
the multiple samples. First, the reverse primer mix was prepared by mixing 
each desired reverse primer to a final concentration of 3 uM per primer. The 
RT mix was prepared by mixing 2 uL of 5 x RT buffer, 0.75 uL of 10 mM dNTP 
mix, 0.1 RNase inhibitor, 1.75 uL of ddH2O and 0.4 uL of reverse transcriptase. 
A No-RT mix was prepared in the same way but without enzyme. DNase I 
master mix was prepared by mixing 1 uL of DNase I 10 x buffer, 0.9 uL of 
DNase I, 0.1 uL of RNase inhibitor and 0.5 uL ddH2O. Then, for each sample, 
8 uL of RNA extract with at least 700 ng/uL of RNA and 2.5 uL of DNase I 
master mix were added to the well of a 96 well plates for PCR. The plate was 
mixed and placed in a thermocycler at 37C for 20 minutes, and then at 75C 
for 10 minutes. 2.5 uL of the reverse primer mix was added to each well and 
mixed. The plate was heated at 72C for 3 minutes and then immediately 
placed on ice. The RNA samples were split in two wells and 5 uL of RT mix, 
or 5 uL No-RT mix, was added to each well. The plate was spun, mixed and 
heated to 55C for one hour. Finally, 190 uL of ddH2O was added to each well 






DNA samples retrieved by Reverse Transcription, Chromatin 
Immunoprecipitation or RNA Immunoprecipiation were analysed by 
quantitative PCR (qPCR) using the SYBR green method and the 384-well 
Lightcycler 480 II (Roche) equipment. Each qPCR reaction contained 2 uL of 
2xSYBR Green III Master Mix (Agilent), 0.25 uL of 3 uM forward primer, 0.25 
uL of 3 uM reverse primer, and 2.5 uL of DNA samples. The qPCR program 
used is listed in the table below.  
 
qPCR program 
Step 1: 94°C 02:00 
Step 2: 94°C 00:10 
Step 3: 60°C 00:10 
Step 4: 72°C 00:15 
Step 5: repeat steps 2-4 x 35 
Step 6: 95°C 00:10 
Step 7: 60°C 00:10 
Step 8: ramp to 94°C 00:30 
 
 
To analyse the data, threshold cycle (Ct) values were retrieve and the relative 
abundance of the amplicon was calculated by dividing 2-Ct of the query 
amplicon against 2-Ct of the control amplicon. Unless otherwise stated, the 
control amplicon was for ALG9 in the case of RT-qPCR analysis, for U2 in the 
case of RIP analysis, or the amplicon of the lowest value within each gene in 
the case of ChIP analysis. For the ChIP analysis, the relative abundance of the 
amplicon in the immunoprecipitate was divided against that of the 10% input 








Chromatin immunoprecipitation was performed through the following 
procedure, optimized by Ross Alexander and Ema Sani, with minor 
modifications.  
 
Cross-linking and cell disruption 
 
50 mL of log phase culture were placed in a 50 mL falcon tube containing 1.37 
mL of 37% formaldehyde, and shaken gently for 10 minutes.  2.5 mL of 2.5 M 
glycine was added to the tube and shaken gently for 5 minutes. The cells were 
harvested by centrifugation. The cell pellet was washed with ice-cold PBS, 
once with 50 mL and then again with 1 mL, and transferred to a 2-mL screw 
cap tube. 300 uL of zirconia beads and 350 uL of FA1 buffer where added to 
the tube. The cells were disrupted by shaking three times at 2,000 rpm in a 
Mini-Beadbeater-24 (BioSpec Products) for 2 minutes, with 2 minutes on ice in 
between. To separate the lysate from the zirconia beads, the tube was 
perforated in the bottom with a flame-heated needle, and placed inside a 5-
mL syringe (without its plunger) that is inside a 15-mL falcon tube. This 
assembled device was spun for 1 minute at 1000 x g and the lysate was 
transferred to a new 1.5-mL tube.  
 
Chromatin extraction and Immunoprecipitation 
 
The lysate was spun at maximum speed for 15 minutes at 4C. The 
supernatant was discarded. The pellet was resuspended in 300 uL of FA1 
buffer, transferred to a Diogenode tube, and sonicated for 10 cyles at 30 
seconds ON and 30 seconds on at 4C. The tube was spun for 5 minutes at 
maximum speed at 4C, and the supernatant was placed in a new tube and 




dynabeads (coupled to protein A or G) and 5 ug of antibody was mixed with 
500 ug of chromatin extract and incubated overnight at 4C in a rotating wheel. 
Then, the beads were washed three times with FA1, three times with FA2, 
three times with FA3 and once with 0.05% Tween-20/TBS buffer. The washed 
beads were transferred to a new tube. To elute the DNA and reverse cross-
link, 150 uL of ChIP elution buffer and 75 ug of Proteinase K were added to 
the washed beads and to 50 ug of chromatin extract as the 10% input control. 
The tubes were incubated for 2 hours at 42C, and 4 hours at 65C, while 
shaking at 1400 rpm. The supernatant was recovered and its DNA was 
purified using the Qiagen MinElute PCR kit. The purified DNA was taken to 




RNA immunoprecipitation was performed as described previously (Tardiff et 
al., 2006), with a few modifications. All steps during and after cell harvesting 
were performed at 4 C. 50 mL of log phase culture was harvested by 
centrifugation and the pellet was washed once with 10 mL TBS, once with 1 
mL IPP150 buffer, and transferred to a 2-mL screw cap tube. 1.5 mL of IPP150, 
40 units of RNaseIN and 500 uL of zirconia beads were added to the tube. The 
cells were disrupted by shaking three times at 2,000 rpm in a Mini-Beadbeater-
24 (BioSpec Products) beads beater for 1 minutes, with 1 minutes on ice in 
between. The lysate was separated from the zirconia beads as described above 
(ChIP protocol), spun at maximum speed for 5 minutes, and the supernatant 
was transferred to a new tube. For immunoprecipitation, 20 uL of dynabeads 
(coupled to protein A or G) and 5 ug of antibody was mixed with the soluble 
lysate and incubated for 2 hours in a rotating wheel. The beads were then 
washed five times with 1 mL of IPP150 (+ 40U/mL of RNaseIN) on a rotating 




and purified following the phenol/chloroform method described above, by 
adding phenol and RNA extraction buffer directly to the washed beads. The 
purified RNA was taken to a final volume of 400 uL with ddH2O and analysed 
by qPCR. 
 
4-thio-uracil labelling of newly synthesized RNA 
 
Strains analysed by this method (4-thio-uracil (4tU) labelling newly 
synthesized RNA (nsRNA)), were previously transformed with pFui-LEU 
plasmid for overexpression of the uracil permease under its own promoter in 
a 2 uM plasmid. After RNA extraction, all following steps were carried out 
using RNase free reagents and materials. The procedure was developed and 




A log phase culture was grown in –ura –leu  (Keiser) drop out YMM. 4 thio 
uracil was added to the culture to at a final concentration of 10 uM, mixed 
vigorously and left for 1 minute in normal growth conditions. 30 mL of this 
culture were added to a 50-mL falcon containing 20 mL of methanol 
previously chilled on dry-ice. The cell pellet was harvested by centrifugation, 
washed with 1 mL of cold PBS and transferred to a 2-mL screw cap tube. RNA 
was extracted following the procedure described above, and the purified RNA 




The resuspended RNA was transferred to a 8-strip PCR tube and heated to 
65C for 15 seconds. 10 uL of HPDP biotin solution (4mM in dimethyl 




biotinylated RNA was purified using 0.5ml Zeba column, using TE buffer and 
following the manufacturer’s instructions. To precipitate, 1/10 volume of 
NaOAc buffer and 2.5 volumes of ethanol was added, mixed, placed at -20C 
for 30 minutes, and spun for 5 minutes at maximum speed at 4C. The 
supernatant was discarded and the pellet was washed with 80% ethanol, once 
on a rotating wheel for 1 hour and a second time overnight at 4C to wash out 
any remaining unincorporated biotin.  
 
Purification of snRNA 
 
The washed pellet of biotinylated RNA was dissolved in 242 uL of ddH2O at 
65C, and 5 uL of dissolved RNA were stored separately for concentration 
determination by nanodrop and later analysis of total RNA. The RNA 
concentration was equalized across the multiple samples. 30 uL of 10xNaTMg 
buffer, 30 uL of 1 M NaPi buffer and 3 uL of 10% SDS were added to the RNA, 
and mixed. To prepare the magnetic streptavidin beads, 50 uL of the slurry 
were added to a low retention 1.5-mL tube and placed on a magnetic rack; 
washed with 200 uL of NaSTPMg buffer; blocked with 200 uL of NaSTPMg 
buffer, 2.5 uL of 5 mg/mL tRNA and 10 uL of 20 mg/mL glycogen for 20 
minutes in a rotating wheel; and washed again with 200 uL of NaSTPMg. The 
prepared beads were incubated with the RNA samples in a rotating wheel for 
30 minutes, washed four times with 200 uL of NaSTPMg, and eluted twice 
with 50 uL of freshly prepared 0.7 M b-mercaptoethanol. To precipitate the 
RNA, 10 uL of 3 M NaOAc pH 5.3 and 2.5 uL of 20 mg/mL glycogen were 
added to the 100 uL elute, mixed and incubated for 1 hour at -20C. The pellet 
was spun for 5 minutes at maximum speed, washed with 70% ethanol, and 
resuspended in 10 uL of TE at room temperature. The quality of the RNA was 





RNA next-generation sequencing 
 
Samples, library preparation and sequencing 
 
Total RNA was extracted and purified as described above. A total of eight 
samples were processed, including the wild-type strain, Prp22 depletion, and 
two mutants of Prp22, in biological duplicates. The quality of the RNA was 
assessed by Agilent Bioanalyzer 2100 RNA Nano-Chip, following the 
instructions of the manufacturer.  
 
RNA samples were shipped in dry-ice to BGI Genomics (Hong Kong) for 
library preparation and strand specific 150 bp paired-end deep sequencing by 
HiSeq Illumina 4000. Total RNA was treated with DNase I and then with Ribo-
Zero Gold rRNA Removal kit for yeast. Retrieved RNA was randomly 
fragmented. First-strand cDNA was synthesized with random primers using 
Invitrogen SuperScript II First-strand Synthesis SuperMix. The product was 
purified with Agencourt RNA Clean XP Beads, followed by synthesis of the 
second strand. The ends of the cDNA library were repaired and then index 
adapters were ligated. To enrich the cDNA fragments, several rounds of PCR 
amplification were performed. The PCR products are purified with Ampure 
XP Beads. Then, the eight libraries were loaded in two wells (1 biological 




After sequencing, the raw reads were filtered by BGI Genomics. Data filtering 
included removal of adapter sequences, contamination and low-quality reads 
from raw reads. The clean reads in FASTQ format were shipped to WTCCB in 
an external hard drive. A report was generated and sent that includes the 











Reads  Clean bases  Q20(%)  GC(%)  
1 57-1  150 210,586,726 31,588,008,900 99.06;97.14  42.3 
2 57-2  150 242,973,566 36,446,034,900 99.02;97.03  42.33 
3 64-1  150 196,993,362 29,549,004,300 98.44;96.74  42.26 
4 64-2  150 203,629,174 30,544,376,100 99.06;96.76  42.4 
5 WT-1  150 210,963,050 31,644,457,500 98.99;96.89  42.25 
6 WT-2  150 192,272,846 28,840,926,900 99.04;96.73  42.5 
7 d-1  150 204,400,598 30,660,089,700 98.92;96.93  42.4 
8 d-2  150 169,650,916 25,447,637,400 98.30;97.16  42.59 
 
 
Further processing and analysis of the reads was performed through the 
Linux-based server (bifx-cli) of the Bioinformatics Core Facility at the WTCCB 
(University of Edinburgh) under the username of s1325554, unless otherwise 
stated. To confirm the quality of the reads, a QC analysis was done using the 
FastQC tool (Andrews, 2010).   
 
Genome mapping was performed by aligning the clean reads to the genome 
sequence of Saccharomyces cerevisiae, using the STAR mapper program (Dobin 
and Gingeras, 2016). First, a genome index was generated using the yeast 
reference genome version sacCer3 and the corresponding GTF file (version 
R64-1-1.88) downloaded from ENSEMBL. Then, the clean reads were mapped 
to the genome using the genome index and the spliced-junction output files 










Code to generate a yeast genome index for STAR mapping: 
STAR --runThreadN 60 --runMode genomeGenerate –-genomeDir /path-to-genome-
directory/ --genomeFastaFiles /path-to-genome-Fasta-
Files/Saccharomyces_cerevisiae.R64-1-1.dna.toplevel.fa --sjdbGTFfile /path-to-
genome-GTF-File/Saccharomyces_cerevisiae.R64-1-1.88.gtf --sjdbOverhang 50 
 
Code to map reads to reference genome: 
STAR --runThreadN 60 --genomeDir /path-to-genome-directory/ --readFilesIn /path-
to-reads-first-strand/cleanreads_1.fq/ path-to-reads-second-strand/cleanreads_2.fq 
 
Analysis of mRNA junctions 
 
First, common gene names and 5’ss-3’ss motifs were annotated to the splice 
junction table (SJ.out.tab) through a program created by Sander Granneman 
called “STARtab2GTF.py”. Then, non-annotated splice junctions were located 
within this table and categorized based on the type and direction of the splice 
site shift (e.g. upstream 5’ss, downstream 5’ss, upstream 3’ss… etc), using a 
program created by Vahid Aslanzadeh called “STARtab2GTF2Juncanot.py”. 
A non-annotated splice junction is defined as a junction within an intron-
containing gene that is not annotated in the GTF file. Data in this table was 
then used to measure relative mRNA abundance and the frequency of splicing 
errors, using a python-based notebook created by Vahid Aslanzadeh called 
“Vahid-altevents.ipynb” as a basis. This python notebook was modified and 
adapted according to the characteristics of my data. For each sample, number 
of reads was normalized relative to the total number of uniquely mapped 
reads. The equation drawn below was used to calculate the Splicing Error 
Frequency (SEF) score, which represent non-annotated junction reads 
proportional to annotated junction reads, within each gene. Prior to SEF score 
calculation, spliced junction events that do not contain at least 1 read in each 
of two replicates from one experiment, were filtered out; this means that not 
every non-annotated spliced junction event contains SEF score, or SEF ratio 






Fisher’s exact test was used to estimate statistical significance between the SEF 
values of mutants compared to wild type. For this test, the average counts 
(reads) from biological replicates, of both annotated and non-annotated, were 
used to calculate the p-value of mutant compared to wild-type (table below) 
and test whether the ratios between strains are imbalanced. 
 
Example of 2x2 contingency table for Fisher’s exact test (giving p-value < 0.05) 
LSM7_down3ss_7nt Prp22 depletion Wild-type 
Non-annotated (37+42)/2 (13+15)/2 
Annotated (148+289)/2 (562+577)/2 
Cells containing average reads of two biological replicates (real sequencing values)  
 
Data visualization was performed using Seaborn and Matplotlib 















number of reads that align to the non-annotated splice junction 











Spliceosome assembly and splicing catalysis have been extensively studied, 
yet there are still many gaps in our understanding of the final steps of the 
spliceosome cycle: disassembly and recycling. One aspect of this that is not 
well understood is what happens to the cycle when assembly goes wrong? 
Specifically, how does the cell deal with aberrant spliceosomes that lack 
essential protein components? To answer this question, with an in vivo 
approach I rapidly knocked down several splicing factors and measured 
changes in abundance of intermediate complexes of the spliceosomes and in 
co-transcriptional assembly of the spliceosome. I show that in the absence of 
Prp4, Prp16 or Prp22, intermediate complexes of the spliceosome accumulate 
and co-transcriptional formation of the pre-spliceosome is reduced (Figure 
3.1). This suggests that, at least in some cases, aberrant spliceosomes that lack 
essential splicing factors are not targeted for disassembly and recycled, 
contrary to what was previously proposed. Furthermore, a kinetic analysis of 
Prp22 depletion suggests that spliceosome recycling is possibly a rate-limiting 
step for splicing and critical in budding yeast, as a recycling defect has an 
immediate negative impact on new rounds of splicing. The work presented 
here warns about potential systematic secondary effects when disturbing 










Splicing has been extensively studied, in most cases with biochemical and 
genetic approaches. As a result, we now have a good mechanistic 
understanding of this process, with many molecular interactions confirmed 
and extended through high resolution cryo-EM modelling (Fica et al., 2017; 
Galej et al., 2016; Hang et al., 2015; Nguyen et al., 2015; Wan et al., 2016b; Yan 
et al., 2015). Nevertheless, some gaps remain. For example, few reports have 
analysed spliceosome assembly in vivo, and even fewer have analysed 
disassembly and recycling in vivo.  
 
In normal conditions, after splicing completion spliced mRNA is released 
from the spliceosome by the RNA-helicase Prp22 (Schwer, 2008; Wagner et al., 
1998). Then, the post-spliceosome complex is disassembled by Prp43, Ntr1 and 
Ntr2 (Arenas and Abelson, 1997; Martin et al., 2002; Tsai et al., 2005), which 
allows the free snRNPs to be recycled into new rounds of splicing. One aspect 
that is not well understood is the link between quality control and spliceosome 
disassembly. Are aberrant spliceosomes detected and disassembled, perhaps 
to prevent errors in splicing?  
 
In vitro-based studies suggest that substrates with suboptimal splice sites are 
discarded from the spliceosome by RNA helicases Prp16, Prp22 and/or Prp43, 
reviewed by (Koodathingal and Staley, 2013). Thus, it was proposed that these 
proteins have the additional role of proofreading splicing. This model aims to 
explain how introns are selected and what happens when the spliceosome 
encounters aberrant pre-mRNAs. However, it does not explain what happens 
to spliceosomes with mutant or missing protein components. Examples of 
cases like these include experiments where spliceosome components are 




associated with human diseases. Are these aberrant spliceosomes targeted for 
disassembly and recycled, just as spliceosomes with aberrant pre-mRNAs are 
proposed to be discarded and disassembled? The answer to this question is 
important in two ways. Firstly, it is important to accurately interpret 
knockdown experiments of spliceosome components. Secondly, it will 
improve our understanding of how cells coordinate the assembly and 
disassembly cycle of the spliceosome and other large molecular particles. 
 
A common way to study the role of splicing factors in vivo is through RNAi or 
protein depletion knockdown techniques, transcriptional repression or 
conditional mutant strains. In some situations, the knockdown of one element 
may cause indirect disturbances in the whole system, making the results 
difficult to interpret. Separating specific from indirect effects is critical for 
most functional analyses. In the case of splicing, because the spliceosome 
exists in a highly dynamic cycle of assembly and disassembly, where elements 
seldom exist in isolation, it is not unlikely that perturbing one element will 
affect other parts the cycle, which can lead to misleading interpretations. This 
is one reason why it is important to understand how aberrant complexes are 
dealt with by the cell. When knocking down splicing factors, if aberrant 
complexes are not disassembled and recycled, it could lead to a recycling 
defect with systematic effects on the assembly pathway making it difficult to 
separate the direct from indirect effects. 
 
To improve our understanding of spliceosome disassembly and recycling in 
vivo, my objectives were to deplete splicing factors required at different stages 
of assembly and ask 1) do arrested complexes accumulate? 2) Is spliceosome 
assembly affected? And, if this is the case 3) how quickly?  To this end, I used 
the auxin-inducible degron (AID) system (Nishimura et al., 2009) for a quick 




RNA immunoprecipitation (RIP) that indicates if intermediate complexes 
have accumulated; and chromatin immunoprecipitation (ChIP) as a proxy for 
spliceosome assembly.  
 
Figure 3.1. Schematic representation of the model of the arrested 
spliceosomes. On normal conditions (WT) spliceosome components (e.g. snRNPs), are 
co-transcriptionally recruited to the newly synthesized pre-mRNA transcripts. After splicing 
completion, spliceosome components are release and are free to bind new transcripts. When 
splicing factors are knocked-down (K.D.) (e.g. protein depletion), arrested spliceosomes can 
accumulate and, as a result, inhibit the recycling process. The schematic bellow shows which 
complex intermediate accumulates when Prp4, Prp16 or Prp22 are depleted. 
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Figure 3.2. AID-tagged Prp4, Prp16, Prp22 and Prp45 were depleted to low levels 
by 30 minutes of auxin induction. Auxin was added to cultures of four different strains, 
each one with an AID*-6FLAG C-terminal tag on (A) PRP45, PRP22, PRP16 or (B) PRP4 
genes. Samples were analyzed before (-) and after 30 minutes (+) of auxin (IAA) addition. The 
abundance of the AID target was measured with anti-FLAG LICOR-based western blotting. 
(C) Protein levels after auxin addition were calculated as the ratio of + auxin/- auxin (x100) of 
anti-FLAG signal, normalized to anti-Pgk1 signal as a loading control. Three biological 
replicates where analyzed (only two of them are shown in panels A-B). Standard error of the 





Depletion of essential splicing factors can cause an accumulation of 
intermediate complexes 
 
I analysed the AID depletion of splicing factors Prp4, Prp16, Prp22 and Prp45 
(Figure 3.2). The main reason I focused on these four proteins is that they act 
at different stages of assembly and, therefore, cumulatively would provide a 
wider perspective of the effects of the absence of essential splicing factors. In 
the AID system, addition of auxin to the medium allows the heterologous 
plant Tir1 protein to direct the AID-tagged target for proteasome degradation. 
There are many variants of the AID tag. I used the AID*-6FLAG (Morawska 
and Ulrich, 2013).  AID-tagged strains Prp16, Prp22 and Prp45 derive from 
YGM1 and Prp4 derives from YBRT1. The differences between YGM1 and 
YBRT1 are explained in more detail in Chapter 4. Based on the time course 
Protein Size (kDa) Protein levels after 30
min. of auxin addition
Prp45* 58 6% ± 0.4
Prp22* 145 6% ± 0.5
Prp16* 137 7% ± 0.2






depletions described in Chapter 4, most analyses presented in this chapter 
were at 30 minutes after auxin addition. At that time, pre-mRNA abundance 
has stabilized at its highest level. 
 
Using RIP to measure changes in the balance of intermediate complexes of the 
spliceosome 
 
To test whether intermediate complexes of the spliceosome accumulate when 
Prp4, Prp16, Prp22 or Prp45 is depleted, I performed RIP. This was done by 
pulling down Lea1 (U2 snRNP) and then measuring assosociated snRNAs 
(released from the beads) by RT-qPCR. In normal conditions, a RIP assay 
results in U2 interacting with U1 and U4 at low levels, but more with U5 and 
U6 (Figure 3.3A). The changes in the level of association between U2 and the 
other snRNPs, can show if complexes are accumulating and if so, helps to 
indicate which intermediate complex accumulates, if the composition is 
relatively homogeneous.  
 
Depletion of Prp4 increases association of U2 with U1 and decreases association of 
U2 with U5 and U6, relative to undepleted 
 
Prp4 is a component of the U4 snRNP and is required for tri-snRNP 
recruitment (Lygerou et al., 1999), which allows the pre-spliceosome to 
transition to Complex B. As expected, when Prp4 is depleted I observe that 
association of Lea1 with U1 is increased, and its association with U4, U5 and 
U6 snRNA decreases, relative to undepleted culture (- auxin) (Figure 3.3B). 
This suggests that without the recruitment of the tri-snRNP, spliceosome 
assembly is stuck at the pre-spliceosome stage, which contains U1 and U2 but 






Depletion of Prp16 reduces association of U2 with U4 and increases association of 
U2 with U5 and U6, relative to undepleted 
 
After the first catalytic step of splicing, the spliceosome undergoes structural 
rearrangements that set the stage for the second catalytic splicing reaction. 
These intermediate complexes, between the first and second step, are called 
Complexes C and C* (catalytically activated). Prp16 is recruited at this stage 
and plays a role in the second step of splicing. Interestingly, when Prp16 is 
depleted, I observe that association of Lea1 with U1 and U4 is decreased and 
its association with U5 and U6 snRNAs is increased relative to undepleted 
(Figure 3.3B), which agrees with an accumulation of Complex C that contains 
U2, U5 and U6 but not U1 or U4 snRNAs (Table 3.1).  
 
Depletion of Prp22 increases association of U2 with U5 and U6, relative to 
undepleted 
 
Prp22’s main role is the release of the mRNA after splicing completion, with a 
proposed additional (ATP-independent) role in the second step of splicing for 
some genes (Schwer and Gross, 1998). This splicing factor is recruited to 
complex C* (Fica et al., 2017), which contains U2, U5 and U6 snRNP. When 
depleting Prp22 I observed that association of Lea1 with U5 and U6 snRNA is 
increased relative to undepleted (Figure 3.3B), almost to the same extent as 
seen with depletion of Prp16. This suggests that, like depletion of Prp4 and 
Prp16, depletion of Prp22 results in accumulation of an arrested complex. The 
lack of decrease in U2’s association with U4 snRNA, in contrast to depletion 








RIP analysis of Prp45 depletion  
 
The nineteen complex, and possibly also Prp45 (Makarov et al., 2002), is 
reported to join complex B, stabilizing complex B* when U1 and U4 snRNPs 
leave (Tarn et al., 1993). When depleting Prp45, I observe smaller changes in 
the association of U2 with the other snRNAs, compared to the other strains. 
Although this RIP profile does not clearly point to the accumulation of any 
specific intermediate complex (Table 3.1), it may reflect a mild accumulation 







Figure 3.3. Intermediate complexes of the spliceosome accumulate in the 
absence of splicing factors. 
(A) RIP assay where Lea1-3HA was pulled down and from the beads U snRNAs were 
measured by RT-qPCR. Data is presented as signal relative to U2 snRNA, to correct for 
differences in pull-down efficiencies. 
(B) RIP assays as in (A), before and after depletion of Prp4-AID*-6FLAG, Prp16-AID*-6FLAG, 
Prp22-AID*-6FLAG or Prp45-AID*-6FLAG. Data are presented as changes relative to 





Table 3.1. Predicted change in Lea1 (U2) interaction with  
U1, U4, U5 and U5 snRNAs (by RIP) when intermediate  









The conclusion from the RIP data  
 
Overall, I conclude that intermediate complexes of the spliceosome 
accumulate in the absence of splicing factors Prp4, Prp16 or Prp22, which 
suggests that proper disassembly does not happen when essential splicing 
factors are missing. The following question is whether the depletions also 
affect new rounds of spliceosome assembly. In other words, does the 
disassembly defect cause a recycling defect?    
 
Pre-spliceosome formation is inhibited when depleting Prp4, Prp12, Prp22 or 
Prp45 
 
ChIP as a measure of spliceosome assembly 
 
Since it was demonstrated by ChIP that splicing happens co-transcriptionally 
(Görnemann et al., 2005; Kotovic et al., 2003; Tardiff and Rosbash, 2006), this 
technique has been used many times to analyse snRNP recruitment in vivo. 
The concept of co-transcriptionality dictates that spliceosome components can 
only be ChIPed to the DNA while they are assembled on newly synthesized 
pre-mRNAs. Therefore, this technique can be used as a proxy for newly 
assembled spliceosomes. From now onwards, frequently I will use the term 
spliceosome assembly or pre-spliceosome formation instead of co-
transcriptional spliceosome recruitment.  
 
A characteristic of this technique is that different splicing factors may produce 
different gene occupancy profiles. The earlier the splicing factor is recruited to 
the transcript, the more 5’ the ChIP signal occurs on the gene. Hence, splicing 
factors crosslink to DNA sites that indirectly correlate with residence within 





As a measurement of assembly of the spliceosome, I performed ChIP on core 
splicing factors Prp40 (U1 snRNP) and Lea1-3HA (U2 snRNP), and qPCR on 
intron-containing genes ACT1, ECM33 and RPS13. U1 and U2 snRNPs are the 
main components of the pre-spliceosome, one of the earliest intermediate 
complexes at the start of the spliceosome cycle. Thus, this combined ChIP 
analysis will indicate whether early spliceosome assembly is affected when 
depleting Prp4, Prp16, Prp22 and Prp45.  
 
Depletion of Prp4 reduces ChIP occupancy of U1 and U2 
 
On normal condition (no auxin), the ChIP profiles I observe are as expected, 
with Prp40 (U1) signal peaking near the 3’ss and Lea1 (U2) around the middle 
of the second exon (Figure 3.4B). The drop in U1 ChIP signal after the 3’ss 
reflects its displacement as the spliceosome cycle progresses. The profile is 
different across the different genes. This is due to the influence of several 
factors including the structure of the gene and the position of the amplicons 
along the gene. This is one reason why more than one gene was analysed. 
Interestingly, after depleting Prp4 I observe a reduced ChIP signal of Prp40 
(U1) and Lea1 (U2), on the three genes analysed (Figure 3.4B), indicating that 
formation of the pre-spliceosome is reduced when recruitment of the tri-
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Figure 3.4. Co-transcriptional assembly of the pre-spliceosome is reduced in 
the absence of splicing factors Prp4, Prp16, Prp22 or Prp45. ChIP of Prp40 (blue 
lines) and Lea1-3HA (green lines) from the U1 and U2 snRNPs, respectively, was performed 
before and after auxin-induced depletion. qPCR was done with primer for ACT1, ECM33 and 
RPS13. Data is presented as ChIP signal relative to the first amplicon of the gene (see 
Materials and Methods). The x-axis contains amplicon location within the structure of the gene. 
Solid lines represent data of undepleted (- auxin) and dashed lines of depleted (+ auxin). Error 
bars denote standard error of three biological replicates. U1 and U2 ChIP when depleting 
Prp45-AID*-6FLAG are plotted separately (E-F) since they are at different scales due to 
experimental variations. (A) Labels of the gene diagrams in the x-axis of (B-E)  (B) Depletion 
of Prp4-AID*-6FLAG (C) Depletion of Prp16-AID*-6FLAG (D) Depletion of Prp22-AID*-6FLAG 









































































Depletion of Prp16, Prp22 or Prp45 increases ChIP occupancy of U1, and reduces 
occupancy of U2 
 
In the depletion of late-acting splicing factors Prp16 or Prp22, or NTC-
associated protein Prp45, I observed a reduced ChIP signal of Lea1 (U2), with 
Prp40 ChIP signal persisting towards the 3’ end of the gene (Figure 3.4C-F). 
The change in Prp40 ChIP profile seems to be gene dependent, as Prp40 (U1) 
is pronouncedly increased on ACT1 but only slightly on ECM33 or RPS13. The 
increase in Prp40 ChIP signal is likely a consequence of the absence of U2 
snRNP. Without the progression of assembly, U1 snRNP is not displaced and 
would crosslink stronger towards the end of the gene compared to the 
untreated control. As in the Prp4 depletion, these results indicate that pre-
spliceosome formation is reduced when depleting Prp16, Prp22 or Prp45.  
 
Together, the RIP and ChIP analyses suggest that, when Prp4, Prp16, Prp22, 
or Prp45 is missing, accumulation of arrested complexes sequesters splicing 
machinery and prevents formation of new pre-spliceosomes. The following 










Figure 3.5. Depletion of Prp16 or Prp22 causes a first step of splicing defect. (A) 
Diagram of the principle behind using RT-qPCR to measure the efficiency of the first and 
second steps of splicing. Samples were analyzed before and after auxin-induced depletion of 
Prp4-AID*-6FLAG, Prp16-AID*-6FLAG, Prp22-AID*-6FLAG or Prp45-AID*-6FLAG on (B) 
ACT1, (C) RPL28 and (D) RPS13. Signal was normalized against ALG9 and data is presented 
as changes relative to undepleted (+auxin/-auxin). Error bars denote standard error of three 






Measuring splicing efficiency in vivo  
 
Splicing efficiency can be measured by RT-qPCR 
 
David Barrass (this lab) designed qPCR primers that specifically detect 5’ 
splice site (5’ss) or branch site (BS), 3’ splice site (3’ss), lariat, mRNA and exon 
(Figure 3.5A) of intron-containing genes (Alexander et al., 2010b), including 
ACT1, RPL28 and RPS13. An increase in 5’ss or BS and 3’ss abundance is 
interpreted as a defect in the first step of splicing; an increase in lariat and 3’ 
splice site abundance is interpreted as a defect in the second step of splicing; 
and a defect in mRNA release would likely result in protection of the excised 
lariat that is still in the post-spliceosome complex, from debranching enzyme 
Dbr1  (Martin et al., 2002), so in this case we will see an increase in lariat but 
not BS or 3’ss. Therefore, with this assay, one can measure the relative 
efficiency of splicing and distinguish between a first and second step defect of 
the two catalytic steps of splicing. 
 
Late-acting splicing factors, Prp16 and Prp22, are required for the first catalytic step 
of splicing in vivo 
 
After depleting Prp16 and Prp22 I observed an increase in lariat and 3’ss 
abundance of ACT1 (Figure 3.5B), which is indicative of a defect in the second 
step. It is important to remember that although Prp22’s main role is mRNA 
release, it has been proposed to have an additional role in the second step of 
splicing (Schwer and Gross, 1998) for some genes, including ACT1 – the gene 
that was analysed here. As predicted by the hypothesis, depletion of Prp16 or 
Prp22  results in a defect of the first step as well as the second step of splicing, 
as seen by an increase in BS signal; in contrast, depletion of Prp4 or Prp45 
results in a first but not a second step defect (Figure 3.5B). This is an interesting 




recruited to the spliceosome before the first step of splicing. The RT-qPCR 
analysis of two other genes, RPL28 and RPS13 (Figure 3.5B), and an exon 
normalization instead of an ALG9 normalization (Figure S3.1), overall show 
similar results as for ACT1. Overall, the results suggest that the accumulation 
of arrested complexes, caused by depletion of Prp16 or Prp22, also affects 
splicing catalysis, not only the co-transcriptional assembly of the spliceosome. 
 
Kinetic analysis of Prp22 depletion 
 
Finally, I asked how soon the recycling defect takes place after depletion of 
Prp22. One reason why addressing this question is important, is that it will 
show if it is possible to separate the direct from indirect effects of the induced 
depletion – something that is desirable in almost any knockdown experiment. 
Secondly, the result would indicate how critical is recycling for new rounds of 
splicing. By depleting Prp22, I take the direct effect as the reduced efficiency 
of the second step of splicing, which eventually feeds-back and indirectly 
affects the first step of splicing. 
 
Depletion of Prp22 quickly causes a defect in the first step of splicing 
 
To this end, I used the 4-thiouracil (4tU) technique developed by David 
Barrass, which allows the measurement of splicing efficiency of 4tU-labelled 
newly synthesised RNA (nsRNA) (Barrass et al., 2015). With this technique, I 
performed a time course analysis, of 0, 3, 6 and 12 minutes after auxin-induced 
depletion of Prp22, with a 1 minute 4tU labelling of each sample. nsRNA 
abundance was measured by RT-qPCR with primers for ACT1, ECM33; 
ribosomal protein genes RPL28, RPS13 and RPL39; and control primers for 






After depleting Prp22, on ACT1 I observed an apparent switch from a second 
step defect (lariat and 3’ss increase) to a first step defect (lariat decrease and 
branchsite increase) of splicing of newly synthesized ACT1 (Figure 3.6A). 
Interestingly, the second step defect (minute 3) of splicing is quickly followed 
by the first step defect (minute 6), with barely enough time to distinguish the 
two states.  This kinetic analysis on ACT1 agrees with the hypothesis that the 
defect in the second step of splicing is a primary consequence of depleting 
Prp22, and the defect in the first step of splicing of ACT1 (and possibly other 
genes too) is a secondary effect.  
 
The first step of splicing of other genes is affected earlier (Figure 3.6B_E). A 
first step defect (5’ss increase) with ECM33 is observed already at 3 minutes, 
slightly earlier than with ACT1. Pre-mRNA abundance (5’ss and/or 3’ss) of 
RPGs RPS13, RPL39 and RPL28 also increases but to a lesser extent (around 
1.5-fold).  However, lariat abundance of RPL28 is more affected (6-fold 
decrease at minute 12) than RPL28 pre-mRNA. In contrast to ACT1, the 
abundance of newly synthesized lariat of RPL28 does not increase before it 
drops, which could suggest that Prp22 is not required for the second step of 
splicing of this transcript or that the first step of splicing appeared so quickly 
that the phenotype associated with the second step of splicing was unresolved 
on this transcript. I conclude that depletion of Prp22 quickly causes a defect in 










































































































































Figure 3.6. Depletion of Prp22 quickly causes a defect in the first step of 
splicing. 4tU-labeled newly synthesized RNA was measured, from time-course samples of 
auxin-induced depletion of Prp22-AID*-6FLAG. RT-qPCR was done with primers for (A) 
ACT1, (B) ECM33, (C) RPL28, (D) RPS13 and (E) RPL39. Total RNA (unlabeled) was also 
analyzed from 0 and 12 minute samples. Signal was normalized against SCR1 and data is 
presented as relative to time 0. X-axis of the time course plots (left) represents minutes after 
addition of auxin. Error bars denote standard error of four biological replicates.  
 
pre-spliceosome formation is quickly reduced 
 
To complement the 4tU kinetics result, I performed an additional Prp22 
depletion time course, with ChIP of Lea1 (U2) and western blot of Prp22 
(Figure 3.7). As anticipated, on ACT1, Lea1 ChIP signal drops at the same time 
(6 minutes after auxin) as the second step defect switches to a first step defect, 
as previously shown by the 4tU RT-qPCR analysis. On ECM33, Lea1 ChIP 
signal is already reduced 3 minutes after auxin addition, which also correlates 
with the 4tU RT-qPCR assay that shows an increase in ECM33 pre-mRNA 
already at minute 3. As for ECM33, Lea1 ChIP signal on the RPGs drops very 
quickly after adding auxin, almost as quickly as Prp22 is being depleted. Prp22 
ChIP analysis on ACT1 and ECM33 confirms that after auxin addition, Prp22 

































levels of Prp22 (Figure S3.3). Taking together the 4tU and ChIP kinetics 
































































































Figure 3.7. Co-transcriptional recruitment of U2 snRNP is quickly inhibited after Prp22 
depletion.  
(A) Anti-FLAG and anti-Pgk1 western blot after auxin addition. 
(B-F) Lea1-3HA ChIP-qPCR of ACT1, ECM33, RPL28, RPS13 and RPL39 after auxin 
addition. ChIP data (blue solid line) is presented as fold over background (ALG9), and relative 
to time 0. Quantification of (A), as Pgk1 normalized and relative to time 0, is plotted in (B-F) 
as dashed green lines. X-axis represents time (minutes) after addition of auxin. Error bars 





Depletion of essential splicing factors can cause an accumulation of 
intermediate complexes 
 
The RIP data suggest that the absence of essential splicing factors can cause 
arrested spliceosomes to accumulate. This means that in vivo, these types of 
aberrant complexes that contain normal substrates but lack an essential 
splicing factor, are not properly disassembled. This is apparently in contrast 
with the proposal that defective spliceosomes are targeted for disassembly, 
mainly based on evidence that mutations in disassembly factors Spp382 
(NTR1) and Prp43 suppress the growth phenotype of prp38-1 and prp8-1  
(Konarska and Query, 2005). Taking together both analyses, it seems plausible 
that when the splicing defect is strong, as in depletion of essential splicing 
factors, if disassembly happens, it is at a rate lower than the rate of 















































splicing factor is not physiologically normal, therefore, it is not difficult to 
believe that the cell is not fully equipped to deal with this situation.  
 
The RIP data have some gaps, in part due to the limitations of the technique. 
Firstly, it must be pointed out that even though the RIP technique produces 
quantitative data, it does not provide accurate quantitative information about 
the level of accumulation of an intermediate complex, with respect to wild 
type. The RIP analysis can only qualitatively tell whether an intermediate 
complex is accumulating and can help to identify which intermediate complex 
accumulates. To give an example, in the case of depletion of Prp16 that we 
predict to accumulate complex C, association of U2 with U5 and U6 is 
increased about 2-fold relative to undepleted Figure 3.3). This does not mean 
that there is a two-fold increase in complex C abundance. In only 1 out of 8 
intermediate complexes of the spliceosomes, U2 is not in complex with U5 and 
U6. Therefore, a hypothetical large increase in the abundance of complex C 
(U2/U5/U6), relative to other complexes, may only mildly increase 
association of U2 with U5 and U6.  
 
Unlike the 4-fold reduction in association of U2 with U4 when Prp16 is 
depleted, the association of U2 with U1 and U4 is not reduced when Prp22 is 
depleted (Figure 3.3), which is different than what is predicted by the 
accumulation of a post-spliceosome (Table 3.1). It is believed that after the 
dissociation of the post-spliceosome, which contains mRNA/U2/U5/U6, the 
tri snRNP (U5/U6-U4) is reformed. However, I speculate that depletion of 
Prp22 can result in an abnormal post-spliceosome complex where U4 snRNP 
is prematurely bound to U6 snRNP to some extent. Alternatively, if Brr2 is 
sequestered, perhaps Complex B forms and dissociates, giving a normal level 
of U1, U2, U4, U5 and U6, in addition to post-spliceosome accumulation. 




observe a reduced association between Lea1 and U4 snRNA relative to 
undepleted. 
 
Alternatively, it could be that a variety of spliceosome intermediate complexes 
accumulate by depleting Prp22, in a substrate-specific manner, in such a way 
that some reduction in the U2/U4 association cancels off when looking at 
global averages. It may also be that this strain is already starting to develop a 
splicing defect (explained in Chapter 4), before auxin induction, which could 
explain why no change is observed in U4 after auxin addition. However, when 
comparing the relative level of association of U2 with the other snRNAs 
(Figure S3.2), before the addition of auxin, I do not observe that in this strain 
the U4 signal ratio is low enough to explain the lack of reduction in U4, in the 
depleted condition.   
The RIP data of Prp45 depletion may reflect a mild accumulation of Complex 
B (that contains all snRNPs) or no accumulation at all (Figure 3.3). Cryo-EM 
structural data has revealed that Prp45 adopts an extended and unstructured 
form within the spliceosome, where it interacts with many proteins (Yan et al., 
2015). Given its extended and embedded nature, it is likely that the depletion 
of this protein will cause the spliceosome to lose structural stability and fall 
apart. Considering this, it is possible that Prp45 depletion does not result in 
the accumulation of a stable and intact intermediate complex, which would 
explain the RIP result.   
 
Spliceosomes can be stalled in vitro 
 
In vitro systems are often used to stall the spliceosome at specific stages to 
individually analyse, by mass-spectrometry for example, the different 
intermediate complexes of the spliceosome. This is done by using a 




splice sites, altering the levels of ATP and/or using temperature-sensitive 
mutant proteins (Fabrizio et al., 2009; Ohrt et al., 2013; Warkocki et al., 2009).  
However, this does not automatically imply that arrested spliceosomes can 
also accumulate in vivo. For example, it is possible that known or unknown 
disassembly factors that are not essential for splicing catalysis per se, may be 
missing in in vitro extracts, allowing the spliceosome to be stalled in vitro but 
not in vivo. In this sense, the observations described in this chapter that 
intermediate complexes of the spliceosome can accumulate in vivo by 
depleting essential splicing factors suggest that this strategy can be used, as 
an alternative to in vitro systems, to enrich and then purify specific 
intermediate complexes. 
 
Depletion of Prp4, Prp16, Prp22 or Prp45 inhibit pre-spliceosome formation 
 
 
The Prp40 (U1) and Lea1 (U2) ChIP assays show that depletion of Prp4, Prp16, 
Prp22 or Prp45 inhibits co-transcriptional pre-spliceosome formation (Figure 
3.4), which suggests that knockdown of essential splicing factors, including 
late-acting splicing factors, can inhibit early spliceosome assembly. Due to the 
nature of the ChIP technique, it could be asked whether depletion affects only 
co-transcriptional assembly, allowing splicing to continue post-
transcriptionally. However, this does not seem to be the case as the RT-qPCR 
analysis of ACT1 splicing, which does not discriminate between co- or post-
transcriptional splicing, shows that depletion of late-acting Prp16 or Prp22 
causes a first step splicing defect (Figure 3.5). This implies that ChIP data do 
not represent an uncoupling of co- and post- transcriptional assembly, but 






The arrested spliceosome model: depletion of a splicing factor can cause a 
recycling defect that feeds back to pre-spliceosome formation  
 
The RIP and ChIP data support the arrested spliceosome model 
 
Together, the RIP and ChIP analyses suggest that, when depleting Prp4, 
Prp16, Prp22 or Prp45, new pre-spliceosomes are not formed because U1 
and/or U2 are sequestered in arrested spliceosomes. In the Prp4 depletion, the 
RIP data suggests that U1 and U2 snRNP are sequestered in arrested 
complexes, while the ChIP data show that co-transcriptional recruitment of 
U1 and U2 snRNP is reduced. With Prp16 or Prp22 depletion, the RIP data 
suggest that U2, U5 and U6 are sequestered in arrested complexes, while the 
ChIP data show that recruitment of U2 (but not U1) snRNP is reduced. The 
good agreement between the RIP and ChIP data argues that the arrested 
spliceosome model is the most likely explanation for the observations.    
 
Arguments against a direct role of Prp4, Prp16 or Prp22 in pre-spliceosome 
formation 
 
An alternative explanation for some of the observations, is that Prp4, Prp16 or 
Prp22 might play a direct role in pre-spliceosome formation. Although this 
“direct-role” hypothesis is tempting, there are good arguments against it that 
are well supported by published proteomic and structural data. These 
published data support the involvement of Prp4 after, but not before, pre-
spliceosome formation. Prp4 is a U6 snRNP component (Banroques and 
Abelson, 1989) that is recruited to the spliceosome, as part of the pre-
assembled tri-snRNP particle (Stevens and Abelson, 1999) that joins the 
spliceosome after binding of U1 and U2 snRNPs to the pre-mRNA to form 
Complex B. Soon after its recruitment, Prp4 and other proteins are released 
during the transition of B to Bact (Fabrizio et al., 2009). Furthermore, In vitro 




recruitment of the tri-snRNP to the pre-mRNA (Banroques and Abelson, 
1989). Recently, a CryoEM yeast tri-snRNP model confirmed these previous 
observations by showing Prp4 extensively interacting with other tri-snRNP 
proteins such as Snu13, Prp31, Prp3 and Prp6 (Nguyen et al., 2015). Therefore, 
it seems that Prp4, similar to other proteins that also containing a WD domain, 
acts as a protein platform to mediate protein-protein interactions that stabilize 
the structure of tri-snRNP (Ayadi et al., 1998). In addition,  it is possibly that, 
together with other tri-snRNP proteins also released during the B to Bact 
transition, Prp4 helps to conceal the catalytic cavity of Prp8 before the 
spliceosome is catalytically activated (Nguyen et al., 2015). As an interaction 
between U1 components and Prp4 have not been observed, nor the presence 
of Prp4 has been detected within the pre-spliceosome in proteomic analysis of 
the pre-spliceosome (Behzadnia et al., 2007), overall there is good evidence 
supporting a role of Prp4 after, but not before, pre-spliceosome formation. 
This agrees with the model that depletion of Prp4 inhibits pre-spliceosome 
formation as an indirect effect caused a recycling defect.  
 
The roles of Prp16 and Prp22 in splicing have been well studied through 
biochemical and genetic approaches. These studies demonstrated that Prp16 
and Prp22 act at late stages of spliceosome assembly, to promote the second 
catalytic step of splicing and the release of the spliced mRNA, respectively 
(Burgess and Guthrie, 1993; Cordin and Beggs, 2013; Schwer, 2008; Schwer 
and Guthrie, 1991; Semlow et al., 2016; Tseng et al., 2011; Wagner et al., 1998). 
It has been observed in vitro, however, that Prp16 can promote the first 
catalytic step of splicing, but only for transcripts that contain a mutated non-
canonical branschsite sequence (Tseng et al., 2011). As virtually all yeast 
intron-containing genes contain consensus branchsite sequences, Prp16 is not 
expected to be required directly for the first step of splicing in vivo. 




Prp22 with Complex C* and the post-spliceosome, but not with earlier 
intermediate complexes, has been confirmed by proteomic analysis (Fabrizio 
et al., 2009; Lardelli et al., 2010) and recent CryoEM modelling (Fica et al., 2017; 
Galej et al., 2016). Overall, there is good evidence supporting a role of these 
proteins after, but not before pre-spliceosome formation or the first catalytic 
step of splicing, which agrees with the model that depletion of Prp16 or Prp22 
inhibit pre-spliceosome formation as an indirect effect caused by a recycling 
defect.  
 
How to explain the combined RIP and ChIP data of Prp45 depletion 
 
The observation that depletion of Prp45 also causes reduced pre-spliceosome 
formation (Figure 3.4E) is somewhat surprising, as the corresponding RIP 
analysis (Figure 3.3) pointed to a mild accumulation of Complex B or no 
accumulation at all. If Complex B were accumulating to significant levels, 
ChIP of U1 would be reduced as in Prp4 depletion (Figure 3.4B), but this is not 
what I observed. On the other hand, the ChIP data by itself could suggest that 
Prp45 is directly required for the recruitment of the U2 snRNP, one step earlier 
than anticipated for a NTC-associated protein. However, this does not seem 
to be the case, as I don’t observe reduced association between Lea1 (U2) and 
all the other snRNAs by RIP.  
 
As discussed with the U2/U4 RIP data of Prp22 depletion, it could be that 
depletion of Prp45 causes accumulation of a mixture of intermediate 
complexes in such a way that the Lea1 (U2)  RIP analysis will give the 
appearance of no change – that is, a global mixture of intermediate complexes 
that individually produce opposite predicted profiles (Table 3.1), such as pre-
spliceosome and Complex Bact. This could be the case if Prp45 is required at 




NTC in Introduction). Although, the data are not sufficient to provide a 
satisfactory explanation for what happens when Prp45 is depleted, it is likely 
that the loss of U2 snRNP recruitment is caused by a recycling defect, as with 
the other depletions.  
 
ChIP signal of Prp40 is low before adding auxin, which is why in this case only 
the U1 and U2 ChIP plots are presented separately. ChIP of Prp40 was first 
performed on the Prp45 AID-tagged strain and was later improved before 
analysing the other AID-tagged strains. For this reason, it is likely that low 
Prp40 signal is due to a suboptimal ChIP assay. However, I cannot rule out 
that the co-transcriptional recruitment of U1 snRNP is already affected before 
adding auxin, due to a possible disruption of Prp45’s activity by the C-
terminal tag. If true, it would be interesting because it might suggest that the 
C-terminal of Prp45 is important for stable binding of U1 to the pre-mRNA.  
 
Depletion of non-RNA helicase proteins can also lead to a recycling defect 
 
It can be argued that the lack of proper disassembly is due to the absence of 
RNA helicases (Prp16 or Prp22), that have been shown to be required for the 
discard and disassembly (proofreading) of spliceosomes with aberrant pre-
mRNAs (Koodathingal and Staley, 2013). However, this argument becomes 
weak with my observation that depletion of Prp4, which is not an RNA 
helicase, also results in the accumulation of an arrested spliceosome; and that 
depletion of Prp4 or Prp45, unexpectedly reduces pre-spliceosome assembly 
(Figure 3.4). Depleting a different tri-snRNP protein, Prp3 (Figure S3.1A), 
produces a very similar RIP result as depleting Prp4, which suggests any 
defect that prevents tri-snRNP recruitment may cause accumulation of an 
arrested pre-spliceosome. Additionally, the proposed role of RNA helicases in 




with the absence of essential splicing factors as I have done. Therefore, it is 
entirely possible that the splicing proofreading machinery is not prepared to 
deal with aberrant spliceosomes that lack an essential protein. They can only 
target normal spliceosomes with aberrant pre-mRNA (e.g. a pre-mRNA with 
non-canonical splice sites). Therefore, the Prp4, Prp45 and Prp3 depletion 
results suggest that knockdown of proteins that are not RNA helicases, may 
also lead to a recycling defect. 
 
Arrested spliceosomes leading to a recycling defect has been observed before  
 
Tardiff and Rosbash (2006) showed that metabolic depletion of U5 snRNA 
leads to the accumulation of arrested pre-spliceosomes and to the reduced co-
transcriptional recruitment of U1 and U2 snRNPs. It is worth pointing out that 
they were more focused on demonstrating the in vivo step-wise recruitment of 
snRNPs than in showing how a global splicing inhibition can lead to a defect 
in the recycling of spliceosome components. In a way, my depletion of Prp4 
(Figure 3.4B) is like Tardiff and Rosbash’s U5 snRNA depletion as both 
approaches will block assembly and recruitment of the tri-snRNP. However, 
one criticism of their work is that their GAL depletion was left for 16 hours, 
therefore their observations may be a secondary effect of a prolonged splicing 
defect. For example, it may be that formation of new pre-spliceosomes was 
prevented due a reduced expression of splicing proteins that are encoded by 
intron-containing genes (like Mud1 and Smd2), as depletion of U5 snRNA 
would stop splicing globally.  
The work presented in this thesis confirms Tardiff and Rosbash’s 
observations, and extends it by showing that knockdown of late-acting 
splicing factors Prp16 or Prp22, or NTC-associated Prp45, also leads to a 
recycling defect. This means that other complexes, besides the pre-




to a recycling defect, which lead me to reason that a recycling defect is a 
common result of knocking down splicing factors. Additionally, I showed that 
spliceosome assembly can be inhibited almost immediately (3-6 minutes) after 
knocking down a splicing component, which is much earlier than the previous 
observation of 16 hours of U5 snRNA depletion by Tardiff and Rosbash. 
 
Prp16 and Prp22 are indirectly required for the first step of splicing 
 
The apparent requirement of Prp16 or Prp22 for the first step of splicing is an 
old observation. I have reproduced this observation with depletion of Prp16 
and Prp22 combined with an RT-qPCR analysis of splicing efficiency (Figure 
3.5). In 1991, Company and others observed more ACT1 pre-mRNA in in vitro 
splicing reactions when a temperature-sensitive prp22 strain was heat-
inactivated (Company et al., 1991). To explain their result, they speculated that 
defective spliceosomes are not recycled into new rounds of splicing, thus 
accumulating pre-mRNA – just like our hypothesis. A similar observation by 
the same lab (John Abelson lab), but in vivo, was presented earlier but was not 
properly discussed (Vijayraghavan et al., 1989). After Company and others 
(1991), the laboratories of Christine Guthrie and John Abelson also observed 
in vivo pre-mRNA accumulation; of RP51A, U3 snRNA and ACT1 with prp22 
cold-sensitive mutants, as well as with prp16 cs mutants (Noble and Guthrie, 
1996); and of ACT1 with heat-sensitive mutant prp22-1 (Wagner et al., 1998). 
To the best of my knowledge, evidence that supports the hypothesis that 
blocking splicing can produce a feed-back effect due to a recycling defect was 
not produced until 2006 (Tardiff and Rosbash, 2006). This issue is now 
resolved here with evidence that depletion of Prp16 and Prp22 leads to a 






A recycling defect appears quickly after depleting Prp22 
 
The U2 ChIP and 4tU kinetic analysis showed that the co-transcriptional 
recruitment of U2 snRNP and the first step of splicing are inhibited almost 
immediately after Prp22 depletion (Figure 3.6), which suggests that blocking 
spliceosome disassembly can quickly cause a recycling defect. This was 
surprising, as our expectation was that the recycling defect would appear late 
after the arrested complexes accumulate gradually over time. To the best of 
my knowledge, it is still not accurately known what proportion of the splicing 
machinery is in its free form compared to how much is within the spliceosome. 
So, this observation is interesting because it could suggest that the pool of free 
spliceosome components is small and that recycling is a rate-limiting step for 
splicing. 
 
Another observation is that the 4tU and ChIP data of RPGs do not entirely 
agree between them, in contrast with the non-RPGs ACT1 and ECM33. U2 
ChIP signal is dramatically reduced (from minute 3) on the RPGs, RPL28, 
RPS13 and RPL39 (Figure 3.7D-F); even though splicing catalysis of these 
genes appear to be only mildly affected when looking at the relative change in 
5’ss and 3’ss signal (Figure 3.6C-E). I speculate on two possible explanations 
for this. It could be that pre-mRNA degradation is relatively higher for RPGs, 
so these pre-mRNAs do not accumulate. In support of this, it has been shown 
that the abundance of pre-mRNA of RPGs is reduced in a variety of stress 
conditions, for example heat shock, glucose depletion or osmotic stress; 
probably due to stress-response mechanisms that down regulate their 
expression (Pleiss et al., 2007). Thus, it may be that the splicing defect is also 
triggering a stress response that contributes to less production of pre-mRNA 
of RPGs, through the down regulation of transcription or increased pre-
mRNA degradation. Alternatively, it could be that the co-transcriptional 




this way, the differences between the two experiments would be due to the 
different nature of the techniques. 4tU RT-qPCR measures total splicing 
catalysis and ChIP only measures co-transcriptional spliceosome assembly.  
 
The data agree with the “hungry spliceosome model” 
 
Interestingly, the kinetic results are compatible with the “hungry spliceosome 
model”, which says that pre-mRNAs compete for a limited pool of 
spliceosome components (Munding et al., 2013). This proposal is mainly based 
on evidence that blocking transcription of RPGs leads to an increase in splicing 
efficiency of other transcripts that are otherwise poorly spliced. So, if pre-
mRNAs are in excess and spliceosome assembly is a rate-limiting step for 
splicing, as their data suggest, it would predict that inhibiting spliceosome 
recycling should immediately affect new rounds of splicing, which is what I 
observe. One novel implication of this model, as pointed out by the authors, 
is that availability of spliceosome components relative to pre-mRNA 
abundance is important for gene expression regulation. In support for this 
idea, an mRNA-seq and mass spectrometry analysis of murine bone marrow 
cells discovered that for some genes, intron retention correlated with 
downregulation of core splicing factors, suggesting that this novel aspect of 
splicing regulation might exist in higher eukaryotes too (Wong et al., 2013).  
 
Can some observations be explained by an uncontrolled depletion? 
 
After the experiments reported in this chapter were completed, it was 
discovered that the Prp22 AID-tagged (YGM1 background) strain I used has 
leaky depletion. By leaky depletion I mean that Prp22 is depleted to a certain 
extent, probably to 60% of wt levels, before the addition of auxin. This is 
because the YGM1 background strain constitutively expresses OsTIR1 to very 




in more detail in Chapter 4). The main potential problem when starting off 
with less target protein, is that the changes measured may be underestimated, 
as almost all comparisons were done against the no auxin culture of the same 
strain. However, in this case it appears that this is not a problem as, in almost 
all my data, I observe a significant change when comparing induced with un-
induced cultures. In addition, Prp22 is an essential protein and no growth 
defect is observed in this AID strain without auxin (Chapter 3). However, I do 
observe a small splicing defect with no auxin. There is about 50% more lariat 
of ACT1 in the Prp22 strain compared to the parental untagged strain (Figure 
S4.2), which suggests that the phenotype after auxin-induction is greater than 
it appears when compared to no auxin, and that Prp22 is reduced to the 
minimum required for normal growth prior to auxin addition. Therefore, I 
conclude that the leakiness effect does not change the interpretation of the 
results or the conclusions. 
 
In relation to the literature 
 
An example where the arrested spliceosome model can provide an alternative 
interpretation to published data 
 
It was reported that depletion of NTC components causes accumulation of the 
free form of U4 snRNA, and concluded that this complex has an indirect role 
in U4/U6 snRNP biogenesis (Chen et al., 2006). As they also observe a 
decrease in total levels of U6 snRNA, they propose that U6 becomes unstable 
and is therefore discarded when spliceosome assembly does not progress in 
the absence of NTC. However, I suggest that, considering the arrested 
spliceosome model, there could an alternative interpretation. If absence of the 
NTC results in the accumulation of an aberrant intermediate complex that 
sequesters U6, perhaps bound to the U2 snRNA, U4/U6 snRNP recycling 




Assuming proteins are important for the stability of the U2/U6 duplex, it is 
likely that this possible increase in U2/U6 association was missed in their 
results since their total RNA extraction method involved breaking cells with 
phenol/chloroform that would have taken apart RNA-protein complexes. So, 
ruling out this possibility would require a native pulldown of U2 snRNP to 
know if its association with U6 snRNA is increased in the depletion.  
 
Is this model valid for higher eukaryotes? 
 
Is there at least some indication that the arrested spliceosome model is 
important for higher eukaryotes as it is for budding yeast? The answer is not 
obvious because it is not known whether higher eukaryotes possess more 
sophisticated quality control mechanisms that will target and disassemble 
aberrant complexes. Also, it is still not known how critical is spliceosome 
recycling in these organisms, it could be that spliceosome components are not 
limiting, as has been proposed for yeast (Munding et al., 2013). If spliceosome 
components are in excess relative to pre-mRNA abundance, it could be that a 
defect in recycling might not have a big impact on new rounds of splicing. To 
try to answer the question, within the scarce literature on the homologues of 
Prp16 and Prp22, I investigated if accumulation of pre-mRNA in the 
knockdown of these late-acting splicing factors has been observed.  
 
Interestingly, I found a report where a homozygous lethal mutation of the 
zebrafish orthologue of Prp22 (called Dhx8) was analysed (English et al., 
2012). Based on a microarray analysis, they selected 19 genes that are less 
expressed in the mutant and involved in hematopoiesis that is the focus of the 
article. Then they measured splicing of these genes using RT-PCR probes 
flanking the intron. Interestingly, in 13 out of 19 genes they observe more 




same function as the yeast Prp22 (release of spliced mRNA from the post-
spliceosome after splicing completion), this suggests that absence of Dhx8 
may be causing a feedback on the earliest stages of splicing; which means that 
the arrested spliceosome model is possibly also valid in higher eukaryotes. 
However, I do not know how many genes are less expressed in the dhx8 
mutant, as the microarray data web link found in the supplementary material 
was outdated. If only a small proportion of transcripts are less expressed 
relative to wild type, it could be that the mutation is not highly penetrant and 
only a few genes are particularly sensitive to defects in spliceosome recycling.  
 
Is there agreement between the model and data of RNAi-knockdown of splicing 
factors?  
 
There is a recent report of particular interest where all core and regulatory 
components of the spliceosome were systematically knocked down with 
RNAi in HeLa cells and the 35 alternative splicing (AS) events were measured 
with high-throughput capillary electrophoresis (Papasaikas et al., 2015). Each 
knockout condition was profiled based on the magnitude and direction of the 
changes in AS. Surprisingly, they observe that knockdown of a significant 
fraction of core splicing factors, produces changes in AS, instead of generally 
reducing splicing efficiency as one would anticipate. Next, by modelling the 
AS profile data they generated a network based on similarities between all 
possible pairs of knockdown conditions.  
 
Within the network, a big and dense cluster can be observed that contains 
most core splicing factors and most of the functional associations of the whole 
network. In contrast, splicing regulators such as SR and hnRNP proteins are 
located at the periphery of the network with few functional associations with 
other individual factors. Not surprisingly, this means that knockdown of core 




knockdown of regulatory splicing proteins, which produce distinct effects. If 
it is true that knocking down essential splicing factors often results in a feed-
back effect on the earliest stages of assembly as I propose, it is possible that 
this phenomenon is contributing to the high degree of similarities that the 
authors observe among core splicing factors.  
 
On the other hand, the big and dense cluster is not entirely homogeneous. 
Within this cluster there are sub-clusters, which tend to contain splicing 
factors that physically interact or share functions, thus they estimate that 
about half of all associations can be explained by previous knowledge. This 
means that, despite the overall similarities, knocking-down different core 
splicing factors can produce different effects on AS. Based on this surprising 
observation, the authors propose that core splicing factors have regulatory 
potential. However, at least a fraction of such differences may be due to 
differences in the efficiency of the RNAi-knockdown, as it is known that RNAi 
is generally inefficient and no evidence was presented of knockdown 
efficiency in this report. Colleagues and I have some evidence to suggest that 
a recycling defect, of the type I have observed, requires a complete knockdown 
of the splicing factor target. Therefore, it could be that if the RNAi-knockdown 
were near 100% efficient, then the differences they observed would be smaller.  
 
A recycling defect may require a complete knockdown 
 
When Isabella Maudlin and Ema Sani, members of this lab (Beggs lab), 
analysed the splicing defect of the depletion of Prp22 AID-tagged in a different 
background strain (YBRT1 instead of YGM1) by RT-qPCR, they were 
surprised to observe what appeared to be a disassembly defect but not a first 
step defect with ACT1. The data are not shown here because they do not 




to my work and it addresses an important point. At first, the result appeared 
to disagree with the arrested spliceosome model. If disassembly is blocked 
then why is there no recycling defect that inhibits the first step of splicing? The 
simplest explanation for this is that the YBRT1 strain, although is not leaky 
does not deplete as efficiently as YGM1 (see Chapter 3). After 30 minutes of 
auxin-induction, Prp22 (YBRT1) was only depleted down to 40% of normal 
levels (data of Isabella Moudlin). Therefore, it seems that splicing is not 
globally affected enough to cause a recycling defect. Satisfyingly, when auxin 
induction was left for more than 1 hour, a first step defect was now observed 
in this strain too. Overall, this suggests that only a strong splicing defect will 
cause a recycling defect. Perhaps that is one reason why disease-related 
mutations of core splicing factors do not affect splicing systematically, since 
generally in these cases the splicing defect is not highly penetrant. 
 
Concluding remarks and perspectives 
 
The results described here send a reminder that perturbing one element of a 
dynamic complex, such as the spliceosome, often cause unwanted systematic 
effects on the assembly cycle. As evidence for this, I have shown that the 
biggest effects seen with my depletions are the consequence of secondary 
effects that are not directly related to the precise function of the depleted 
factors. In addition, I have shown that the secondary effect appears almost 
immediately after depletion, suggesting that it is technically difficult to 
completely separate it from the direct effect. The take-home message is, to 
avoid misinterpreting data derived from perturbing spliceosome components, 
one should think about recycling inhibition as a possible source of secondary 
effects.  
The Prp22 depletion kinetic analyses, supports the idea that spliceosome 




splicing. Together with the “hungry spliceosome model” (Munding et al., 
2013), this supports the need to better understand the relationship between 
the availability of spliceosome components and alternative splicing. One way 
to start answering this question would be to reduce the expression level of 
recycling factors and see if this correlates with changes in alternative splicing. 
If true, this would suggest that for the cell it is important to maintain an 
adequate balance between the abundance of the spliceosome components and 
the abundance of pre-mRNA substrates, as changes in these ratios could 
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In the AID system, fusion of the gene of interest with an AID tag, allows the 
plant Tir1 protein to target this fusion protein for degradation when auxin is 
added to the medium. I observe that high expression levels of Tir1 lead to a 
fast depletion of the target protein, but also to an uncontrolled depletion 
without auxin addition, suggesting that an optimal expression level of Tir1 is 
critical. To further develop this technique, I created a new version of the AID 
system where Tir1 expression is rapidly induced by B-estradiol prior to auxin 
addition. I show that this gratuitous B-estradiol AID provides a fast depletion 
of the target protein, with low uninduced depletion. An AID system with 




Probably the most widely used strategy to study the functions of essential 
genes in vivo, is to analyze the effect of blocking their expression and/or 
activity with conditional systems (reviewed in Chapter 1). Ideally, the 
conditional system should be fast and specific, to avoid secondary and off-
target effects. The traditional conditional systems for budding yeast are 
temperature-sensitive mutants and metabolic regulation (e.g. GAL and MET 
promoters). These tools have been very useful in functional studies. However, 
they have disadvantages, including: 1) changes in temperature or growth 
medium can cause other, unwanted effects on cell metabolism, for example on 
transcription and splicing (Bergkessel et al., 2011; Kresnowati et al., 2006; 




both the mRNA transcript and the encoded protein must be turned-over 
before the phenotype is manifested.  
 
The auxin-inducible degron (AID) is a recent technique that has become 
increasingly popular mainly because it allows fast depletion of the target 
protein, the inducer is a small molecule auxin that does not perturb the cells, 
and it is easy to implement. Setting up the AID system involves 1) the 
heterologous expression of Tir1, a plant auxin-binding receptor that is part of 
the conserved E3 ubiquitin ligase complex and 2) fusion of the gene of interest 
with an AID tag (plant derived) that allows Tir1 to direct this protein for 
polyubiquitination that targets it for degradation by the proteasome 
(Nishimura et al., 2009). The AID system is described in more detail in Chapter 
1. 
 
In the original AID system for budding yeast, Oryza sativa (rice) TIR1 (OsTIR1) 
expression was driven by a GAL promoter. To avoid perturbations to cell 
metabolisms associated with the GAL system, we initially used other strains 
where OsTIR1 is under control of constitutive promoters of different strength, 
with mixed levels of success. I observed that depletion rate, and also 
uncontrolled depletion of the target protein in the absence of auxin, correlates 
with a high expression level of OsTir1, which agrees with previous 
observations in Arabidopsis thaliana (Gray et al., 1999; Dos Santos Maraschin et 
al., 2009). This indicates that constitutive expression of TIR1 in yeast is not 
ideal either.  
 
Using the novel B-estradiol expression system where transcription of a gene 
of interest is induced in a highly specific manner with no off-target effects, I 
generated a new version of the AID system for budding yeast, called B-




auxin. I show that this system does not deplete the target in the absence of 
auxin and can still quickly deplete the target protein after less than 30 minutes 
of auxin addition. An abundant target protein was also quickly depleted, 
which suggests that target abundance is not an obstacle. Furthermore, I 
constructed a centromere plasmid that contains all the elements for the B-
estradiol-mediated expression of OsTir1, and which can be introduced into a 




YGM1 strain allows fast AID depletion 
 
Selecting the AID tools to use 
 
My first aim in the lab was to generate strains for auxin-induced depletion of 
the proteins of interest. Instead of the original AID tools for yeast, GAL-OsTir1 
and IAA17 (as the AID tag) (Nishimura et al., 2009), I used newer ones that we 
believed would work better, including: 1) a codon optimized OsTIR1 for 
improved yeast expression, controlled by a constitutive promoter, to avoid the 
problems associated with the GAL expression system and 2) an AID*-6FLAG 
to easily detect the target using a commercially available antibody, and to 
avoid a big C-terminal tag that might affect the activity of the target protein. 
The AID* (IAA1771-114) (Morawska and Ulrich, 2013) is a small derivative of 









Generating the YGM1 strain and testing its depletion efficiency  
 
To generate the OsTir1-expressing strain, I integrated a StuI-digested pMK200 
(Kanemaki lab) plasmid into the ura3-1 locus of strain W303. pMK200 contains 
a yeast codon-optimized OsTIR1 under the control of a strong 689 bp ADH1 
constitutive promoter (PADH1-689) (Figure S4.1). This yeast strain was called 
YGM1. 
 
I C-terminally tagged splicing factors Prp45, Prp46, Prp22 and Syf1 with 
pHyg-AID*-6FLAG on the genome of YGM1. These proteins were selected 
because of the initial interest in studying two candidates coupling factors of 
splicing with transcription, Prp45 and Syf1, and the interaction partners of 
Prp45: Prp46 and Prp22. Afterwards, I measured their growth rate, without 
and with addition of IAA (auxin) at 0.75 mM. This allowed me to confirm that 
OsTir1 expression, auxin and the AID tags by themselves do not inhibit 
growth (Figure 4.1). The exception is the AID-tagged Syf1 strain that grew 
slower than wild-type in the absence of auxin.  Also, I observed that auxin 
addition reduces growth rate of all four AID tagged strains, which was the 
first indication that this depletion system works, as all target proteins are 
essential for growth.          
 
To test depletion efficiency, I measured the levels of the target proteins before 
and after auxin addition. First, I performed a time course western blot analysis 
of AID-tagged Prp46 and Prp22. With this, I observed that target protein levels 
dropped to around 5% within 10 minutes after auxin addition. Afterwards, I 
observed that AID-tagged Prp45 and Syf1 are also efficiently depleted, 
reaching 5% of starting levels by 30 minutes of auxin addition. The AID-
tagged Syf1 strain was not further analyzed due to its growth deficiency. The 





Through a time-course RT-qPCR analysis of splicing intermediates of ACT1 
transcripts, I measured changes in splicing efficiency when Prp45, Prp46 and 
Prp22 were depleted (Figure 4.2). With this I observed that depletion of Prp45 
results in more branch site and 3’splice site, and less lariat, mRNA and exon2 
signal of ACT1 transcripts. This is indicative of a defect in the first step of 
splicing, as expected considering that Prp45 joins the spliceosome before the 
first step of splicing (Fabrizio et al., 2009; Ohi et al., 2002). Depletion of Prp46 
shows a similar result as Prp45 depletion, except that the splicing defect seems 
milder. Depletion of Prp22 results in more branch site, 3’splice site and lariat, 
and less mRNA and exon of ACT1 transcripts, which may suggest that absence 
of Prp22 reduced the efficiency of both the first and the second step of splicing 
(Chapter 3). Accumulation of splicing intermediates appears to stabilize 
between 20 and 30 minutes after auxin addition. The results confirm that 
auxin-induced depletion of splicing factors Prp45, Prp46 and Prp22, quickly 
leads to a splicing defect.  With two additional experiments, I attempted to 
verify that the strains do not have a splicing defect without the addition of 
auxin; however, because the data generated cannot be directly compared to 
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Figure 4.1. Prp45, Prp46, Prp22 or Syf1 were depleted to low levels, using the 
auxin-inducible degron system.  
(A) Growth rate analysis of the AID-tagged strains, including the untagged parental strain 
YGM1 and wild-type W303, with (+) or without (-) auxin. * = AID*-6FLAG tag. 
(B) Abundance of AID*-6FLAG tagged proteins was measured at 0, 10, 20 or 30 minutes after 
auxin addition, through anti-FLAG LICOR-based western blotting. Relative abundance was 
calculated as the ratio of + auxin/- auxin anti-FLAG signal, normalized to anti-Gapdh signal as 
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Figure 4.2. Splicing efficiency analysis by RT-qPCR of ACT1, after auxin-
induced depletion of Prp45, Prp46 and Prp22. Time course analysis of auxin addition. 
Data were normalized to ALG9. Error bars for the Prp45-AID*6FLAG strain denote standard 
error of two biological replicates. Data of only one trial is presented for Prp46-AID*6FLAG and 
Prp22-AID*6FLAG strains.  
  
 
YGM1 has low success rate  
 
Many additional genes were later AID-tagged in YGM1 by Barbara Terlow 
and myself. Only 11 out of 21 of these strains did not grow on auxin-
containing media, even though all tagged genes are essential for growth (Table 
4.1). In contrast, all genes AID-tagged in a different background strain created 
by Barbara called YBRT1, where OsTir1 is expressed by a weak 397 bp ADH1 
promoter (PADH1-397), resulted in strains that responded to auxin but the 



































































































tagged strains, I speculated that the high strength of PADH1-689 controlling 
OsTir1 expression in YGM1 may be lethal when combined with the AID-
tagging of some genes, which may force cells to adapt by inactivating the AID 
pathway.     
 
The B-estradiol AID allows fast and tightly-controlled depletion 
 
To investigate the relationship between Tir1 expression level and a possible 
uncontrolled depletion of the target protein, and at the same improve the 
current AID system for yeast, I constructed a new strain (YZTR41), where 
OsTir1 is only expressed when adding B-estradiol to the medium (Figure 4.3). 
This variation of the AID system was named B-estradiol AID. The B-estradiol 
expression system (McIsaac et al., 2013), is composed of an artificial promoter 
(PZ4EV) that is specifically activated by its Z4EV artificial transcription factor 
(ATF) bound to B-estradiol. It should be noted that I added an N-terminal 
nuclear localization signal (NLS) to this OsTIR1 gene, although it is not 
expected it to be important, as it was previously shown that the addition of an 
























Figure 4.3. Illustration of the principle behind the B-estradiol auxin-inducible 
degron (B-estradiol AID). Key to this system, is that rice Tir1 (OsTir1) is only expressed 
when B-estradiol (McIsaac et al., 2013) is added to the media. Therefore, depletion of the AID 
target requires the addition of two inducers, B-estradiol and auxin. 
(1) The presence of B-estradiol allows the Z4EV artificial transcription factor to be translocated 
to the nucleus, where it specifically binds the Z4EV artificial promoter (PZ4EV). (2) This 
activates transcription of the downstream gene OsTIR1, a component of the E3 ubiquitin 
ligase complex (SCR).  (3) When auxin is present, it binds OsTir1 and this allows the 






























OsTIR1 expressed to high levels causes uncontrolled depletion 
 
To test the system, first I AID-tagged Yhc1 (U1) splicing factor in the B-
estradiol AID strain (YZTR41). Then I performed a western blot time course 
after B-estradiol addition (Figure 4.4) without auxin. OsTir1 is first detected 
20 minutes after B-estradiol addition and its signal continuously increases, 
reaching levels of 280 times above background at 120 minutes, which 
demonstrates that the product is quickly and strongly expressed after 
induction. As predicted, AID-tagged Yhc1 levels inversely correlated with 
OsTir1 levels. Ych1 signal drops to 30% of its initial value 120 minutes after B-
estradiol addition. Interestingly, I do not observe Yhc1 levels significantly 
reduced (below 90%) during the first 20 minutes, the time during which 
OsTir1 is not detected. This demonstrates that, even in the absence of auxin, 









































































Figure 4.4. When Tir1 is expressed to high levels, the AID-tagged protein is 
depleted even in the absence of auxin.  
(A) A time course western blot analysis of B-estradiol induction of OsTIR1-V5. OsTir1-V5 and 
Yhc1-AID*-6FLAG were probed with anti-V5 and anti-FLAG antibodies using LICOR system. 
Protein signal was normalized against anti-Pgk1.  
(B) Quantitation of (A). Data are presented as relative to the highest value. 
(C) A time course western blot analysis where auxin was added to the cultures 30 minutes 
after addition of B-estradiol. 




Adding auxin at the right time allows a fast and controlled depletion 
 
To test the auxin-induced depletion efficiency of the system, I performed an 
additional time course analysis where auxin was added after B-estradiol. To 
achieve the fastest depletion possible, the idea is to give enough time for 
OsTIR1 levels to build up and then add auxin, before the target protein level 
starts to drop. Based on the previous results (Figure 4.5), I decided to add 
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initial level (time 0 of B-estradiol addition). However, at the time auxin was 
added, Yhc1 was at 85% of initial level, which means that auxin should be 
added slightly sooner, ideally before target levels drop below 90%. 
 
Afterwards, two additional proteins were AID-tagged, Prp22 and exosome 
component Rrp44. As with AID-tagged Yhc1, two sequential time course 
analyses were performed, the first with B-estradiol-only (to optimize timing) 
and the second with addition of auxin after B-estradiol (to test depletion 
efficiency). Based on the results of the first time-course (Figure 4.5), I decided 
to add auxin 20 and 40 minutes after B-estradiol to Prp22 and Rrp44 AID-
tagged cultures, respectively. At the time of auxin addition, Prp22 and Rrp44 
levels are 95% and 88% of initial values respectively, almost within the 
acceptable range. After 15 minutes of auxin addition, Prp22 and Rrp44 levels 
quickly dropped to 11% and 4% respectively. Together, the results 
demonstrate that by optimizing the time of auxin addition relative to B-
estradiol addition, one can achieve a fast and controlled depletion of the target 







Figure 4.5. Prp22 and Rrp44 are quickly depleted by the B-estradiol AID. 
(A) Western blot analysis on Prp22 and Rrp44 AID*-6FLAG tagged Z4TR41 strains after B-
estradiol addition. Data are presented as anti-FLAG signal relative to time 0 and Pgk1-
normalized (relative abundance). 
(B) As in (A) but auxin addition 20 and 40 minutes after B-estradiol addition, on cultures of the 
Prp22-AID*-6FLAG and Rrp44-AID*-6FLAG strains, respectively. 
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A quick depletion requires high expression levels of OsTIR1 
 
Finally, I compared the B-estradiol AID strain YZTR41, with the previous AID 
strains than constitutively express OsTir1, YGM1 and YBRT, through a time 
course depletion of AID-tagged Prp22 (Figure 4.7). The first observation to 
note is that OsTir1 is dramatically more abundant in YGM1 than in the other 
strains; it was not even detected in YBRT1. Secondly, without auxin Prp22 
abundance is at similar levels in YBRT1 and YZTR41 but about 40% lower in 
YGM1. This shows that an uncontrolled depletion is also observed on AID 
strains that grow and splice well, like this AID-tagged Prp22 YGM1 strain. 
Thirdly, by 30 minutes of auxin addition, Prp22 levels dropped to 4% and 11% 
in YGM1 and YZTR41, but only to 75% in YBRT1, relative to normal levels. 
Together, these observations suggest that a quick depletion requires high 
levels of Tir1, and that a controlled and efficient depletion of the target protein 




























































Figure 4.7. B-estradiol AID (YZTR41 strain) allows fast and controlled depletion of the 
target protein. Depletion efficiency and starting values of Prp22-AID*-6FLAG were compared 
between B-est AID strain YZTR41 (PZ4EV-OsTIR1), YGM1 (PADH1-689-OsTIR1) and YBRT1 
(PADH1-397-OsTIR1). 
(A) A time course western blot analysis of auxin induction. B-estradiol was added 20 minutes 
before auxin on cultures of the B-est AID strain, YZTR41.  
(B) Quantitation of (A). Data are presented as raw values/1000.  Error bars denote standard 
error of two biological replicates. 
 
A new plasmid containing the B-estradiol TIR1 components 
 
The current B-estradiol AID strain has two inconveniences. The first is that 
transferring all components to a different background strain would require at 
least two transformation steps of homologous recombination, which is 
inefficient. The second is that it may not be possible to make further 
modifications to the current strain, as most selection markers are already used, 
only ura and leu are available. To solve this, I cloned the PACT1-Z4EV ATF and 
PZ4EV-OsTIR1-V5 constructs, into a plasmid containing a centromere self-
replicating origin (CEN6/ARS) and a LEU2 marker (Figure 4.6). This plasmid 
will allow the quick incorporation of the B-estradiol AID components into 
almost any budding yeast strain. Unlike YZTR41, in this plasmid OsTIR1 lacks 
NLS at its N-terminus (see above). Due to lack of time, I could not test this 
plasmid. Fortunately, Isabella Maudlin (Beggs lab) has successfully used it to 

























































new versions of it with different markers, increasing even further the 




Figure 4.6. Map of plasmid pZ4-TIR1-CEN-LEU. It can be used for the B-estradiol 














High auxin concentrations inhibit growth on minimal media 
 
Members of the Tollervey lab observed that auxin (IAA) at 750 uM, the 
concentration that we routinely used, inhibits growth on CSM recipe of yeast 
minimal media (YMM). Thus, before performing experiments that required 
growing cells on YMM, I attempted to reproduce their result and to titrate 
auxin down to non-detrimental levels. 
 
With a spotting assay, I evaluated the growth of W303, YGM1, PRP22-AID*-
6FLAG (YGM1) and PRP9-AID*-6FLAG (YBRT1) strains on Kaiser or CSM 
recipes of YMM. AID-tagged strains were included in the analysis as a 
negative control for growth. I observed that non AID-tagged strains grew less 
well on Kaiser YMM with 750 uM of auxin (IAA) (Figure 4.8A). In contrast, no 
growth was observed on CSM YMM with the same high concentration of 
auxin (Figure 4.8B). This suggests that the apparent toxic effect of auxin is 
related to nutrient content in the media, as the CSM mix has fewer and less 
nutrients than Kaiser. I then performed an additional spotting assay with a 
range of auxin concentrations (7.5, 30, 75 and 750 uM) on 2x Kaiser YMM 
(Figure 4.8C). I used 2x instead of 1x Kaiser with the hope that an increase in 
the amount of nutrients would decrease even further the inhibitory effect on 
growth. With this, I observed no difference in growth between no auxin and 
75 uM or lower of auxin. A growth rate analysis of YGM1 and PRP22-AID*-
6FLAG strains on 2x Kaiser YMM broth confirmed that addition of 75 uM by 







Figure 4.8. A low auxin concentration (75 uM) does not inhibit grown on Kaiser 
(2x) YMM 
(A) Cells of W303, YGM1, PRP22-AID*-6FLAG (YGM1) and PRP9-AID*-6FLAG (YBRT1) 
strains, were spotted on agar containing Kaiser YMM without (-) or with 750 uM of auxin (IAA) 
(B) As (A) but on CSM YMM 
(C) As (A) but on Kaiser (2x) YMM without (-) or with 7.5 - 750 uM of auxin (IAA) 
Assays from different panels were produced on different days 
(D) Growth rate of YGM1 and PRP22-AID*-6FLAG (YGM1) on Kaiser (2x) YMM were 
measured without (-) or with 75 uM of auxin (+) 
 
 
Finally, I investigated whether depletion is as efficient when adding low 
amounts of auxin, as when adding the usual high amounts. In cultures grown 
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auxin addition, and observed that Prp22 levels are similar when adding 30, 75 
or 750 uM of auxin. I therefore conclude that addition of 75 uM of auxin (IAA) 
leads to the efficient depletion of AID-tagged Prp22 (Figure 4.9). Overall, the 
results suggest that it is important to induce with only the minimal amount of 
auxin to avoid possible secondary effects associated with the growth 




Figure 4.9. Addition of 750, 75, or 30 uM of auxin lead to similar depletion efficiencies 
of Prp22 (2x Kaiser YMM) 
(A) Prp22-AID*-6FLAG (YGM1) abundance at 0, 6 and 12 minutes after adding 30, 75 or 750 
uM of auxin (IAA) 
(B) Quantitation of (A). Data are presented as Pgk1-normalized, relative to time 0. Error bars 


































































High TIR1 abundance leads to fast but uncontrolled depletion 
 
It was previously suggested that Tir1 is a rate-limiting factor of auxin response 
in Arabidopsis thaliana. This was based on observations that over-expression of 
Tir1 leads to an auxin-response phenotype (Gray et al., 1999) and depletion of 
Tir1 substrates (Aux/IAA proteins) (Dos Santos Maraschin et al., 2009), even 
without exogenous auxin. It is likely that the endogenous plant auxin is 
mediating the Tir1 induced auxin-response the authors observed.  
 
Here I present evidence that confirms that, in the transgenic plant-derived 
AID system of budding yeast, Tir1 is also a rate-limiting factor, and that the 
target protein may be depleted without auxin addition when Tir1 is expressed 
to high levels, as seen in plants. This does not imply that Tir1 can bind its 
target in the absence of auxin. It could be that uncontrolled depletion is 
mediated by residual auxin in the growth media and/or endogenous auxin 
(IAA), as evidence suggests that budding yeast can synthesize IAA (Rao et al., 
2010). Therefore, it is possible that using minimal media instead of rich media 
can help to reduce uncontrolled depletion, as the former does not contain 
yeast extract.   
 
Why does YGM1 have a low success rate? 
 
Strains generated by AID tagging essential genes on YGM1 fell into one of 
three categories according to their growth phenotype (Table 4.1). In the first 
category, strains grew normally without auxin and slowly after auxin addition 
(for example, AID-tagged Prp45, Prp16 and Prp22) which is the expected 
phenotype. In the second, growth was normal even after auxin addition (for 




without auxin and slower after auxin addition (for example, AID-tagged Syf1 
and Prp3).  
 
The recent evidence linking OsTIR1 expression levels with uncontrolled 
depletion (Figure 4.4), can now explain why many of these AID-tagged strains 
do not respond to auxin (second category). It seems that the process of AID 
tagging certain genes is lethal and thus creates a strong selective pressure for 
a compensatory mutation or, more likely, the ejection of the pMK200 from the 
genome, which would break the AID pathway and uncontrolled depletion 
and therefore allow the cells to grow. In agreement with this, we generally 
observed that a low transformation efficiency (data not shown) coincided with 
a lack of growth inhibition when adding auxin.  
 
As for the third category, it seems that in some cases the degree of un-induced 
depletion may not be high enough to kill the cells, but enough to negatively 
affect growth rate. This could be the case of AID-tagged Syf1 (Figure 4.1). 
Before auxin addition, AID-tagged Syf1 strain grows slower than wild-type. 
Although it appears that AID-tagged Syf1 is less abundant than AID-tagged 
Prp45, Prp16 and Prp22 proteins, this does not necessarily suggest that the 
levels of AID-tagged Syf1 are already reduced even without auxin addition. 
One reason for this is that these AID-tagged proteins were probed and 
scanned separately, on different days. Therefore, one cannot reliably compare 
protein levels across the images, due to technical variations of the assay and 
differences in the brightness adjustments of the images.  
 
Overall, the data suggests that the degree of un-induced depletion is protein 
dependent, and/or that cells can grow well even with low amount of some 
essential proteins. It could be that even the AID-tagged strains (YGM1-




category), may partially deplete the target even before auxin addition. An 
example of this is AID-tagged Prp22 (YGM1). Considering this, it may be 
useful to investigate if levels of AID-tagged Prp45, Prp46 or Syf1 are already 
reduced before adding auxin, as the case of AID-tagged Prp22. This would 
require generating a new set of strains where the proteins of interest are 
tagged with 6FLAG, lacking the AID* domain, or AID*-FLAG tagging into the 
genome of a strain that does not express OsTir1. However, I decided not to 
pursue this, because it did not seem to be a high priority experiment that might 
affect my main conclusions.     
 
The B-estradiol AID system  
 
An ideal induction system should be gratuitous, tightly controlled and fast. 
The original yeast AID based on GAL-OsTIR1 (Nishimura et al., 2009) 
presumably does not have the problem of uncontrolled depletion without 
auxin, as OsTir1 expression is only induced before auxin addition. However, 
this system is not ideal because it perturbs cell metabolism due to the shifts in 
medium nutrients (from glucose to galactose). Here I have shown that the 
constitutive expression of Tir1 is not ideal either, because a strong promoter 
may lead to uncontrolled depletion (e.g. the YGM1 strain) and a weak 
promoter may deplete inefficiently (e.g. the YBRT1 strain) (Figure 4.7). In 
principle, one may find a constitutive promoter of intermediate strength that 
expresses OsTir1 at optimal levels for a certain target. However, it is likely that 
the optimal OsTir1 level depends on the abundance of the target protein, as 
my observations suggest (Figure 4.5). Furthermore, observations by Isabella 
Maudlin suggest that even the very low expression levels of OsTir1 in YBRT1 






I showed that the gratuitous B-estradiol expression of OsTir1 solves the issues 
of the previous AID systems, as it allows for a fast and controlled depletion of 
the target protein (Figure 4.7). An additional advantage of this system is that 
the time between B-estradiol and auxin addition can be tuned according to the 
abundance of the target protein. More abundant targets may require a longer 
time of B-estradiol pre-incubation, which will lead to higher OsTir1 
abundance and therefore higher depletion efficiency. This feature is not only 
useful for abundant targets but also to specifically modulate depletion speed. 
In most cases the fastest depletion is better, but there are situations where a 
gradual depletion of the target is desirable, as it has been suggested that 
different degrees of depletion can produce different outcomes (see discussions 
in Chapter 3).   
 
Why does auxin at high concentrations inhibit growth? 
 
There are at least two possible reasons why cells grow slowly on YMM 
containing high concentrations of auxin (IAA). An interesting and recent 
report, shows that auxin induces adhesion and filamentation in budding yeast 
– morphological changes associated with plant infection, which suggests that 
yeast can perceive and respond to auxin (Prusty et al., 2004). In relation to this, 
growing evidence indicates that the plant/yeast phytohormone signalling is 
bidirectional, as it has been shown that yeast can synthesize a variety of plant 
hormones including auxin, reviewed by (Chanclud and Morel, 2016; Fu et al., 
2015). Prusty and others (2004) also observed that auxin at high concentrations 
inhibits cell growth, and that the expression profile of cells treated with sub 
inhibitory concentrations of auxin (100 uM) is distinct to that of cells exposed 
to diverse environmental stress conditions. So, based on the literature it seems 




auxin-induced response of yeast while infecting plants, as discussed by the 
authors. 
 
Alternatively, it is possible that auxin at high concentrations interferes with 
yeast metabolism. Auxin is structurally similar to its precursor amino acid, 
tryptophan. Based on this, it may be that an excess of auxin competes with the 
biochemical reactions of tryptophan (e.g. misincorporation into proteins). The 
inverse correlation between the richness of the medium and the degree of 
growth inhibition at high auxin concentrations agrees with this; growth was 
more inhibited in CSM YMM (50 mg/L Tryptophan) than in Kaiser YMM (76 
mg/L Tryptophan) medium (Figure 4.8); in contrast, no growth inhibition was 
observed in YPDA. Although this idea is speculative, it would not be 
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Prp22 is a spliceosomal RNA helicase that contributes to splicing fidelity by 
proofreading exon ligation. To better understand the function of Prp22 in 
splicing fidelity, I globally measured splicing errors in the absence of Prp22 or 
its helicase activity, using the B-estradiol auxin-inducible degron (AID), 
combined with high depth RNA-sequencing. Through this analysis, I 
generated preliminary data to suggest that highly expressed genes compete 
better for splicing factors, when they become limiting due to a splicing defect. 
Secondly, I show that absence of Prp22 or its helicase activity leads to 
proportionately more errors in 3'ss selection, which demonstrates that Prp22 
is required for proper 3'ss selection of transcripts of endogenous genes in vivo. 
In summary, this chapter presents promising preliminary data that will be 
analysed in more depth on ongoing studies. The expectation is that the 





Splicing fidelity is important, as incorrect splicing of a gene transcript can lead 
to its reduced expression, or to its translation into an aberrant protein that may 
be toxic to the cell. It was proposed that splicing fidelity is influenced by 
spliceosomal RNA helicases, including Prp16, Prp22, Prp43 and Prp5, as a 
secondary role mechanistically associated to their main role in triggering 
structural transitions throughout the spliceosome cycle. The current model 
suggests that these RNA helicases promote splicing fidelity by rejecting 




Prp22's main role is to release the spliced mRNA from the post catalytic 
spliceosome and, in addition, evidence suggests that it proofreads exon 
ligation by rejecting sub-optimal 3' splice sites through the same RNA 
unwinding mechanism that releases spliced mRNA.  
 
Although our understanding of splicing proofreading has advanced 
significantly, there are many important mechanistic details that are waiting to 
be uncovered. One interesting question that has not been fully answered is, 
how does the spliceosome distinguish between the canonical splice site and a 
potentially competing sub-optimal splice site?   
 
As previous reports are mainly based on in vitro systems containing artificial 
pre-mRNAs with non-consensus splice sites or chemically modified snRNAs, 
a global in vivo analysis has the potential to provide new insights. To try to fill 
this gap, I performed an RNA-sequencing analysis to measure the frequency 
of splicing errors in the absence of Prp22 or its helicase activity. The main goals 
were to 1) confirm the requirement of Prp22 for proper 3’ splice site selection 
and 2) to identify possible substrates subject to Prp22-dependant rejection. In 
wild-type I detected around 180 aberrant 3’ splice sites (consistent with 
previous reports), and observed that about 20% of these are significantly more 
frequent in prp22 mutants compared to wild-type. The data will be analysed 
in more depth in ongoing studies to try to better understand how Prp22 











Swapping expression of wild-type Prp22 for mutants of Prp22 
 
The experimental approach was to analyse three conditions: 1) depletion of 
Prp22, 2) depletion of Prp22 with the simultaneous induced expression of 
ATPase-deficient Prp22 mutant T757A or 3) simultaneous induction of 
ATPase-hyperactive Prp22 mutant I7564. All strains are upf1∆ and therefore, 
deficient in non-sense mediated decay (NMD). For simplicity, I will often refer 
to these strains (conditions) as ∆22/-, ∆22/T757A and ∆22/I764A, 
respectively. Both mutants lack RNA unwinding activity (Schneider et al., 
2004), which was observed to be important for rejection of non-consensus 3'ss 
(Mayas et al., 2006). I included these mutants in this study to 1) determine 
whether the in vivo role of Prp22 in splicing fidelity is related to its RNA 
unwinding activity and 2) to avoid a possible inhibition of the second catalytic 
step of splicing, as it has been proposed that Prp22 has an ATPase-
independent role in the second catalytic step of splicing on some gene 
transcripts (Schwer and Gross, 1998).   
 
The strains ∆22/T757A and ∆22/I764A that express Prp22 mutant proteins 
were generated by transforming a B-estradiol AID strain (YZTR41) that is 
Prp22 AID-tagged (∆22/-), with a centromeric plasmid (Figure S5.2) 
containing the T757A or I764A mutant alleles under the control of the B-
estradiol-regulated artificial promoter PZ4EV (Figure 5.1). I tested the three 
different conditions by performing a western blot time-course analysis. At 
time 0, B-estradiol and auxin were added simultaneously to achieve a gradual 
depletion, as it is likely that this would allow more time for the spliceosome 
to make fidelity mistakes before the first step of splicing is inhibited as a 




Through this assay, I verified that wild-type Prp22 was efficiently depleted in 
the three strains, and at a slower rate than in the previous experiment, where 
I added auxin 20 minutes after B-estradiol (Chapter 4 Figure 4.7). In this new 
experiment, 15, 30 and 45 minutes after addition of the inducers, Prp22 levels 
were reduced to about 80%, 30% and 10% of normal levels, respectively. Also, 
I observed that the Prp22 T757A and I764A mutant proteins were produced 
quickly, reaching detectable levels at 15 minutes and about 6 or 10 times more 
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Figure 5.1. The B-estradiol AID system is used to simultaneously induce 
gradual depletion of WT Prp22, and express Prp22 helicase-deficient mutants. 
A) Illustration highlighting the key elements of the system. The simultaneous addition of B-
estradiol and auxin leads to expression of OsTIR1 and Prp22 mutants through the B-estradiol 
promoter (PZ4EV), and depletion of AID-*6FLAG tagged Prp22 (WT). ATPase-deficient 
mutant T757A and ATPase-hyperactive mutant I764A are both deficient in RNA unwinding. 
They are reported to allow the second step of splicing in vitro but not mRNA release from the 
post-spliceosome (Schneider et al., 2004). 
B) Time course analysis of simultaneous addition of B-estradiol and auxin to cultures of AID*-
6FLAG tagged Prp22 containing plasmids p360-mock, p360-PZ4EV-prp22-T757A or p360-
PZ4EV-prp22-I764A; hereafter these strains will be referred to as ∆22/-, ∆22/T757A and 
∆22/I764A, respectively. Extracts from cells containing plasmid p360-PRP22-V5 was added 
as a control (lanes 13 and 20).  
C) Quantitation of (B). Data is presented as Pgk1-normalized and relative to time 0 or to the 
control of lanes 13 and 20 in (B). Error bars denote standard deviation of two biological 
replicates. 
 
Prp22 mutants T757A and I764A inhibit growth 
 
I then investigated whether cell growth is affected when mutant proteins are 
expressed in combination with the wild-type. To this end, I measured the 
growth rate of strains lacking an AID tag on wild-type Prp22, and containing 
the plasmids for the B-estradiol-induction of the mutants. I observed that over-
expression of either of the mutants inhibited growth to about the same low 
level as when depleting wild-type Prp22 (Figure  5.2), which indicates that 
these mutants are semi-dominant or dominant negative but not recessive, in 
apparent contradiction to published data (Schneider et al., 2004). 
 
Loss of Prp22 RNA unwinding activity causes a first step of splicing defect 
 
I then analysed the splicing phenotype of ∆22/-, ∆22/T757A and ∆22/I764A 
strains 30 and 45 minutes after B-estradiol and auxin addition, by RT-qPCR of 
ACT1, ECM33, RPL28, RPS13 and RPL39 transcripts. I observed more lariat 
and pre-mRNA (5'ss, branchsite and 3'ss amplicons) compared to wild-type 
(Figure 5.3), as I previously observed with depletion of Prp22 in the YGM1 
strain (Chapter 3 Figures 3.5). As one mutant retains a high level of ATPase 




loss of Prp22's RNA unwinding activity, is sufficient to cause a recycling defect 
leading to a block in the first step of splicing. Generally, I observe similar 
qualitative results across the three strains. However, the ones expressing a 
mutant protein accumulate more lariat and pre-mRNA than the depletion 
only, especially at 30 minutes. This can be explained by the apparent dominant 
nature of the mutants, combined with the observation that, after B-estradiol 
and auxin addition, the protein levels of the mutants start to increase before 
wild-type levels start to drop (Figure 5.1). This difference in the degree (or 
timing) of the splicing defect should be considered for interpreting the 
following results.  
 
 
Figure 5.2. Prp22 mutant proteins, T757A and I764A, inhibit growth even without wild-
type depletion. B-estradiol and auxin were added at time 0 and optical density was measured 
every following hour on strains with induced over-expression of Prp22 wild-type (blue), T757A 
(red) or I764A (green). An AID-tagged Prp22 (purple) and a BY4741 wild-type strain (orange) 
were also included in the analysis as positive and negative controls of growth inhibition. 
 
 
In summary, these results demonstrate that 1) the WT-for-mutant swap 
technique works well and 2) that the ∆22/-, ∆22/T757A and ∆22/I764A strains 
produced the expected splicing phenotype when induced; which leads to the 






























































RNA-sequencing analysis to study splicing fidelity 
 
For RNA-sequencing, I used biological duplicate cultures treated for 45 
minutes with B-estradiol and auxin, which were previously analyzed by 
Western blot and RT-qPCR (Figures 5.1 and 5.3). This includes ∆22/T757A, 
∆22/I764A, ∆22/-, and WT that lacks the AID-tag and contains a URA3-
containing mock plasmid. Ribosomal RNA depletion, library preparation (no 
poly-A selection) and paired-end Illumina sequencing was performed by BGI 
Genomics (Hong-Kong). An average of 85 million uniquely mapped reads 
were generated per sample, out of which 0.9-1.9 million are mRNA junction 
reads (Table 5.1). Samples from mutants contain about half as many junction 
reads as WT, due to their splicing defect.      
 
         Table 5.1. Total number of mapped reads per sample 
 
 
Sample (replicate) Mapped reads* Junctions**
∆22/I757A (1) 89,855,130 903,293
∆22/I757A (2) 104,000,443 1,033,597
∆22/T764A (1) 84,386,081 910,649
∆22/T764A (2) 86,571,595 889,714
∆22/- (1) 87,701,109 1,358,104
∆22/- (2) 71,259,795 1,025,710
WT (1) 88,473,836 1,904,651
WT (2) 79,995,411 1,667,470
* Number of uniquely mapped reads





Figure 5.3. Induced expression of Prp22 helicase-deficient mutants leads to 
reduced splicing efficiency. Cell samples were prepared as in Figure 5.1. Splicing 
efficiency was analyzed at time 0, 30 and 45 minutes after induction, through RT-qPCR with 
amplicons to lariat (L), 5’ splice site (5), branch site (BS), 3’ splice site (3), mRNA (M) and/or 
second exon (E) of ACT1, ECM33, RPL28, RPS13 and RPL39 transcripts. The control strain 
(WT) contains plasmid p360-mock and is not Prp22 AID*-6FLAG tagged.  Data are presented 




Abundant transcripts appear to be less affected by the splicing defect 
 
To measure the splicing defect per gene, I divided mRNA junction reads of 
mutants by WT, which I then used to generate a clustered heatmap (Figure 
5.4A). Here, I observed a lower mutant/WT junction ratio for most intron-
containing genes, confirming that depletion of Prp22 or absence of its RNA 
unwinding activity globally inhibits splicing. This splicing inhibition is likely 
due to reduced spliceosome assembly and not splicing catalysis, as it was 
previously demonstrated that these RNA helicase mutants affect spliced 
mRNA release from the post-spliceosome, but not the second step of splicing 
(Schneider et al., 2004).  
 
Also, I observe that Ribosomal Protein Gene (RPG) transcripts are 
proportionally less affected by the splicing defect. To investigate whether this 
is due to their higher expression level compared to non-RPGs, I produced a 
correlation plot between number of junction reads in WT against the 
mutant/WT junction ratio (Figure 5.4B), as an attempt to compare "expression 
level" vs. "splicing defect". Here, I observe an inverse correlation between 
these two features, within both RPGs and non-RPGs. Therefore, it seems that 
intron-containing gene transcripts that are very abundant (with high number 
of junction reads in WT), such as most RPGs, tend to be proportionately less 
affected by a splicing defect (high mutant/WT ratio of junction reads), and 
vice versa. This complements previous evidence that RPGs are spliced 
particularly fast (Barrass et al., 2015), co-transcriptionally and efficiently 
(Wallace and Beggs, 2016) and that they compete better for spliceosome 

































































































































































Figure 5.4. Spliced mRNA is less abundant compared to WT, and genes that are 
less expressed are more affected by this splicing defect. Illumina RNA sequencing 
analysis was performed from cultures treated with B-estradiol and auxin for 45 minute as 
described previously, which includes depletion of Prp22 (∆22/-), depletion of Prp22 with 
simultaneous expression of T757A (∆22/T757A) or I764A (∆22/I764A) Prp22 mutants, and 
WT. mRNA junction reads of mutants were divided by those of WT. Data represent the 
average of two biological duplicates.  
A) Hierarchical clustering of ratios of spliced mRNA reads relative to WT. Names of non-
ribosomal protein genes (non-RPG) were labeled in red and ribosomal protein genes (RPG) 
in blue. 
B) Correlation analysis between ratios of mRNA reads relative to WT (y-axis), and mRNA 




The normal frequency of splicing errors 
 
To measure the errors in splicing, I first discarded the non-annotated splicing 
events that do not have at least 1 read on each two replicates from one 
experiment. Then, for each non-annotated junction, I obtained the splicing 
error frequency (SEF) score, which is the proportion of reads of the non-
annotated junction with respect to the number of reads of the annotated 
junction. For wild-type only, I then plotted the SEF of non-RPGs and RPGs 
separately, according to the type of splice site shift (downstream 5'ss, 
downstream 3'ss… etc) (Figure 5.5). This allowed me to confirm, as very 
recently shown by a similar splicing fidelity analysis (Aslanzadeh et al., 2017, 
in review), that normally splicing errors:  1) are mostly rare – only 77 out of 
308 non-annotated junctions have a SEF > 0.01, 2) are rarer for RPG than non-














Figure 5.5. The normal frequency of non-annotated spliced mRNAs is 
dependent on the gene category (RPG) and type of splice site shift. Here, 
a splicing error is defined as a downstream or upstream shift relative to the annotated 5’ss 
and/or 3’ss (A). The splicing error frequency (SEF) for each detected non-annotated splicing 
event (a total of 308) in WT, was calculated as the read counts of the non-annotated junction 
divided by the read counts of the annotated junction within the same gene. Data were plotted 




Depletion of Prp22 or its RNA-unwinding activity alters the frequency of 
aberrant junctions 
 
I then asked whether the frequency of splicing errors is increased in mutant 
relative to wild-type. First, as a general overview, I generated a correlation 
plot of SEF scores, ∆22/T757A, ∆22/I764A or ∆22/- against WT. Here, I 
observe that the frequency of about 1/5 of all aberrant splicing events, is 
significantly different (p-value < 0.05) in mutant compared to wild-type. 
Surprisingly, the change happens in both directions (for different transcripts 
there can be more or fewer aberrant events in mutant than in WT), which 
indicates that absence of Prp22 does not cause an indiscriminate increase in 
splicing errors. Furthermore, I observe changes in aberrant junctions that have 
low frequency error and also in the ones that have high frequency error 
(Figure 5.6), which indicates that the effect is not biased by how rare the 







Figure 5.6. Absence of Prp22 or its RNA unwinding activity changes the 
frequency of splicing errors of many non-annotated junctions. SEF scores of 
mRNA junctions in ∆22/- , ∆22/T757A and ∆22/I764A, are plotted against WT. Splicing events 
that are significantly different from WT (p-value < 0.05) are shown in red (non-RPG) or blue 
(RPG); the ones with p-values > 0.05 are shown in grey. Data represents the average of 
biological duplicates.  
 
 
Aberrant 3'ss are more frequent in depletion over wild-type 
 
To analyse the changes in splicing error frequency in more detail, I then 
plotted the ratio of SEF scores of mutant over wild-type, according to the type 
of the splice site shift (Figure 5.7). I only included the non-annotated junctions 




about 60 splicing events. Within this set, most events correspond to 
downstream shifts of the 3'ss (blue) or 5'ss (orange), or an upstream shift of 
the 3'ss (green), relative to the annotated splice sites; other types of splice site 
shifts were very rare or absent, and were therefore not included in this plot.  
 
Interestingly, I observe that many non-annotated splicing events with a 3'ss 
shift are more frequent in mutant than in wild-type (Figure 5.7A). In contrast, 
virtually none of the 5'ss shifts show this effect, which confirms that Prp22 is 
important for proper selection of 3'ss in particular. This holds true for Prp22 
depletion (∆22/-) and for the induced expression of helicase-deficient mutants 
(∆22/T757A, ∆22/I764A); although the effect is more pronounced in ∆22/-.  
 
Next, I plotted the data separately for non-RPGs and RPGs (Figure 5.7B). 
Although, I do observe that virtually all 5'ss shifts that are affected in the 
mutant belong to RPGs, this likely not unusual considering that this bias is 
also observed in wild-type (Figure 5.5). There may be a tendency of aberrant 
upstream 3'ss, but not downstream 3'ss, of non-RPG to be more affected in the 
mutant, although I do not have a reasonable explanation for this. I only 
present the data for non-RPGs and RPGs separately for ∆22/-, as I observed 






Figure 5.7. The frequency of many non-annotated 3’ss is increased relative to 
wild-type. The SEF score relative to WT (as in Figure 5.6) was calculated separately for 
mRNA junctions with a downstream (blue) or upstream shift (green) in 3’ss selection, and 
downstream shift in 5’ss selection (orange), for ∆22/T757A, ∆22/I764A and ∆22/- (A). Non-








I then compared the mutant/WT SEF ratio across strains using a clustered 
heatmap (Figure 5.8). From this analysis, it seems that the effect is mostly 
similar between the three strains, although the depletion looks slightly 
different than for the two helicase-deficient mutants. Compared with the 
helicase-deficient mutants, the depletion appears shifted towards positive 
log2 values, as observed in the previous plot (Figure 5.6).  These differences 
may be due to differences in the strength (or timing) of the splicing defect 
(Figures 5.1 and 5.3), which may indicate that a prolonged splicing defect, like 
the case of ∆22/T757A and ∆22/I764A, reduces the chances of detecting the 
rare aberrant junctions, maybe due to RNA turnover.  
 
Overall, the results demonstrate that Prp22 is required for suppression of 
many non-annotated 3'ss in vivo. The observation that, in this respect, there 
are more similarities than differences between depletion and mutants (Figure 
5.7) confirms that it is the RNA unwinding activity, and not the physical 
presence of the Prp22 protein by itself, that is important for its role in splicing 










Figure 5.8. Absence of Prp22 protein (∆22/-) or its RNA unwinding activity 
(∆22/T757A or ∆22/I764A) results in a similar splicing error frequency profile. A 
clustered heat map was generated with the SEF scores relative to WT, of the non-annotated 
splicing events that were detected in all conditions (∆22/T757A, ∆22/I764A, ∆22/- and WT).  
 
 
Top 10 hits 
 
I then selected 10 aberrant junctions, to show that there are at least a few 
aberrantly spliced transcripts that are notably affected by the absence of wild-
type Prp22, both in relative and absolute numbers. As the Prp22 depletion 
strain (∆22/-) generally showed the largest difference with respect to wild-
type, from this data set I selected 10 aberrant junctions, that have a SEF score 
> 0.05 and a fold over wild-type SEF  > 2 (and p-value < 0.05) (Figure 5.9) – 
read counts shown in Figure S5.3.  
 
One of the most dramatic cases is a junction from LSM7 transcript, where an 
alternative 3'ss was used 7 nt downstream of the annotated 3'ss. In wild-type 
conditions, this aberrantly spliced junction represents about 6% of the total 
population of LSM7 spliced mRNAs but, when Prp22 is depleted, this number 
increases to about 67%.  Another notable example is an aberrantly spliced 
mRNA of YCL002C, with a 3'ss shift 22 nt upstream. When Prp22 is depleted 
the frequency of this splicing event changes from about 33% to 203%, relative 
to wild-type.  
 
In all top 10 aberrantly spliced transcripts, as in most non-annotated spliced 
transcripts, frameshifts in the coding sequences introduce stop codons, and 
they would therefore be targeted for NMD. This supports the idea that both 
the splicing machinery and RNA degradation proteins, contribute to the 
quality control of spliced mRNAs, as part of a tier-two strategy (Egecioglu and 




the splicing proofreading mechanism are targeted for degradation in the 
cytoplasm, ensuring that only accurately spliced transcripts are translated. 
 
 
Figure 5.9. Top 10 non-annotated spliced junctions. 10 non-annotated junctions were 
selected for having a high frequency (SEF > 5%) and the largest increase in frequency relative 
to WT [(∆22 SEF) / (WT SEF)]. * SEF values with statistical significant difference against WT 





How to study the role of Prp22 in splicing fidelity in vivo? 
 
It is not trivial to study the role of Prp22 in splicing fidelity in vivo. Firstly, its 
role in fidelity is associated with its RNA unwinding activity, which is 
essential for cell viability. Therefore, it may not be not possible to generate a 
mutant allele of Prp22 that has lost its function in splicing fidelity while still 
conserving normal function of releasing the spliced mRNA from the post-
0 5 10 15 20 25
SEF as %
SEF fold over WT
GIM5 up-3ss 22 1 19 4 13*
RAD14 up-3ss 13 3 10 7 31*
LSM7 down-3ss 7 6 23* 28* 67*
HNT2 up-3ss 26 2 14 3 16*
YCL002C up-3ss 22 33 118* 350* 203*
PHO85 up-3ss 29 2 7* 15* 14*
IWR1 down-3ss 32 4 56* 43 18*
DID4 down-3ss 20 2 20* 5 9*
VPS75 up-3ss 8 10 17 19 33*
PTC7 down-3ss 10 11 29* 45* 26*































spliceosome – its canonical role in the spliceosome cycle. So, at the moment 
one cannot perturb its role in fidelity in a very specific manner. Furthermore, 
in Chapter 3 I showed that a quick depletion of Prp22 quickly inhibits the first 
catalytic step of splicing – a secondary effect that appears only a few minutes 
after the primary effect (Chapter 3 Figure 3.6). In other words, shortly after 
depleting Prp22, there is less production of newly spliced mRNAs, which 
includes the aberrantly spliced mRNAs I aimed to measure. This could mean 
that aberrantly spliced mRNAs may be difficult to detect under these 
conditions.  
 
Fortunately, my data from Chapter 3 suggest that depletion of Prp22 
accumulates arrested complexes. These complexes likely contain spliced 
mRNAs, including aberrantly spliced mRNAs. Furthermore, data generated 
by Isabella Maudlin shows that a mild depletion of Prp22 does not globally 
inhibit the first step of splicing (data not shown), which suggests that a 
gradual depletion of Prp22 may allow more time for the spliceosome to make 
mistakes, before the first step of splicing is inhibited due to accumulation of 
arrested complexes. Considering all arguments, there was good reason to 
believe that if Prp22 is required for in vivo splicing fidelity, its depletion will 
lead to more errors in splicing that are detectable by RNA sequencing. 
However, for the reasons mentioned above, it is likely that the measured effect 
is an underestimate of the full contribution of Prp22 to splicing fidelity.  
 
Swapping expression of wild-type for mutant 
 
By depleting wild-type Prp22 while inducing expression of a mutant Prp22, I 
demonstrated that the B-estradiol AID system can facilitate the study of 
mutant alleles in vivo. Alternatively, an experiment like this could have been 




and Met promoters). However, most metabolic regulation systems require 
nutrient shifts that result in pleiotropic effects and, in addition, may not be as 
fast-acting as the B-estradiol AID.  
 
This swap technique can be especially useful for studying recessive or semi-
dominant mutants that may not show the full phenotype unless the wild-type 
is absent. In the case of recessive mutants, it may be sufficient to express the 
mutant alleles under their native promoter instead of through an inducible 
promoter.      
 
Prp22 mutants behave as dominant negative  
 
As published evidence suggests that the Prp22 mutants T757A and I764A are 
recessive, based on 5-FOA plasmid shuffling (Schneider et al., 2004), initially 
I had these alleles under control of their native promoter (p360-PRP22-V5 
plasmids).  However, I observed that the expression level of these mutant 
proteins is about 10 times less than wild-type (data not shown). Based on this, 
I then constructed new plasmids by substituting the native promoter for the 
PZ4EV B-estradiol promoter, and with these I performed a growth rate analysis 
that suggests that the mutants are indeed not recessive (Figure 5.2). To explain 
these apparently contradictory observations, I speculate that the attempt to 
simultaneously express Prp22 wild-type and dominant-negative mutants 
T757A and I764A (e.g. through plasmid shuffling), may result in strong 
selective pressure to reduce expression of these toxic proteins through a 







RNA unwinding activity of Prp22 is indirectly required for the first step of 
splicing in vivo 
 
In the previous chapter I showed that depletion of Prp22 protein indirectly 
leads to a defect in the first step of splicing. Here, I complement those previous 
results by showing, through an RT-qPCR analysis, that the induced expression 
of Prp22 helicase-deficient mutants also negatively affects the first step of 
splicing (Figure 5.3). Although there is no direct evidence that these mutants 
physically associate with the spliceosome, there are good reasons to believe 
so, including: 1) although lacking RNA unwinding activity it was shown, 
through an RNA binding assay, that these mutants can bind to an RNA 
substrate (Schneider et al., 2004), 2) it was shown that a Prp22 cold-sensitive 
mutant (ATPase-deficient at restrictive temperature) physically associates 
with a stuck post-spliceosome (Lardelli et al., 2010), and 3) the apparent 
dominant nature of the T757A and I764A mutants implies that they compete 
with the WT Prp22 for binding to the spliceosome. Overall, the data suggest 
that loss of Prp22 RNA unwinding activity without loss of the protein per se, 
is sufficient to inhibit spliceosome disassembly and recycling in vivo. 
 
Abundant gene transcripts appear to be are less affected by the splicing 
defect 
 
I have observed that for highly abundant transcripts, when splicing is 
inhibited, very often the number of mRNA junctions is proportionally less 
reduced in mutants compared to WT (Figure 5.4A). This is interesting because 
it may suggest that intron-containing transcripts that are highly expressed, 
tend to compete better for splicing machinery that has become limiting – in 
this case due to absence of Prp22 function that inhibits recycling of splicing 
components. This supports the proposition that, at least in budding yeast, pre-




"hungry spliceosome" (Munding et al., 2013). It also supports the idea that 
intron-containing RPG transcripts, which are highly abundant, are spliced 
faster (Barrass et al., 2015) more co-transcriptionally (Carrillo Oesterreich et 
al., 2016; Wallace and Beggs, 2016) and more faithfully (Aslanzadeh et al., 
2017, in review). It is likely that these associations between expression level 
and many aspects of splicing efficiency are the reflection of natural selection 
favouring efficient mRNA processing of highly transcribed genes. 
  
Alternatively, there could be a different non-mutually exclusive explanation 
for this observation. Theoretically, the mutant/WT ratio of mRNA junctions I 
used as a measure of the splicing defect, depends on splicing efficiency, and 
to some extent also on the turn-over rate of spliced mRNAs. In other words, 
some spliced mRNAs that were already there before the splicing defect will 
be present at the time cell samples were taken. So, if spliced mRNA transcripts 
that are more abundant tend to be turned over at a slower rate, then it could 
be that the apparent inverse correlation between "level of gene expression" 
and "degree of splicing defect" is actually due to differences in mRNA stability 
rather than differences in their ability to compete for limiting splicing 
components. So, to discard this possibility, later on it might be useful to do a 
similar analysis as Figure 5.4B but using read counts within the intron (un-
spliced pre-mRNAs) instead of mRNA junction reads. Either way, there is no 
easy way to measure splicing efficiency without the influence of RNA 
turnover rate, except probably by isolating newly synthesized RNA through 
a fast labelling technique (Barrass et al., 2015). Therefore, although my 
observations fit well with previously proposed models, they should be 






Prp22 is important for suppression of suboptimal 3'ss  
 
Through a genome-wide analysis of splicing errors, I showed that the 
frequency of many non-annotated 3'ss is increased in the absence of Prp22 or 
its helicase activity (Figure 5.7). This is the first evidence that Prp22 is required 
for proper 3'ss selection with endogenous gene transcripts in vivo, as most 
previous studies linking RNA helicases with splicing fidelity were based on 
in vitro assays. Furthermore, I showed a few examples where absence of Prp22 
leads to a substantial increase in non-productive splicing (Figure 5.9). 
Although indirect, this is the first evidence to indicate that the role of Prp22 in 
splicing fidelity is physiologically important.  
 
As only about a fifth of all aberrant 3'ss are more frequent in mutant relative 
to wild-type, it may be that Prp22 only proofreads a particular set of 
suboptimal substrates. As mentioned above, because the fidelity function of 
Prp22 is linked to its essential role in splicing, it is likely that the measured 
splicing error is an underestimate with respect to the full contribution of Prp22 
to splicing fidelity. Therefore, it could also be that the effect of many aberrant 
3'ss is masked by the splicing defect.  
 
It was unexpected that, compared to wild-type, many of the aberrant 5'ss have 
a lower SEF (Figure 5.7) in the mutants, suggesting that splicing fidelity is 
higher in these cases. I can only speculate that this is due to the reduced pool 
of splicing components caused by depletion of Prp22. If the availability of the 
splicing machinery is reduced, then optimal splice sites may compete even 
better for splicing, thus suboptimal substrates will be spliced less frequently. 






Errors in 3'ss selection are common 
 
I have confirmed that 3'ss selection in wild-type is particularly prone to errors 
(Figure 5.5). This is interesting, but probably not surprising given that the 
consensus 3' motif is short (AT/CAG-), compared to the 5' motif (AAG-
GTATGTT) or the branchsite (TACTAACA). In other words, because there is 
less information to find the appropriate 3'ss, the spliceosome may very often 
use alternative AG- sequences near the branchsite. This is one reason why 3'ss 
proofreading may be especially important. On the other hand, typically the 
first T/CAG- immediately after the branchsite is selected for splicing, so 
branchsite location constrains 3'ss selection. This explains why there are many 
more aberrant downstream 3'ss than upstream 3'ss even in wild-type, as the 
distance between the branchsite and canonical 3'ss is limited. In this sense, it 
would be interesting to investigate whether Prp22 contributes to the 
preferential selection of T/CAG- 3'ss that are closer to the branchsite.  
 
To try to understand what type of sub-optimal substrates are targeted by 
Prp22, I manually inspected the most significant aberrant introns listed in 
Figure 5.9. Some of these contain upstream 3'ss with non-consensus motif (e.g. 
AAG-), including GIM5, YCL002C, RAD14, HNT2, PHO85 transcripts (Figure 
S5.2). This may suggest that Prp22 specifically inhibits non-consensus 3'ss 
(NAG-) located between the branchsite and the canonical 3'ss. On the other 
hand, there are other aberrant introns that contain a consensus 3'ss 
downstream of the canonical 3'ss, including LSM7, IWR1 and PTC7 
transcripts. This may suggest that, in addition, Prp22 inhibits downstream 3'ss 
that may compete with the annotated 3'ss. So, it seems that Prp22 influences 
3'ss selection based on motif sequence and also on branch site proximity. 
Although this is a very preliminary observation based on manual inspection, 
it does suggest that it is worth performing a systematic analysis as part of 




In search for non GT/AG introns 
 
Canonical 5'ss (-GT) and 3'ss (AG-) motifs represent the vast majority of both 
canonical and aberrant introns (Kawashima et al., 2014). For this reason, all 
the analyses described in this chapter, only include aberrant junctions derived 
from spliced GT/AG introns. As it was previously shown that helicase-
deficient Prp22 mutants, but not wild-type Prp22, allow in vitro splicing of a 
non AG- 3'ss (TAC-) (Mayas et al., 2006), I became interested in searching for 
this type of aberrant introns within my sequencing data. However, I later 
discovered that STAR mapper does not annotate strandness to the junction 
output file (SJ.out.tab) for those introns with motifs different than GT/AG, 
GC/AG and AT/AC. Therefore, they are filtered out in the downstream data 
analysis.  
 
So, as a crude attempt to search for potentially interesting "non-canonical" 
introns, I manually inspected the SJ.out.tab files that contain read counts 
linked to intron coordinates but no gene name annotations. However, I did 
not find splicing events that seemed promising. The few sequence 
discontinuities with 1) motifs different than GT/AG and 2) different number 
of reads in mutants compared to wild-type, do not appear to originate from 
splicing events, as they flank sequences of < 50 or > 1000 bp, or belong to 
intron-less protein coding genes or non-coding RNAs. So, it is possible that 
Prp22 is not particularly required for rejection of aberrant introns containing 
non GT/AG motifs as was previously observed in vitro. However, to rule this 




One reason why this study is valuable, is that the resulting dataset may allow 




involve investigating whether the set of aberrantly spliced introns that become 
more frequent in mutant relative to wild-type, have unusual features. For 
example, one could look for associations between changes in the frequency of 
splicing errors and specific 3'ss sequences, secondary structure strength 
within different regions of the pre-mRNA, distance to the branchsite or 
canonical 3'ss, among others.   
  
Finally, in the first part of the RNA-seq analysis I attempted to quantify the 
splicing defect, and to compare it across genes with different expression level. 
Through this analysis, I produced preliminary evidence of a correlation 
between expression level and the strength of the splicing defect, which may 
confirm that highly expressed genes tend to compete better for a limited pool 
of spliceosomes. However, mRNA stability may influence the mRNA junction 
ratio of mutant/wild-type (which was my measure of the splicing defect). 
Therefore, it is worth to complement this previously observed correlation 
using intron-read density instead of mRNA junction reads. This is an 
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Molecular tools to conditional repression gene expression are very useful in in 
vivo functional studies of cell biology. The ideal purpose of these tools is to 
specifically disrupt the element of interest without causing unwanted 
secondary effect. The AID is one of few systems that has the potential of 
accomplishing this. However, others and I have observed that previous 
version of this system for budding yeast had one of three possible issues: they 
stressed the cells, had leaky depletion, or depleted slowly. In this regard, one 
of my most important contribution was the development of the B-estradiol 
AID. This system does not appear to have any of the issues of the previous 
systems, and has the added benefit of tuneable depletion rate to accommodate 
depletion of low or highly abundant target proteins.  
 
However, one limitation of the B-estradiol AID is that it requires the addition 
of two effectors, and this could increase the chances of causing pleiotropic 
effects. A global analysis has shown that the transcriptome profile of yeast is 
virtually unchanged by the addition of B-estradiol to the medium (McIsaac et 
al., 2013). On the other hand, although addition of auxin does not affect cell 
growth on normal condition, a good transcriptomic analysis of yeast exposed 
to auxin under diverse conditions is still lacking. Others and I have observed 
that exposing yeast to high concentrations of auxin can be detrimental to 
growth, under conditions of nutrient deprivation (Figure 4.8) or under stress 
(Prusty et al., 2004). Furthermore, there is evidence that yeast can perceive and 
respond to auxin as part of a plant-infection pathway (Prusty et al., 2004). 
Therefore, for future studies it would be both useful and interesting to 
perform a systematic genome wide analysis of yeast exposed to auxin under 





Prp22 is an interesting protein because, as other spliceosomal RNA helicases, 
it directly triggers key structural changes within the spliceosome and, in 
addition, it was proposed to proofread the second step of splicing catalysis. 
As most previous studies of Prp22 were based on in vitro assays, I became 
interested in studying the role of this protein in vivo. My first observation was 
that the absence of this protein inhibits the first stages of spliceosome assembly 
and splicing catalysis. This was initially surprising, as this protein acts at the 
final stages of splicing. Although many year ago it was reported that 
disruption of late-acting splicing factors, such as Prp22, inhibits the first step 
of splicing (Company et al., 1991; Noble and Guthrie, 1996), the explanation 
given for why this happens has not been well supported by evidence.  
 
Given the gap in the literature, my first objective was to demonstrate why 
Prp22 appears to be required for the earliest stages of in vivo splicing. I later 
observed that depletion of this protein, or others, correlates with accumulation 
intermediate complexes of the spliceosome and to a very quick reduction of 
co-transcriptional assembly of the sequestered splicing components. This 
strongly indicates that Prp22 is only indirectly required for the first step of 
splicing, as its absence leads to a recycling defect and, therefore, to reduced 
formation of new spliceosomes. This finding is important in two ways. Firstly, 
it helped to better understand the role of Prp22 in splicing in vivo and, 
secondly, it showed that perturbing one element of the spliceosome can cause 
unwanted systematic effects on the assembly cycle. 
 
Finally, I used the improved AID system to study the proposed role of Prp22 
in splicing fidelity in vivo, by combining a novel depletion approach with an 
RNA sequencing analysis. With this, I observed that absence of Prp22 or its 
ATPase activity correlates with a higher frequency of aberrantly spliced 3’ss 




important for proper splice site selection on endogenous genes in vivo, which 
strongly indicates that splicing proofreading is a physiologically relevant 
process. The challenge of these experiments derived from the fact that, as I 
previously observed, depletion of this protein indirectly inhibits the first steps 
of splicing. This meant that the type of aberrantly spliced mRNA transcripts 
that I aimed to detect, were rare. However, because the transcripts were 
sequencing with very high-depth, it was possible to measure these rare events, 
and to compare them with wild-type conditions. The plan for the near future, 
is to attempt to find common features within the genes that become more 
affected, to try to better understand the process by which Prp22 rejects 
suboptimal 3’ss.  
 
In summary, I believe that the molecular tools I generated, together with my 
observation that strong and quick secondary effects may arise when 






























































Figure S3.1. Additional analysis of the RIP data relate to Figure 3.3 Data was normalized 
to U2 snRNA signal to correct for differences in pull-down efficiencies. Error bars denote 
standard error of three biological replicates.  
(A) When Prp3-AID*-6FLAG (tri-snRNP) is depleted, interaction of Lea1-3HA (U2 snRNP) 
with U1 is increased, and with U4, U5 and U6 snRNAs is decreased, like in the Prp4-AID*-
6FLAG depletion.  
(B) Starting values (before auxin-induced depletion) of the -AID*-6FLAG strain, demonstrating 
the necessity of normalized the data and presenting it as the ratio of depleted/undepleted, 
since experiments done at different days can produce values of different scales.   
(C) Same data as in (B) but presented as relative to the sum of U1, U4 U5 and U6 (U2 
normalized), to correct for differences in scale. This allows one to compare, between the 














Figure S3.2. Data as in Figure 3.5 presented as signal relative to exon 2 instead of 
normalized to ALG9. This normalization corrects for potential differences in expression rate 




Figure S3.3. Anti-FLAG ChIP of Prp22-AID*-6FLAG depletion, related to Figure 3.7. This 
confirms that after induced depletion, Prp22-AID*-6FLAG engaged in co-transcriptional 
splicing, drops as quickly as total levels of Prp22-AID*-6FLAG (as shown in Figure 3.6. by 
western blotting). Only ACT1 and ECM33 are shown because, with the primers available at 
the time of the experiment, ChIP of Prp22-AID*-6FLAG to RPL28, RPS13 or RPL39 was 






































Figure S4.1. Map of plasmid pMK200. StuI linearize pMK200 (Kanemaki lab) was inserted 
























Figure S4.2. Abundance of splicing intermediates of ACT1 transcript of YGM1 strain 
and its derivatives. Related to Figure 4.2.  
(A)  Wild-type strain W303 and AID-tagged strains compared with their untagged parental 
strain YGM1. Data are presented as relative to YGM1 and normalized to exon.  
(B)  Effect of auxin addition on YGM1 strain. Data are presented as relative to time 0 and 
normalized to exon.  
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Figure S5.1. Map of plasmids p360-PZ4EV-prp22 (-WT, -T757A or -I764A). Series of 
centromeric plasmids for the B-estradiol induced expression of Prp22 wild-type, or Prp22 














Figure S5.2. Related to Figure 5.9. Alt intron = non-annotated intron, BS = branchsite, blue 











































































































































































































































































































































































































































































































































































































































































































Abovich, N., and Rosbash, M. (1997). Cross-intron bridging interactions in the yeast 
commitment complex are conserved in mammals. Cell 89, 403–412. 
 
Achsel, T., Brahms, H., Kastner, B., Bachi, A., Wilm, M., and Lührmann, R. (1999). A 
doughnut-shaped heteromer of human Sm-like proteins binds to the 3’-end of U6 snRNA, 
thereby facilitating U4/U6 duplex formation in vitro. EMBO J. 18, 5789–5802. 
 
Alexander, R., Innocente, S., Barrass, J., and Beggs, J.D. (2010a). Splicing-dependent RNA 
polymerase pausing in yeast. Mol. Cell 40, 582–593. 
 
Alexander, R., Barrass, J., Dichtl, B., Kos, M., Obtulowicz, T., Marie-cecile, R., Koper, M., 
Karkusiewicz, I., Mariconti, L., Tollervey, D., et al. (2010b). RiboSys, a high-resolution, 
quantitative approach to measure the in vivo kinetics of pre-mRNA splicing and 3′-end 
processing in Saccharomyces cerevisiae. RNA 16, 2570–2580. 
 
Andrews, S. (2010). FastQC: a quality control tool for high throughput sequence data. 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc. 
 
Arenas, J.E., and Abelson, J.N. (1997). Prp43: An RNA helicase-like factor involved in 
spliceosome disassembly. Biochemistry 94, 11798–11802. 
 
Ares, M., Grate, L., Pauling, M.H., Ares, M., Grate, L., and Pauling, M.H. (1999). A handful 
of intron-containing genes produces the lion’s share of yeast mRNA. RNA 5, 1138–1139. 
 
Aronova, A., Bacíková, D., Crotti, L.B., Horowitz, D.S., and Schwer, B. (2007). Functional 
interactions between Prp8, Prp18, Slu7, and U5 snRNA during the second step of pre-
mRNA splicing. RNA 13, 1437–1444. 
 
Ayadi, L., Callebaut, I., Saguez, C., Villa, T., Mornon, J.-P., and Banroques, J. (1998). 
Functional and structural characterization of the Prp3 binding domain of the yeast Prp4 
splicing factor. J. Mol. Biol. 284, 673–687. 
 
Bae, E., Reiter, N.J., Bingman, C.A., Kwan, S.S., Lee, D., Jr, G.N.P., Butcher, S.E., and 
Brow, D.A. (2007). Structure and Interactions of the First Three RNA Recognition Motifs of 
Splicing Factor Prp24. 367, 1447–1458. 
 
Banroques, J., and Abelson, J.N. (1989). PRP4: a protein of the yeast U4/U6 small nuclear 
ribonucleoprotein particle. Mol. Cell. Biol. 9, 3710–3719. 
 
Barrass, J.D., Reid, J.E.A., Huang, Y., Hector, R.D., Sanguinetti, G., Beggs, J.D., and 
Granneman, S. (2015). Transcriptome-wide RNA processing kinetics revealed using 
extremely short 4tU labeling. Genome Biol 16, 282. 
 
Behrens, S.E., Tyc, K., Kastner, B., Reichelt, J., and Lührmann, R. (1993). Small nuclear 
ribonucleoprotein (RNP) U2 contains numerous additional proteins and has a bipartite RNP 
structure under splicing conditions. Mol. Cell. Biol. 13, 307–319. 
 
 
Behzadnia, N., Golas, M.M., Hartmuth, K., Sander, B., Kastner, B., Deckert, J., Dube, P., 
Will, C.L., Urlaub, H., Stark, H., et al. (2007). Composition and three-dimensional EM 






Bellí, G., Garí, E., Piedrafita, L., Aldea, M., and Herrero, E. (1998). An activator/repressor 
dual system allows tight tetracycline-regulated gene expression in budding yeast. Nucleic 
Acids Res. 26, 942–947. 
 
Bergkessel, M., Whitworth, G.B., and Guthrie, C. (2011). Diverse environmental stresses 
elicit distinct responses at the level of pre-mRNA processing in yeast. RNA 17, 1461–1478. 
 
Bertram, K., Agafonov, D.E., Liu, W.-T., Dybkov, O., Will, C.L., Hartmuth, K., Urlaub, H., 
Kastner, B., Stark, H., and Lührmann, R. (2017). Cryo-EM structure of a human spliceosome 
activated for step 2 of splicing. Nature 542, 318–323. 
 
Braberg, H., Jin, H., Moehle, E.A., Chan, Y.A., Wang, S., Shales, M., Benschop, J.J., Morris, 
J.H., Qiu, C., Hu, F., et al. (2013). From structure to systems: high-resolution, quantitative 
genetic analysis of RNA polymerase II. Cell 154, 775–788. 
 
Brosi, R., Gröning, K., Behrens, S.E., Lührmann, R., and Krämer, A. (1993). Interaction of 
mammalian splicing factor SF3a with U2 snRNP and relation of its 60-kD subunit to yeast 
PRP9. Science 262, 102–105. 
 
Brugiolo, M., Herzel, L., and Neugebauer, K.M. (2013). Counting on co-transcriptional 
splicing. F1000Prime Rep. 5, 9. 
 
Burgess, S.M., and Guthrie, C. (1993). A mechanism to enhance mRNA splicing fidelity: The 
RNA-dependent ATPase Prp16 governs usage of a discard pathway for aberrant lariat 
intermediates. Cell 73, 1377–1391. 
 
Burgess, S., Couto, J.R., and Guthrie, C. (1990). A putative ATP binding protein influences 
the fidelity of branchpoint recognition in yeast splicing. Cell 60, 705–717. 
 
Carrillo Oesterreich, F., Preibisch, S., and Neugebauer, K.M. (2010). Global analysis of 
nascent RNA reveals transcriptional pausing in terminal exons. Mol. Cell 40, 571–581. 
 
Carrillo Oesterreich, F., Herzel, L., Straube, K., Hujer, K., Howard, J., and Neugebauer, K.M. 
(2016). Splicing of Nascent RNA Coincides with Intron Exit from RNA Polymerase II. Cell 
165, 372–381. 
 
Chan, S.P., and Cheng, S.C. (2005). The Prp19-associated complex is required for 
specifying interactions of U5 and U6 with pre-mRNA during spliceosome activation. J. Biol. 
Chem. 280, 31190–31199. 
 
Chan, S.P., Kao, D.I., Tsai, W.Y., and Cheng, S.C. (2003). The Prp19p-associated complex 
in spliceosome activation. Science 302, 279–282. 
 
Chanarat, S., Seizl, M., and Strässer, K. (2011). The Prp19 complex is a novel transcription 
elongation factor required for TREX occupancy at transcribed genes. Genes Dev. 25, 1147–
1158. 
 
Chanclud, E., and Morel, J. (2016). Review Plant hormones : a fungal point of view. 1–9. 
 
Chang, J.S., and McPheeters, D.S. (2000). Identification of a U2/U6 helix la mutant that 
influences 3’ splice site selection during nuclear pre-mRNA splicing. RNA 6, 1120–1130. 
 
Chathoth, K.T., Barrass, J.D., Webb, S., and Beggs, J.D. (2014). A splicing-dependent 
transcriptional checkpoint associated with prespliceosome formation. Mol. Cell 53, 779–790. 
 
Chen, C.-H., Kao, D.-I., Chan, S.-P., Kao, T.-C., Lin, J.-Y., and Cheng, S.-C. (2006). 




spliceosome recycling. RNA 12, 765–774. 
 
Chen, J.Y.F., Stands, L., Staley, J.P., Jackups, R.R., Latus, L.J., and Chang, T.H. (2001). 
Specific alterations of U1-C protein or U1 Small nuclear RNA can eliminate the requirement 
of Prp28p, an essential DEAD Box splicing factor. Mol. Cell 7, 227–232. 
 
Chiang, T.-W., and Cheng, S.-C. (2013). A weak spliceosome-binding domain of Yju2 
functions in the first step and bypasses Prp16 in the second step of splicing. Mol. Cell. Biol. 
33, 1746–1755. 
 
Chorev, M., and Carmel, L. (2012). The function of introns. Front. Genet. 3, 1–15. 
 
Chung, S., Mclean, M.R., and Rymond, B.C. (1999). Yeast ortholog of the Drosophila 
crooked neck protein promotes spliceosome assembly through stable U4/U6.U5 snRNP 
addition. RNA 5, 1042–1054. 
 
Company, M., Arenas, J., and Abelson, J.N. (1991). Requirement of the RNA helicase-like 
protein PRP22 for release of messenger RNA from spliceosomes. Nature 349, 487–493. 
 
Cordin, O., and Beggs, J.D. (2013). RNA helicases in splicing. RNA Biol. 10, 83–95. 
 
Couto, J.R., Tamm, J., Parker, R., and Guthrie, C. (1987). A trans-acting suppressor 
restores splicing of a yeast intron with a branch point mutation. Genes Dev. 1, 445–455. 
 
David, C.J., Boyne, A.R., Millhouse, S.R., and Manley, J.L. (2011). The RNA polymerase II 
C-terminal domain promotes splicing activation through recruitment of a U2AF65-Prp19 
complex. Genes Dev. 25, 972–983. 
 
Didychuk, A.L., Montemayor, E.J., Brow, D.A., and Butcher, S.E. (2016). Structural 
requirements for protein-catalyzed annealing of U4 and U6 RNAs during di-snRNP 
assembly. Nucleic Acids Res. 44, 1398–1410. 
 
Dobin, A., and Gingeras, T. (2016). Mapping RNA-seq Reads with STAR. Curr. Protoc. 
Bioinform. 51:11.14.1-11.14.19. doi: 10.1002/0471250953.bi1114s51. 
 
Dohmen, R.J., and Varshavsky, A. (2005). Heat‐Inducible Degron and the Making of 
Conditional Mutants. In Methods in Enzymology, pp. 799–822. 
 
Egecioglu, D.E., and Chanfreau, G. (2011). Proofreading and spellchecking: a two-tier 
strategy for pre-mRNA splicing quality control. RNA 17, 383–389. 
 
 
English, M.A., Lei, L., Blake, T., Wincovitch, S.M., Sood, R., Azuma, M., Hickstein, D., and 
Liu, P.P. (2012). Incomplete splicing, cell division defects, and hematopoietic blockage in 
dhx8 mutant zebrafish. Dev. Dyn. 241, 879–889. 
 
Fabrizio, P., Dannenberg, J., Dube, P., Kastner, B., Stark, H., Urlaub, H., and Lührmann, R. 
(2009). The evolutionarily conserved core design of the catalytic activation step of the yeast 
spliceosome. Mol. Cell 36, 593–608. 
 
Fica, S.M., Tuttle, N., Novak, T., Li, N.-S., Lu, J., Koodathingal, P., Dai, Q., Staley, J.P., and 
Piccirilli, J.A. (2013). RNA catalyses nuclear pre-mRNA splicing. Nature 503, 229–234. 
 
Fica, S.M., Oubridge, C., Galej, W.P., Wilkinson, M.E., Bai, X.-C., Newman, A.J., and Nagai, 
K. (2017). Structure of a spliceosome remodelled for exon ligation. Nature 542, 377–380. 
 




P., and Lührmann, R. (2013). Dissection of the factor requirements for spliceosome 
disassembly and the elucidation of its dissociation products using a purified splicing system. 
Genes Dev. 27, 413–428. 
 
Frank, D., and Guthrie, C. (1992). An essential splicing factor, SLU7, mediates 3’ splice site 
choice in yeast. Genes Dev. 6, 2112–2124. 
 
Fu, S.-F., Wei, J.-Y., Chen, H.-W., Liu, Y.-Y., Lu, H.-Y., and Chou, J.-Y. (2015). Indole-3-
acetic acid: A widespread physiological code in interactions of fungi with other organisms. 
Plant Signal. Behav. 10, e1048052. 
 
Galej, W.P., Oubridge, C., Newman, A.J., and Nagai, K. (2013). Crystal structure of Prp8 
reveals active site cavity of the spliceosome. Nature 493, 638–643. 
 
Galej, W.P., Nguyen, T.H.D., Newman, A.J., and Nagai, K. (2014). Structural studies of the 
spliceosome: Zooming into the heart of the machine. Curr. Opin. Struct. Biol. 25, 57–66. 
 
Galej, W.P., Wilkinson, M.E., Fica, S.M., Oubridge, C., Newman, A.J., and Nagai, K. (2016). 
Cryo-EM structure of the spliceosome immediately after branching. Nature 537, 197–201. 
 
Garí, E., Piedrafita, L., Aldea, M., and Herrero, E. (1997). A Set of Vectors with a 
Tetracycline-Regulatable Promoter System for Modulated Gene Expression 
inSaccharomyces cerevisiae. Yeast 13, 837–848. 
 
Gautam, A., Grainger, R.J., Vilardell, J., Barrass, J.D., and Beggs, J.D. (2015). Cwc21p 
promotes the second step conformation of the spliceosome and modulates 3′ splice site 
selection. Nucleic Acids Res. 43, 3309–3317. 
 
Ghetti, A., Company, M., and Abelson, J.N. (1995). Specifity of Prp24 binding to RNA: a role 
for Prp24 in the dynamic interaction of U4 and U6 snRNAs. RNA 1, 132–145. 
 
Gietz, R.D., and Schiestl, R.H. (2007). High-efficiency yeast transformation using the 
LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2, 31–34. 
 
Görnemann, J., Kotovic, K.M., Hujer, K., and Neugebauer, K.M. (2005). Cotranscriptional 
spliceosome assembly occurs in a stepwise fashion and requires the cap binding complex. 
Mol. Cell 19, 53–63. 
 
Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by 
tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A. 89, 5547–5551. 
 
Grainger, R.J., and Beggs, J.D. (2005). Prp8 protein: At the heart of the spliceosome. RNA 
11, 533–557. 
 
Gray, W.M., Pozo, J.C., Walker, L., Hobbie, L., Risseeuw, E., Banks, T., Crosby, W.L., 
Yang, M., Ma, H., and Estelle, M. (1999). Identification of an SCF ubiquitin–ligase complex 
required for auxin response in Arabidopsis thaliana William. Genes Dev 53, 1678–1691. 
 
Hang, J., Wan, R., Yan, C., and Shi, Y. (2015). Structural basis of pre-mRNA splicing. 
Science 349, 1191–1198. 
 
Haruki, H., Nishikawa, J., Laemmli, U.K., Young, R.A., Sali, A., Blobel, G., Frank, J., Hager, 
G., Bustin, M., and Misteli, T. (2008). The anchor-away technique: rapid, conditional 
establishment of yeast mutant phenotypes. Mol. Cell 31, 925–932. 
 
Hilleren, P.J., and Parker, R. (2003). Cytoplasmic Degradation of Splice-Defective Pre-





Hollands, K., Proshkin, S., Sklyarova, S., Epshtein, V., Mironov, A., Nudler, E., and 
Groisman, E.A. (2012). Riboswitch control of Rho-dependent transcription termination. Proc. 
Natl. Acad. Sci. U. S. A. 109, 5376–5381. 
 
Hossain, M.A., Claggett, J.M., Edwards, S.R., Shi, A., Pennebaker, S.L., Cheng, M.Y., 
Hasty, J., and Johnson, T.L. (2016). Posttranscriptional Regulation of Gcr1 Expression and 
Activity Is Crucial for Metabolic Adjustment in Response to Glucose Availability. Mol. Cell 62, 
346–358. 
 
Howe, K.J., Kane, C.M., and Ares, M. (2003). Perturbation of transcription elongation 
influences the fidelity of internal exon inclusion in Saccharomyces cerevisiae. RNA 993–
1006. 
 
James, S.-A., Turner, W., and Schwer, B. (2002). How Slu7 and Prp18 cooperate in the 
second step of yeast pre-mRNA splicing. RNA 8, 1068–1077. 
 
Juneau, K., Palm, C., Miranda, M., and Davis, R.W. (2007). High-density yeast-tiling array 
reveals previously undiscovered introns and extensive regulation of meiotic splicing. Proc. 
Natl. Acad. Sci. 104, 1522–1527. 
 
Juneau, K., Nislow, C., and Davis, R.W. (2009). Alternative Splicing of PTC7 in 
Saccharomyces cerevisiae Determines Protein Localization. Genetics 183, 185–194. 
 
Kanemaki, M.T. (2013). Frontiers of protein expression control with conditional degrons. 
Pflugers Arch. 465, 419–425. 
 
Kawashima, T., Douglass, S., Gabunilas, J., Pellegrini, M., and Chanfreau, G.F. (2014). 
Widespread Use of Non-productive Alternative Splice Sites in Saccharomyces cerevisiae. 
PLoS Genet. 10, e1004249. 
 
Konarska, M.M., and Query, C.C. (2005). Insights into the mechanisms of splicing: more 
lessons from the ribosome. Genes Dev. 19, 2255–2260. 
 
 
Koodathingal, P., and Staley, J.P. (2013). Splicing fidelity. RNA Biol. 10, 1073–1079. 
 
Koodathingal, P., Novak, T., Piccirilli, J.A., and Staley, J.P. (2010). The DEAH box ATPases 
Prp16 and Prp43 cooperate to proofread 5’ splice site cleavage during Pre-mRNA splicing. 
Mol. Cell 39, 385–395. 
 
Koonin, E. V (2006). The origin of introns and their role in eukaryogenesis: a compromise 
solution to the introns-early versus introns-late debate? Biol. Direct 1, 22. 
 
Kotovic, K., Lockshon, D., Boric, L., and Neugebauer, K.M. (2003). Cotranscriptional 
Recruitment of the U1 snRNP to Intron-Containing Genes in Yeast. Mol. Cell. Biol. 23, 
5768–5779. 
 
Kötter, P., Weigand, J.E., Meyer, B., Entian, K.-D., and Suess, B. (2009). A fast and efficient 
translational control system for conditional expression of yeast genes. Nucleic Acids Res. 
37, e120. 
 
Kresnowati, M.T.A.P., Van Winden, W.A., Almering, M.J.H., Ten Pierick, A., Ras, C., 
Knijnenburg, T.A., Daran-Lapujade, P., Pronk, J.T., Heijnen, J.J., and Daran, J.M. (2006). 
When transcriptome meets metabolome: fast cellular responses of yeast to sudden relief of 





Lacadie, S.A., and Rosbash, M. (2005). Cotranscriptional spliceosome assembly dynamics 
and the role of U1 snRNA:5’ss base pairing in yeast. Mol. Cell 19, 65–75. 
 
Laggerbauer, B., Achsel, T., and Lührmann, R. (1998). The human U5-200kD DEXH-box 
protein unwinds U4/U6 RNA duplices in vitro. Proc. Natl. Acad. Sci. U. S. A. 95, 4188–4192. 
 
Lardelli, R.M., Thompson, J.X., Yates, J.R., and Stevens, S.W. (2010). Release of SF3 from 
the intron branchpoint activates the first step of pre-mRNA splicing. RNA 16, 516–528. 
 
Lesser, C.F., and Guthrie, C. (1993). Mutations in U6 snRNA that alter splice site specificity: 
implications for the active site. Science 262, 1982–1988. 
 
Listerman, I., Sapra, A.K., and Neugebauer, K.M. (2006). Cotranscriptional coupling of 
splicing factor recruitment and precursor messenger RNA splicing in mammalian cells. Nat. 
Struct. Mol. Biol. 13, 815–822. 
 
Lygerou, Z., Christophides, G., and Séraphin, B. (1999). A novel genetic screen for snRNP 
assembly factors in yeast identifies a conserved protein, Sad1p, also required for pre-mRNA 
splicing. Mol. Cell. Biol. 19, 2008–2020. 
 
Makarov, E.M., Makarova, O. V, Urlaub, H., Gentzel, M., Will, C.L., Wilm, M., and Lührmann, 
R. (2002). Small nuclear ribonucleoprotein remodeling during catalytic activation of the 
spliceosome. Science 298, 2205–2208. 
 
Mao, X., Hu, Y., Liang, C., and Lu, C. (2002). MET3 promoter: A tightly regulated promoter 
and its application in construction of conditional lethal strain. Curr. Microbiol. 45, 37–40. 
 
Martin, A., Schneider, S., and Schwer, B. (2002). Prp43 is an essential RNA-dependent 
ATPase required for release of lariat-intron from the spliceosome. J. Biol. Chem. 277, 
17743–17750. 
 
Martin-tumasz, S., Richie, A.C., Ii, L.J.C., Brow, D.A., and Butcher, S.E. (2011). A novel 
occluded RNA recognition motif in Prp24 unwinds the U6 RNA internal stem loop. 39, 7837–
7847. 
 
Mata, M. De, Alonso, C.R., Fededa, J.P., Pelisch, F., Cramer, P., Bentley, D., and Kornblihtt, 
A.R. (2003). A slow RNA Polymerase II affects alternative splicing in vivo. Mol. Cell 12, 525–
532. 
 
Matera, A.G., and Wang, Z. (2014). A day in the life of the spliceosome. Nat. Rev. Mol. Cell 
Biol. 15, 108–121. 
 
Maya, D., Quintero, M.J., de la Cruz Muñoz-Centeno, M., and Chávez, S. (2008). Systems 
for applied gene control in Saccharomyces cerevisiae. Biotechnol. Lett. 30, 979–987. 
 
Mayas, R.M., Maita, H., and Staley, J.P. (2006). Exon ligation is proofread by the DExD/H-
box ATPase Prp22p. Nat. Struct. Mol. Biol. 13, 482–490. 
 
Mayas, R.M., Maita, H., Semlow, D.R., and Staley, J.P. (2010). Spliceosome discards 
intermediates via the DEAH box ATPase Prp43p. Proc. Natl. Acad. Sci. U. S. A. 107, 
10020–10025. 
 
Mayes, A.E., Verdone, L., Legrain, P., and Beggs, J.D. (1999). Characterization of Sm-like 
proteins in yeast and their association with U6 snRNA. EMBO J. 18, 4321–4331. 
 
McCracken, S., Fong, N., and Yankulov, K. (1997). The C-terminal domain of RNA 





McIsaac, R.S., Oakes, B.L., Wang, X., Dummit, K. a, Botstein, D., and Noyes, M.B. (2013). 
Synthetic gene expression perturbation systems with rapid, tunable, single-gene specificity 
in yeast. Nucleic Acids Res. 41, e57. 
 
McPheeters, D.S., and Muhlenkamp, P. (2003). Spatial Organization of Protein-RNA 
Interactions in the Branch Site-3 Splice Site Region during pre-mRNA Splicing in Yeast. Mol. 
Cell. Biol. 23, 4174–4186. 
 
Montemayor, E.J., Curran, E.C., Hong Hong, L., Andrews, K.L., Treba, C.N., Butcher, S.E., 
and Brow, D.A. (2014). Core structure of the U6 small nuclear ribonucleoprotein at 1.7-Å 
resolution. Nat. Struct. Mol. Biol. 21, 544–551. 
 
Morawska, M., and Ulrich, H.D. (2013). An expanded tool kit for the auxin-inducible degron 
system in budding yeast. Yeast 30, 341–351. 
 
Morris, D.P., and Greenleaf, A.L. (2000). The splicing factor, Prp40, binds the 
phosphorylated carboxyl-terminal domain of RNA polymerase II. J. Biol. Chem. 275, 39935–
39943. 
 
Munding, E.M., Shiue, L., Katzman, S., Donohue, J., and Ares, M. (2013). Competition 
between Pre-mRNAs for the splicing machinery drives global regulation of splicing. Mol. Cell 
51, 338–348. 
 
Newman, A.J., and Norman, C. (1992). U5 snRNA interacts with exon sequences at 5’ and 
3’ splice sites. Cell 68, 743–754. 
 
Nguyen, G.T.D.T., Scaife, M.A., Helliwell, K.E., and Smith, A.G. (2016a). Role of 
riboswitches in gene regulation and their potential for algal biotechnology. J. Phycol. 52, 
320–328. 
 
Nguyen, T.H.D., Galej, W.P., Bai, X., Savva, C.G., Newman, A.J., Scheres, S.H.W., and 
Nagai, K. (2015). The architecture of the spliceosomal U4/U6.U5 tri-snRNP. Nature 523, 47–
52. 
 
Nguyen, T.H.D., Galej, W.P., Fica, S.M., Lin, P.-C., Newman, A.J., and Nagai, K. (2016b). 
CryoEM structures of two spliceosomal complexes: starter and dessert at the spliceosome 
feast. Curr. Opin. Struct. Biol. 36, 48–57. 
 
Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T., and Kanemaki, M. (2009). An 
auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nat. 
Methods 6, 917–922. 
 
Noble, S.M., and Guthrie, C. (1996). Identification of novel genes required for yeast pre-
mRNA splicing by means of cold-sensitive mutations. Genetics 143, 67–80. 
 
Ohi, M.D., Link,  a. J., Ren, L., Jennings, J.L., McDonald, W.H., and Gould, K.L. (2002). 
Proteomics Analysis Reveals Stable Multiprotein Complexes in Both Fission and Budding 
Yeasts Containing Myb-Related Cdc5p/Cef1p, Novel Pre-mRNA Splicing Factors, and 
snRNAs. Mol. Cell. Biol. 22, 2011–2024. 
 
Ohrt, T., Odenwälder, P., Dannenberg, J., Prior, M., Warkocki, Z., Schmitzová, J., 
Karaduman, R., Gregor, I., Enderlein, J., Fabrizio, P., et al. (2013). Molecular dissection of 
step 2 catalysis of yeast pre-mRNA splicing investigated in a purified system. RNA 19, 902–
915. 
 




sequences on Drosophila chorion transcripts. Cell 43, 143–151. 
 
Pan, Q., Shai, O., Lee, L.J., Frey, B.J., and Blencowe, B.J. (2008). Deep surveying of 
alternative splicing complexity in the human transcriptome by high-throughput sequencing. 
Nat. Genet. 40, 1413–1415. 
 
Papasaikas, P., Tejedor, J.R., Vigevani, L., and Valcarcel, J. (2015). Functional splicing 
network reveals extensive regulatory potential of the core spliceosomal machinery. Mol. Cell 
57, 7–22. 
 
Parenteau, J., Durand, M., Véronneau, S., Lacombe, A.-A., Morin, G., Guérin, V., Cecez, B., 
Gervais-Bird, J., Koh, C.-S., Brunelle, D., et al. (2008). Deletion of many yeast introns 
reveals a minority of genes that require splicing for function. Mol. Biol. Cell 19, 1932–1941. 
 
Parenteau, J., Durand, M., Morin, G., Gagnon, J., Lucier, J.F., Wellinger, R.J., Chabot, B., 
and Elela, S.A. (2011). Introns within ribosomal protein genes regulate the production and 
function of yeast ribosomes. Cell 147, 320–331. 
 
Pleiss, J.A., Whitworth, G.B., Bergkessel, M., and Guthrie, C. (2007). Rapid, Transcript-
Specific Changes in Splicing in Response to Environmental Stress. Mol. Cell 27, 928–937. 
 
Prusty, R., Grisafi, P., and Fink, G.R. (2004). The plant hormone indoleacetic acid induces 
invasive growth in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. 101, 4153–4157. 
 
Raghunathan, P.L., and Guthrie, C. (1998a). RNA unwinding in U4/U6 snRNPs requires 
ATP hydrolysis and the DEIH-box splicing factor Brr2. Curr. Biol. 8, 847–855. 
 
Raghunathan, P.L., and Guthrie, C. (1998b). A spliceosomal recycling factor that reanneals 
U4 and U6 small nuclear ribonucleoprotein particles. Science 279, 857–860. 
 
Rao, R.P., Hunter, A., Kashpur, O., and Normanly, J. (2010). Aberrant synthesis of indole-3-
acetic acid in Saccharomyces cerevisiae triggers morphogenic transition, a virulence trait of 
pathogenic fungi. Genetics 185, 211–220. 
 
Ronen, M., and Botstein, D. (2006). Transcriptional response of steady-state yeast cultures 
to transient perturbations in carbon source. Proc. Natl. Acad. Sci. U. S. A. 103, 389–394. 
 
van Roon, A.-M.A.M., Oubridge, C., Obayashi, E., Sposito, B., Newman, A.J., Seraphin, B., 
and Nagai, K. (2017). Crystal structure of U2 snRNP SF3b components: Hsh49p in complex 
with Cus1p binding domain. RNA 23, 968–981. 
 
Ryan, D.E., Stevens, S.W., and Abelson, J. (2002). The 5’ and 3’ domains of yeast U6 
snRNA: Lsm proteins facilitate binding of Prp24 protein to the U6 telestem region. RNA 8, 
1011–1033. 
 
Dos Santos Maraschin, F., Memelink, J., and Offringa, R. (2009). Auxin-induced, SCFTIR1-
mediated poly-ubiquitination marks AUX/IAA proteins for degradation. Plant J. 59, 100–109. 
 
Schneider, C., Agafonov, D.E., Schmitzová, J., Hartmuth, K., Fabrizio, P., and Lührmann, R. 
(2015). Dynamic Contacts of U2, RES, Cwc25, Prp8 and Prp45 Proteins with the Pre-mRNA 
Branch-Site and 3’ Splice Site during Catalytic Activation and Step 1 Catalysis in Yeast 
Spliceosomes. PLOS Genet. 11, e1005539. 
 
Schneider, S., Campodonico, E., and Schwer, B. (2004). Motifs IV and V in the DEAH box 
splicing factor Prp22 are important for RNA unwinding, and helicase-defective Prp22 





Schwer, B. (2008). A conformational rearrangement in the spliceosome sets the stage for 
Prp22-dependent mRNA release. Mol. Cell 30, 743–754. 
 
Schwer, B., and Gross, C.H. (1998). Prp22, a DExH-box RNA helicase, plays two distinct 
roles in yeast pre-mRNA splicing. EMBO J. 17, 2086–2094. 
 
Schwer, B., and Guthrie, C. (1991). PRP16 is an RNA-dependent ATPase that interacts 
transiently with the spliceosome. Nature 349, 494–499. 
 
Semlow, D.R., and Staley, J.P. (2012). Staying on message: Ensuring fidelity in pre-mRNA 
splicing. Trends Biochem. Sci. 37, 263–273. 
 
Semlow, D.R., Blanco, M.R., Walter, N.G., and Staley, J.P. (2016). Spliceosomal DEAH-Box 
ATPases Remodel Pre-mRNA to Activate Alternative Splice Sites. Cell 164, 985–998. 
 
Shcherbakova, I., Hoskins, A. a., Friedman, L.J., Serebrov, V., Corrêa, I.R., Xu, M.Q., 
Gelles, J., and Moore, M.J. (2013). Alternative Spliceosome Assembly Pathways Revealed 
by Single-Molecule Fluorescence Microscopy. Cell Rep. 5, 151–165. 
 
Da Silva, N.A., and Srikrishnan, S. (2012). Introduction and expression of genes for 
metabolic engineering applications in Saccharomyces cerevisiae. FEMS Yeast Res. 12, 
197–214. 
 
Small, E.C., Leggett, S.R., Winans, A. a., and Staley, J.P. (2006). The EF-G-like GTPase 
Snu114p Regulates Spliceosome Dynamics Mediated by Brr2p, a DExD/H Box ATPase. 
Mol. Cell 23, 389–399. 
 
Song, E.J., Werner, S.L., Neubauer, J., Stegmeier, F., Aspden, J., Rio, D., Harper, J.W., 
Elledge, S.J., Kirschner, M.W., and Rape, M. (2010). The Prp19 complex and the Usp4Sart3 
deubiquitinating enzyme control reversible ubiquitination at the spliceosome. Genes Dev. 24, 
1434–1447. 
 
Sontheimer, E.J., and Steitz, J.A. (1993). The U5 and U6 small nuclear RNAs as active site 
components of the spliceosome. Science 262, 1989–1996. 
 
Staley, J.P., and Guthrie, C. (1999). An RNA Switch at the 5’ Splice Site Requires ATP and 
the DEAD Box Protein Prp28p. Mol. Cell 3, 55–64. 
 
Stevens, S.W., and Abelson, J. (1999). Purification of the yeast U4/U6.U5 small nuclear 
ribonucleoprotein particle and identification of its proteins. Proc. Natl. Acad. Sci. U. S. A. 96, 
7226–7231. 
 
Tanaka, S., Miyazawa-Onami, M., Lida, T., and Araki, H. (2015). iAID: an improved auxin-
inducible degron system for the construction of a “tight” conditional mutant in the budding 
yeast Saccharomyces cerevisiae. Yeast 32, 567–581. 
 
Tardiff, D., and Rosbash, M. (2006). Arrested yeast splicing complexes indicate stepwise 
snRNP recruitment during in vivo spliceosome assembly. RNA 12, 968–979. 
 
Tardiff, D., Lacadie, S., and Rosbash, M. (2006). A genome-wide analysis indicates that 
yeast pre-mRNA splicing is predominantly posttranscriptional. Mol. Cell 24, 917–929. 
 
Tarn, W.Y., Lee, K.R., and Cheng, S.C. (1993). Yeast precursor mRNA processing protein 
PRP19 associates with the spliceosome concomitant with or just after dissociation of U4 
small nuclear RNA. Proc. Natl. Acad. Sci. U. S. A. 90, 10821–10825. 
 




(1994). Functional association of essential splicing factor(s) with PRP19 in a protein 
complex. EMBO J. 13, 2421–2431. 
 
Taxis, C., and Knop, M. (2012). TIPI: TEV Protease-Mediated Induction of Protein Instability. 
In Methods in Molecular Biology (Clifton, N.J.), pp. 611–626. 
 
Teigelkamp, S., Newman, A.J., and Beggs, J.D. (1995). Extensive interactions of PRP8 
protein with the 5’ and 3’ splice sites during splicing suggest a role in stabilization of exon 
alignment by U5 snRNA. EMBO J. 14, 2602–2612. 
 
Tsai, R.-T., Tseng, C.-K., Lee, P.-J., Chen, H.-C., Fu, R.-H., Chang, K.-J., Yeh, F.-L., and 
Cheng, S.-C. (2007). Dynamic Interactions of Ntr1-Ntr2 with Prp43 and with U5 Govern the 
Recruitment of Prp43 To Mediate Spliceosome Disassembly. Mol. Cell. Biol. 27, 8027–8037. 
 
Tsai, R.T., Fu, R.H., Yeh, F.L., Tseng, C.K., Lin, Y.C., Huang, Y.H., and Cheng, S.C. (2005). 
Spliceosome disassembly catalyzed by Prp43 and its associated components Ntr1 and Ntr2. 
Genes Dev. 19, 2991–3003. 
 
Tseng, C.-K., Liu, H.-L., and Cheng, S.-C. (2011). DEAH-box ATPase Prp16 has dual roles 
in remodeling of the spliceosome in catalytic steps. RNA 17, 145–154. 
 
Umen, J.G., and Guthrie, C. (1996). Mutagenesis of the yeast gene PRP8 reveals domains 
governing the specificity and fidelity of 3’ splice site selection. Genetics 143, 723–739. 
 
Verdone, L., Galardi, S., Page, D., and Beggs, J.D. (2004). Lsm Proteins Promote 
Regeneration of Pre-mRNA Splicing Activity. Curr. Biol. 14, 1487–1491. 
 
Vijayraghavan, U., Company, M., and Abelson, J. (1989). Isolation and characterization of 
pre-mRNA splicing mutants of Saccharomyces cerevisiae. Genes Dev 3, 1206–1216. 
 
Villa, T., and Guthrie, C. (2005). The Isy1p component of the NineTeen Complex interacts 
with the ATPase Prp16p to regulate the fidelity of pre-mRNA splicing. Genes Dev. 19, 1894–
1904. 
 
Wagner, J.D., Jankowsky, E., Company, M., Pyle, A.M., and Abelson, J.N. (1998). The 
DEAH-box protein PRP22 is an ATPase that mediates ATP-dependent mRNA release from 
the spliceosome and unwinds RNA duplexes. EMBO J. 17, 2926–2937. 
 
Wallace, E.W.J., and Beggs, J.D. (2016). Extremely fast and incredibly close: co-
transcriptional splicing in budding yeast. RNA 23, 601–610. 
 
Wan, R., Yan, C., Bai, R., Huang, G., and Shi, Y. (2016a). Structure of a yeast catalytic step 
I spliceosome at 3.4 Å resolution. Science 353, 895–904. 
 
Wan, R., Yan, C., Bai, R., Wang, L., Huang, M., Wong, C.C.L., and Shi, Y. (2016b). The 3.8 
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